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Clinical Algorithms (CAs) are flowcharts that graphically summarize some
of the medical procedures described in Clinical Practice Guidelines (CPGs),
such as diagnosis, management or treatment of certain diseases. Generally,
the development of CAs is done manually with the cooperation of several
health care experts of different specialties which represents a laborious task.
Moreover, the individual differences of the patients causes great variances
in the application of CAs in daily practice. In real world, chronic patients
use to suffer from more than one disease (comorbidities) and each case has
some particularities that may not be considered by the CA.
The automatic induction of structures like CAs from hospital databases
and medical resources solves the previous drawbacks. It reduces the high
costs of the manual generation and it allows the analysis of health care in
comorbidities. Today some computer technologies exist to carry out the
induction of procedural knowledge represented as CAs from the hospital
databases, but they suffer from several drawbacks: the structures produced
by these technologies may not be explicit medical structures that doctors
are familiar or satisfied with, they are only based on statistical measures
that do not necessarily respect medical criteria which can be essential to
guarantee medical correct structures, or they are not prepared to deal with
the incremental arrival of data which is worth to consider in medicine where
hospital databases are constantly updated with new information generated
during daily practice.
In this thesis, we propose a methodology to automatically induce med-
ically correct CAs from hospital databases. These CAs are represented
according to a knowledge model called SDA. The methodology considers
relevant background knowledge of a medical domain that has been previ-
ously validated by health care experts, and it is able to work in an incre-
mental way, so that the CAs generated are updated as soon as new data
arrive.
The methodology has been tested in the domains of hypertension, dia-
betes mellitus and the comborbidity of both diseases. As a result, we pro-
pose an effective repository of background knowledge for all these patholo-
gies and provide the SDA diagrams which have been automatically induced
from hospital databases using this repository. Later analyses show that the
results are medically correct and comprehensible when validated with health
care professionals, and compared against the results obtained by previous
technologies.
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Clinical Practice Guidelines (CPGs) (BGK+02) are medical documents that guide de-
cisions and criteria regarding diagnosis, management, and treatment in specific areas
of health-care based on an examination of current evidence. In general, they gather
all the available evidence related to a disease. Their main aim is to support and pro-
mote good clinical practice but they are also used to provide a homogeneous prac-
tice, to improve the quality, the equality and the equity of patient care, to avoid
several kinds of risk and to reduce costs. Most of the CPGs include Clinical Algo-
rithms (CAs) (SfMDM92; Had95) which are flowcharts that graphically summarize
some of the medical procedures described in the guideline.
CPGs are usually produced at national or international levels by medical associa-
tions or governmental bodies which are based on scientific rigor, employing systematic
reviews and meta-analyses (GR93). Generally, the development of CPGs represents a
laborious task that implies the cooperation of several health care experts of different
specialties. Moreover, the manual generation of CPGs suffers from other drawbacks
due to the individual differences of each patient or the differences on the treatment
depending on the presence of comorbidities (VSS+09).
Some approaches have been carried out to automatically induce part of the knowl-
edge contained in CPGs from the hospital databases, specially procedural knowledge
(MSL+08). These approaches are not necessarily based on the medical evidence but on
the experience of the medical daily practice. Some work has been done on the induction
of clinical pathways represented as Petri nets (MSSvdA08; MSL+08) which is based on
a technique called workflow mining (vdAvDH+03). However, the structures induced by
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those systems are not explicit medical structures that doctors are familiar with. Other
approaches (RLVT08; BRLV12) directly generate CAs which are pure medical struc-
tures. Although these approaches have obtained good results in concrete medical appli-
cations, they suffer from two major drawbacks. On the one hand, the current algorithms
to induce CAs are only based on statistical measures and do not consider any kind of
medical or clinical background knowledge which is not explicit in the hospital databases.
However, attending to the indications of this knowledge it is essential to guarantee
medical correct and comprehensible structures (LVRC07; LVRC12b; LVRB12). On the
other hand, they are not able to deal with incremental data which is of great impor-
tance in medicine because the hospital databases are being constantly updated with
new information generated in daily clinical practice.
The objective of this thesis is to propose a methodology to induce medically correct
and comprehensible CAs represented using the State Decision Action (SDA) knowledge
model (Ria07; BRLV12) from hospital databases that fulfill the Episode Of Care (EOC)
data model (Ria10). The methodology considers the relevant background knowledge of
the domain, previously validated by health care experts, which is represented using
different kinds of structures: graphs, hypergraphs, layered partial orders and concept
hierarchies. Moreover, the methodology is able to work in an incremental way, so that
the CAs generated are updated as soon as new data arrives.
The main contributions of the thesis are the following:
Contribution 1: Formalization of background knowledge structures that support
the automatic induction of medically correct and comprehensible CAs.
Contribution 2: Construction of a background knowledge repository for the dis-
eases of hypertension (ohhs03), diabetes mellitus (CL08) and the comorbidity of both
diseases (MSRS07).
Contribution 3: Development of both an incremental and a non incremental
methodology to induce medically correct and comprehensible CAs based on medical
background knowledge.
Contribution 4: Application of these methodologies to automatically generate
SDA diagrams representing correct and comprehensible CAs for the long term man-
agement of hypertension, diabetes mellitus and the comorbidity of both diseases in the
primary care centers of the SAGESSA Health-Care Group (SAG).
2
The different hospital databases of patients and other medical resources used in
this thesis belong to the SAGESSA Health-Care Group. During the development of
this thesis we have been assisted by health care professionals from SAGESSA who were
one of the main sources of expertise and experience during the knowledge acquisition
process, previous to the construction of the repository of background knowledge. These
health care professionals also supervised the medical validity of the thesis and they
helped in the analysis of the partial and the final results obtained.
The structure of this document is the following:
Chapter 1: An introduction to the thesis, its general objective, the main contri-
butions and the structure of the document.
Chapter 2: Analysis of the current state of the art of the different techniques,
methodologies, structures and models related to the topics of this thesis.
Chapter 3: Formalization of the medical background knowledge needed to solve
each one of the problems involved in the automatic induction of CAs (contribution 1)
and presentation of a repository of background knowledge for hypertension, diabetes
mellitus and the comorbidity of both diseases (contribution 2).
Chapter 4: Proposal of non-incremental and incremental algorithms to solve the
two main problems in the automatic induction of CAs using background knowledge,
and their integration into a global methodology to generate CAs (contribution 3).
Chapter 5: Set of tests regarding the performance of the background knowledge
and incrementality, the adherence of the results to the database and related medical
issues, the analysis of the results and the presentation of the final SDA diagrams for
three chronic pathologies (contribution 4).
Chapter 6: Conclusions and final discussion about the thesis.





State of the art
The automatic induction of procedural knowledge from hospital databases is a medi-
cal informatics problem which has been object of research using several approaches in
the bibliography. In our approach, the knowledge structures used are SDA diagrams
representing clinical algorithms about long term treatments. These SDA diagrams are
induced from hospital databases that follow the EOC data model. The induction of
these knowledge structures follows a complex procedure involving clustering and deci-
sion making techniques. During the induction of SDA diagrams, we consider background
knowledge of the domain in order to assure the medical correctness of the results. This
background knowledge may be represented using tools like graphs, partial orders, con-
cept hierarchies, etc. Moreover, if the induction of SDA diagrams is made incremental,
our methods will be able to efficiently cope with the arrival of new data to the hospital
databases.
All the concepts and techniques involved in the knowledge-based, incremental, and
automatic induction of SDA diagrams are presented in the following sections together
with a review of the most relevant related bibliography.
2.1 Clustering
Clustering is the mathematical problem of, given a set of patterns, classify them into
classes (clusters), so that similar patterns belong to the same cluster and dissimilar
ones belong to different clusters.
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Formally speaking, a clustering problem (X, C) consists of a domain of patterns X
and a set of clusters C. Each cluster Ci ∈ C contains a subset of the patterns in X.
Clustering is a common practice in health care, for example classifying profiles of
patient, defining health care patient states within the treatment of a disease, grouping
different kinds of features about patients, risk factors or drugs.
2.2 Decision making
Decision making is the mathematical problem of, given a situation, choosing one action
out of a set of actions to be performed for that situation.
Formally speaking, a decision problem (X, D, f) consists of a domain X, a set of
decisions D, and a decision function f : X→ D. The problem of decision is equivalent
to the problem of classification (Jam86).
In medicine, decisions are made continuously with different purposes: screening,
diagnosing, prognosing, drug and therapy prescription, etc. Through the years, multiple
structures have been proposed to formalize these decision processes. They range from
statistical approaches as Bayesian Networks (LvdGAH04; VdCFL07) or probabilistic
models (DH04) to symbolic approaches as decision trees (GC03; PKSR02; Tur09),
decision tables (Shi97) or decision rules (CN89).
2.3 Clustering algorithms
The clustering problem has been widely treated in artificial intelligence. It is raised
as the unsupervised classification of instances (patterns, observations, data items, or
feature vectors) into classes (clusters) usually based on a proximity measure or, in a
more general way, on the properties that data share.
Formally, an instance x is a single data item which consists of a vector of m
measurements x = (a1(x), ..., am(x)). Each position i of the vector corresponds to
a certain attribute or feature ai which has a value ai(x) for the instance x. An in-
stance set (or data set) is denoted X = {x1, ..., xn} where the ith instance is denoted
xi = (a1(xi), ..., am(xi)). Each instance xi is classified into a cluster Cj of a finite set
of clusters C = {C1, ..., Ck}. A cluster can be viewed as a source of instances whose
6
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distribution in the space of features is governed by a probability density specific to the
cluster.
Clustering is used to solve very different kinds of problems, thus the bibliogra-
phy is full of different clustering algorithms. Several attempts have been made to
classify clustering algorithms (JMF99; KP04; XW05). One of the most typical classi-
fications is between hard-clustering (McQ67; KR90; Hua98), fuzzy-clustering (Dun73)
or overlapping-clustering (Lel94; RD00; Cle04; BKG+05; CH06; FGK+09).
In hard-clustering each instance is assigned to a single cluster. We attempt to seek
a k-partition of X, C = {C1, ..., Ck} (k ≤ n) such that:




• Ci ∩ Cj = ∅, i, j = 1, ..., k and i 6= j
Some examples of hard-clustering can be found in (McQ67; KR90; Hua98).
Conversely, the fuzzy-clustering methods propose an organization in which each in-
stance participates to the definition of each cluster. An instance is allowed to belong
to all clusters with a degree of membership ui,j ∈ 0..1, which represents the member-
ship coefficient of the jth instance in the ith cluster and satisfies
∑k
i=1 ui,j = 1, ∀j
and
∑n
j=1 ui,j < n, ∀i. The most popular fuzzy clustering algorithm is fuzzy c-means
(FCM) (Dun73).
Finally, in overlapping-clustering rather than assigning an instance to only one
cluster, we allow an instance to belong to one or several clusters, final clusters thus
intersect. We attempt to seek a covering of X, C = {C1, ..., Ck} (k ≤ n) such that:




• x ∈ Ci 6⇒ x /∈ Cj , i, j = 1, ..., k and x ∈ X
Some examples of overlapping-clustering are axial-k-means algorithm (Lel94), pyra-
midal clustering (RD00), PoBOC (Cle04), MOC (BKG+05), OPC (CH06) and the
graph-based clustering method in (FGK+09).
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Another typical classification of clustering algorithms is among partitioning meth-
ods and hierarchical methods, although several less important approaches have been
carried out like density-based methods, grid-based methods or model-based methods.
Partitioning methods classify n instances into k clusters, where k is specified by
the user. The partitional techniques usually produce clusters by optimizing a criterion
function defined either locally (on a subset of the instances) or globally (defined over
all of the instances). The most intuitive criterion function in partitional clustering
techniques is the squared error criterion. The k-means (McQ67) is the simplest and
most commonly used algorithm employing a squared error criterion. It starts with a
random initial partition and keeps reassigning the instances to clusters based on the
similarity between the instance and the cluster centers until a convergence criterion
is met. Other similar methods are k-medoids (or PAM), clara (Clustering LARge
Applications) (KR90) and k-modes (Hua98).
Hierarchical clustering builds a cluster hierarchy also known as a dendrogram. Ev-
ery cluster node contains sibling clusters which partition the points covered by their
common parent. Such an approach allows exploring data on different levels of granular-
ity. Hierarchical clustering methods are categorized into agglomerative (bottom-up) as
agnes (AGglomerative NESting) (KR90) and divisive (top-down) as diana, Divisive
Analysis (KR90). An agglomerative clustering starts with one-point (singleton) clusters
and recursively merges the two (or more) most appropriate clusters. A divisive cluster-
ing starts with one cluster of all data points and recursively splits the most appropriate
cluster. The process continues until a stopping criterion (frequently, the requested num-
ber k of clusters) is achieved. Some examples of other kinds of hierarchical clustering
algorithms are cobweb (Fis87), cure (SGS98), birch (TZL96), Chameleon (GKK99),
rock (GRS00) and the overlapping pyramidal clustering (RD00).
Clustering is a common technique applied in lots of domains in biomedicine. It has
been used in bioinformatics in order to group genes (TBK09), in medical image pro-
cessing (MS99) but also in the health care domain. Some work has been done applying
clustering methods to group different kinds of risk factors (SvLTO02; RGO+04; Poo07;
AP09) and respiratory parameters (BAL+01). Concerning diseases, in (MAEB04)
spacetime clustering is examined amongst cases of lymphoma in children. (KN08)
proposes a new clustering technique based on Ant Colony Optimization which is used
to classify types of arrhythmia. A conceptual clustering method is applied over cancer
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data in (dV96). And (PAKS09) presents Onto-clust, a methodology that combines
clustering analysis and ontological methods in order to identify groups of comorbidities
for developmental disorders.
2.4 Decision making algorithms
Artificial intelligence has a long tradition inducing decision functions. Having a set of
instances (patterns, observations, data items, or feature vectors) and a set of decisions
(classes, or actions), a decision function is automatically learned such that given a
certain instance it is able to propose a decision. This methodology is also referred to
as supervised classification.
Formally, an instance x is a single data item which consists of a vector of m questions
and one decision x = (q1(x), ..., qm(x), dx). Each position i of the first m positions of
the vector corresponds to a certain question or test qi which has a value qi(x) for the
instance x. The last position corresponds to a certain decision dx for this instance. An
instance set (or data set) is denoted X = {x1, ..., xn} where the ith instance is denoted
xi = (q1(xi), ..., qm(xi), dxi).
There are several mechanisms to represent decisions, which can be induced from
data (KZP06). Some mechanisms are logic-based as decision trees (PKSR02; GC03;
Tur09) and decision rules (CN89), some are perceptron-based as single (FS99) or
multi layered (Zha00) perceptrons and RBF networks (RH01), some are statistical ap-
proaches as Bayesian Networks (LvdGAH04; VdCFL07) and some others are instance-
based (CH67) or support vector machines (Bur98). In this thesis we focus on Decision
Trees (DTs).
A tree is a mathematical concept that denotes a simple, undirected, connected and
acyclic graph. The edges are known as branches, the vertices of order 1 are called leaves
and the rest of the vertices, internal nodes. A rooted tree is a tree in which a special
node is singled out. This node is called root. In such kind of trees, nodes which are
one edge away from a given node n are called successors of n.
DTs (PKSR02; GC03; Tur09) are rooted trees used as decisional structures to solve
a decisional problem (X, D, f). Each internal node contains a question qi taken from
a set of questions Q on the elements of X that represents the function qi : X → ∆i
such that any element x ∈ X is given an answer qi(x) in the answer domain ∆i. Each
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internal node with question qi represents a partition of the domain ∆i and it has as
many successors as parts are in that partition. Each branch leading from an internal
node qi to a successor of qi is labeled with one of the possible parts of the partition
that the internal node represents. The leaves of the DT contain final single decisions
from the set D.
Figure 2.1 depicts an example of a simple DT for the treatment of hypertension. It
contains sequences of questions that lead to two alternative decisions Lifestyle modi-
fication and Lifestyle modification+Pharmacological treatment. The DT uses question
stage, meaning the stage of Hypertension (HT) in which the analyzed patient is, with
answers pre-HT, 1 and 2, 3 and question risk group, meaning the level of health fragility
of the analyzed patient, with answers A, B and C.
Figure 2.1: Example of decision tree
In a decision problem (X, D, f), a DT may act as the decision function f . Given
an instance x ∈ X, such that qi(x) = vi where vi is the answer to question q1 for x,
the DT determines a path from the root node to a certain leaf. To decide which path
corresponds to instance x, at each internal node ni containing a question qi, the next
node of the path ni′ is the successor connected to ni by the branch labeled δj such
that δj ∈ ∆i and vi ∈ δj (i.e., at each internal node the branch whose label matches
the answer of the question for x is followed). This process is repeated until the path is
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completed and, thus, a leaf with a final decision d is reached.
Each path from the root to a leaf might be seen as a constraint over the answers of
the questions in the path expressed as a conjunction. It is equivalent to a rule {q1(x) ∈
δ1} ∧ {q2(x) ∈ δ2} ∧ . . . ∧ {qn(x) ∈ δn} → dx where qi is the question corresponding
to the ith node of the path, each δi is one of the different parts of the partition ∆i,
and dx ∈ D is the decision contained in the leaf confirming that all the elements x ∈ X
arriving to this leaf satisfy f(x) = dx.
For example, the DT in figure 2.1 is used to make a decision on a new instance
(patient) x starts asking question stage. If stage(x)=1 the instance goes down through
the left branch labeled pre-HT, 1. According to the DT, the next question to ask is risk
group. Supposing that risk group(x)=A we finally make decision Lifestyle modification.
Although DTs can be build by hand, one of the main processes to automate the
construction of DTs is by induction or supervised learning. This means that, given
a set of instances X and a set of decisions D, the DT is automatically built using an
inductive learning algorithm.
The various heuristic methods to induce DTs can be divided into top-down ap-
proaches and bottom-up approaches, although other alternatives exists like hybrid and
tree growing-pruning approaches (SL91).
Top-down is the strategy of starting from the root node and generating the suc-
cessive internal nodes of the tree until reaching the leaves. All the data set used to
generate the DT is placed in the root node and then one of the questions is selected
to split them into the different branches of the node. This selection is done by means
of a node splitting rule. The procedure is repeated for the successors and so on until
the algorithm decides to place a leaf. For example, when a certain percentage of the
instances have the same decision. When a leaf is placed, a decision is made for all the
instances in this leaf. Usually, the decision made is the one with the highest proba-
bility. Most of the research is concentrated in the area of finding the splitting rule.
One of the main approaches followed is using the information gain (Qui86; Qui93).
The information gain criterion measures the amount of information (SW48) gained by
partitioning the data set according to the answers of a single question. This is to say,
the information gain of a given question qi with respect to the decision set D is the
reduction of uncertainty about the decision to make when the value of qi is known. The
11
2. STATE OF THE ART
uncertainty about the decision set D is measured by the entropy E(D). We define the




Pr(D = di) log2(Pr(D = di)) (2.1)
If the value of qi is already known, we define the uncertainty about D by the




Pr(qi = δj)E(D|qi = δj)) (2.2)
Thus, the information gain of qi with respect to D is defined as equation 2.3.
I(D; qi) = E(D)− E(D|qi) (2.3)
One of the most famous DT inductive algorithms based on the concept of informa-
tion gain is ID3 (Qui86). Essentially, it builds the tree by computing at each internal
node the information gained when splitting the data set using each of the questions
and selecting the one that maximizes the gain. The main disadvantage of using the
information gain is that it has a strong bias in favor of the questions with many an-
swers. Another algorithm called C4.5 (Qui93) solves this by using the so-called gain
ratio criterion. The idea is to use the gain ratio GR(D; qi) in equation 2.4 to select the





In equation 2.4, S(D; qi) is known as the split information which is sensitive to how




Pr(qi = δj |D) log2
1
Pr(qi = δj |D)
(2.5)
The C4.5 algorithm has another important improvement with respect to ID3. This
is the incorporation of pruning strategies to simplify the DT and to avoid overfitting.
In bottom-up approaches (LTG+83) the DT is constructed using some distance
measure, such as Mahalanobis-distance or pair-wise distances between a priori defined
classes. Then, in each step the classes with the smaller distance are merged to form a
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new group. The mean vector and the covariance matrix for each group are computed
from the training samples of classes in that group, and the process is repeated until one
is left with one group at the root. This has some of the characteristics of a hierarchical
clustering approach.
In health care, the problem of decision is so frequent that sometimes it receives
special names as diagnosing (i.e., decide on the sort of disease), assessing a patient
condition (i.e., decide the severity of a disease sign or symptom) or prescribing a treat-
ment (i.e., decide on the proper therapy). In the case of DTs, they have been widely
applied to solve medical problems (PKSR02; GC03). For example, DTs have been used
to predict cesarean delivery (SMC+00), to classify patients as having acute cardiac is-
chemia (LGSD93) or to enhance the tuberculosis prevention in nontraditional settings
and relationships (KMB+05).
2.5 Background knowledge
In machine learning, background knowledge (or prior knowledge) is any information that
can be fed by an expert of the domain or that can be extracted from a source of knowl-
edge, which is not explicitly included in the input data source of the learning process.
Background knowledge is used in complex domains, like medicine, where the input data
source is not enough informative to obtain correct results. This background knowledge
may contain constraints that must be fulfilled, relations or orderings between variables,
additional criteria that must be taken in account, labeled data, expert’s settings of
learning parameters, etc. Including background knowledge in the design of learning
methods is important. Firstly, the role of the expert in asserting background knowl-
edge imposes certain requirements to the way knowledge can be expressed. Attention
has to be paid to aspects of understandability for expressing the required background
knowledge. On the other hand, the use of prior knowledge also creates some new prob-
lems. There is the question of priority. In case of conflict or contradiction between a
partial solution being built from data and the knowledge expressed at the beginning
of the learning process, background knowledge can help to resolve these conflicts and
also to ensure that prior knowledge does not preclude the extraction of really useful
models (SC00).
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In section 2.5.1 we introduce the tools that have been used in this thesis to represent
background knowledge, then in section 2.5.2 and section 2.5.3 we make a brief survey on
how background knowledge has been incorporated in clustering and decision making,
respectively.
2.5.1 Representation of background knowledge
The way that background knowledge is represented must be simple so that it can be
easily understood by the expert, but it also must be complex enough to gather all the
required knowledge. In the bibliography, background knowledge has been represented
by different means such as graphs, partial orders, concept hierarchies, cost functions,
etc. (LYWZ04; LWY04; COR05; SAM05; BJ06; SY06; MCKD+06; FCPB07; LVRC07;
VMFC09; LVRC12b; LVRB12; XW12).
2.5.1.1 Graphs and hypergraphs
In mathematics, a graph refers to a collection of points called vertices (or nodes) and
a collection of lines called edges connecting pairs of vertices. Any binary relation is a
graph, so graphs can be used to represent essentially any relationship.
Definition 2.5.1 (Graph) A graph G is defined as an ordered pair G = (V,E) com-
prising a set V of vertices and a set E of edges. An edge is defined as a pair of vertices
vi, vj ∈ V .
In an undirected graph the edges are unordered pairs {vi, vj}, so the relations be-
tween pairs of vertices are symmetric and they have no directional character. In a
directed graph (or digraph) the edges are ordered pairs (vi, vj) having a directional
character and which are represented as arrows. A labeled graph is a graph such
that its edges have a label that gives them a different meaning. Figure 2.2 shows
an undirected graph where V = {IN ,BN ,SBDC,SBD,SBDF ,SCDF ,SCD,SCDC}
and E = {{IN ,BN},{BN ,SBDC},{SBDC,SBD},{SBD,SBDF},{SBDF ,SCDF},
{SCDF , SCD}, {SCD,SCDC},{SCDC,IN},{IN ,SCDF},{BN ,SBDF},{SCDC,-
SBDC},{SCD,SBD},{SCDC,SBD},{SCDC,SBDC}}. This graph is a representa-




Figure 2.2: Example of undirected graph
Figure 2.3 depicts a graphical representation of a directed labeled graph where V =
{Patient,AngioV isit,CoronaroExam,Symptom,RiskFactor} and E = {(Patient, -
AngioV isit),(AngioV isit,CoronaroExam),(Patient,Symptom),(Patient,RiskFactor)}.
This graph is a subpart of the Multimedia Temporal Graphical Model presented in (COR05).
Figure 2.3: Example of directed labeled graph
There is an alternative tabular representation which is useful when dealing with
large graphs. For example, table 2.1 contains the graph in figure 2.2. For each pair
of vertices we mark with ’X’ if they are related. In this case, as this is an undirected
graph, we only need to fill the cells above the main diagonal (the cells below the main
diagonal represent the same relationships). On the contrary, for directed graphs, if we
have the edge (vi, vj) we would mark the cell in the row of vi and the column of vj ,
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while if we have (vj , vi) we would mark the cell in the row of vj and the column of vi.
With labeled graphs, we mark the cells with the label of the edge rather than with ’X’.
Table 2.1: Example of undirected graph represented as a table
IN BN SBDC SBD SBDF SCDF SCD SCDC
IN X X X
BN X X X
SBDC X X





A hypergraph is a generalization of a graph, where an edge can connect any number
of vertices.
Definition 2.5.2 (Hypergraph) A hypergraph H is defined as an ordered pair H =
(V,E) comprising a set V of vertices and a set E of hyperedges. A hyperedge is defined
as a non-empty subset of V . Therefore, E is a subset of P(V )− ∅.
Figure 2.4 depicts two different graphical representations of a same hypergraph
where V = {EGF ,BRCA1,BRCA2,RB,RAS,myc} and E = {{EGF ,BRCA1,BRCA2,-
RAS},{BRCA1,BRCA2,RB},{RAS,myc}}. This is a subpart of a hypergraph pre-
sented in (MPM10) representing breast cancer knowledge. In the hypergraph, genes
BRCA1, BRCA2 and RB are connected with a relationship called tumor suppressor
gene, EGF , BRCA1, BRCA2 and RAS with a breast cancer relationship, and myc
and RAS with a oncogene relationship.
Figure 2.4: Example of labeled hypergraph
16
2.5 Background knowledge
If we are dealing with large hypergraphs we can represent them in a tabular way
(see table 2.2). Column 1 contains the name of the hyperedge and column 2, the related
vertices. The horizontal lines separate the different sets of related vertices.







tumor suppressor gene RB
BRCA1
BRCA2
Several concepts of graph theory have been widely applied to solve several kinds of
problems in biomedicine (BCM+05; RWL+08; BP09; LXH+10; MPM10). Concretely in
health care, (BCM+05) has applied graph theory to identify instances of deprivation and
high morbidity and mortality in health data sets and in (LXH+10) to study adverse drug
events. Graphs (in some cases simply referred to as relationships between elements)
are also becoming a common tool to represent biomedical knowledge (COR05; BJ06;
VMFC09; XW12). In (COR05) graphs are used in the representation of a clinical
database for cardiology patients. In (XW12), background knowledge, represented using
drug-gene relationships, is used to improve the extraction of pharmacogenomics specific
drug gene relationships from free text.
2.5.1.2 Partial orders and LPOs
In mathematics, a partially ordered set (or poset) formalizes the intuitive concept of
an ordering, sequencing, or arrangement of the elements of a set.
Definition 2.5.3 (Partial order) A relation ≤ is a partial order on a set S if it has:
1. Reflexivity: a ≤ a for all a ∈ S
2. Antisymmetry: a ≤ b and b ≤ a implies a = b, a, b ∈ S
3. Transitivity: a ≤ b and b ≤ c implies a ≤ c, a, b, c ∈ S
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Definition 2.5.4 (Partially ordered set) A partially ordered set P is defined as an
ordered pair (S,≤) where S is called the ground set of P and ≤ is a partial order on
the set S.
Two elements a, b ∈ S are comparable if either a ≤ b or b ≤ a or both.
Given three elements a, b, c ∈ S such that a ≤ b ≤ c then b is said to be between a
and c.
Definition 2.5.5 (Cover) Given a partially ordered set (S,≤) and two elements a, b ∈
S we say a covers b if a ≤ b and there is not any c ∈ S such that a ≤ c ≤ b or if b ≤ a
and there is not other c ∈ S such that b ≤ c ≤ a. In the first case, a is a lower cover
of b (a ≺ b) and in the second case a is an upper cover of b (b ≺ a). We denote c(a)
the set of covers of a (i.e., c(a) = {b ∈ S : a ≺ b or b ≺ a}).
Definition 2.5.6 (Chain) A subset C ⊆ S is called a chain in P = (S,≤) if and only
if for any pair a, b ∈ C, a ≤ b or b ≤ a or both (i.e., C is a totally ordered subset of S).
Definition 2.5.7 (Length) The length of a partially ordered set P = (S,≤) is the
cardinality of the biggest chain in P .
Definition 2.5.8 (Antichain) A subset C ⊆ S is called antichain in P = (S,≤) if and
only if for any pair a, b ∈ C, (a 6= b) neither a ≤ b nor b ≤ a (i.e., C is a totally
unordered subset of S).
Definition 2.5.9 (Width) The width of a partially ordered set P = (S,≤) is the car-
dinality of the biggest antichain in P .
Definition 2.5.10 (Maximal (minimal) element) Given a partially ordered set (S,≤),
an element a ∈ S is called a maximal (or minimal) element if there is none b ∈ S
for which a ≤ b (or b ≤ a). The set of maximal (or minimal) elements of a partially
ordered set P = (S,≤) is denoted MAX(P ) (or MIN(P )).
Hasse diagrams (PS03) are used to represent partially ordered sets. These diagrams
are a graphical rendering of a partially ordered set displayed via the cover relation of
the partially ordered set with an implied upward orientation. A point is drawn for each
element of the ground set of the partially ordered set, and line segments are drawn
between these points according to the following two rules:
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1. If a ≤ b in the partially ordered set, then the point corresponding to a appears
lower in the drawing than the point corresponding to b.
2. The line segment between the points corresponding to any two elements a and b
of the partially ordered set is included in the drawing if and only if b ∈ c(a).
Figure 2.5 depicts an example of a Hasse diagram of the partially ordered set with
S = {0, I, IIA, IIB, IIIA, IIIB, IV } representing stages of breast cancer according
to (BRR07). It is observed, for example, that I ≤ IIA because I appears in a lower
position of the diagram and there is a way of going up from I to IIA. This represents
the meaning that stage I is better than stage IIA, as far as breast cancer is concerned.
By transitive property, we may conclude also that I ≤ IIIB, 0 ≤ IV , etc. but it is
impossible to say whether IIA ≤ IIB or IIB ≤ IIA.
(a) Hasse diagram (b) Left-right Hasse diagram
Figure 2.5: Example of partially ordered set
In health care, these diagrams are usually represented as left-right Hasse diagrams
as the one depicted in figure 2.5(b) obtained from (BRR07).
Given a partially ordered set P = (S,≤) the order relation ≤ is called a preorder
or a quasiorder if it does not necessarily satisfy the antisymmetry property.
Definition 2.5.11 (Preorder) A relation ≤ is a preorder on a set S if it has:
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1. Reflexivity: a ≤ a for all a ∈ S
2. Transitivity: a ≤ b and b ≤ c implies a ≤ c, a, b, c ∈ S
Notice that partial orders are particular cases of preorders.
Given a partially ordered set P = (S,≤) the order relation ≤ is called a total order
if all the elements are comparable with ≤.
Definition 2.5.12 (Total order) A relation ≤ is a total order on a set S if it has:
1. Reflexivity: a ≤ a for all a ∈ S
2. Antisymmetry: a ≤ b and b ≤ a implies a = b, a, b ∈ S
3. Transitivity: a ≤ b and b ≤ c implies a ≤ c, a, b, c ∈ S
4. Comparability (trichotomy law): ∀a, b ∈ S, {a ≤ b ∨ b ≤ a}
A set S equipped with a total order relation ≤ is called a totally ordered set or
linearly ordered set. Notice that total orders are particular cases of partial orders.
In medicine, an example of partial order is the previously mentioned stages of breast
cancer (BRR07), an example of preorder is the preference of selection of questions
during an encounter according to the health risk of the medical test needed to answer
them and an example of total order is fever. In the first case, the possible stages of
breast cancer are 0, I, IIA, IIB, IIIA, IIIB and IV and the comparison of stages among
the patients must be made according to figure 2.5 and it is not always possible to
determine which patient is worst according to these stages (e.g., patients in stage IIA
are not comparable with patients in IIB). In the second case, a question q1 entails more
risks than a question q2 (i.e., q2 ≤ q1) or their risks can be uncertain (i.e., neither
q1 ≤ q2 nor q2 ≤ q1). But if q1 and q2 are obtained using a same medical test we know
that the health risk of q1 and q2 is exactly the same (i.e., q1 ≤ q2 and q2 ≤ q1). In the
third case, fever can be expressed as the body temperature in Celsius degrees ( ◦ C) or
by the terms normal (36.5-37.5 ◦ C), hypothermia (<35.0 ◦ C), fever (37.5-38.3 ◦ C),
hyperthermia (37.5-38.3 ◦ C) and hyperpyrexia (40.0-41.5 ◦ C) and, therefore, it is
always possible to determine which is the patient with a higher temperature among a
group of patients.
Partial orders have many applications in biomedicine. Partial orders can be induced
from medical data in order to extract knowledge about implicit precedences among
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these data. For example, (BRR07) describes an algorithm that uses data about patient-
professional encounters in order to induce partial orders on the patient conditions of
a disease. In (SA04), partial orders are induced from an ontology of biomedical terms
and in (UFM05) partial orders are extracted from unordered 0-1 data in the domain
of medical genetics. Moreover, partial orders can be used to represent background
knowledge in medical decision making. In (LVRC07), a partial order representing the
medical protocol of asking questions in the treatment of a certain disease is used to
increase the acceptability of decision trees in medicine and in (LVRB12) the same
problem is solved by means of partial orders which may represent several health care
criteria such as economic cost, health-risk or comfortability.
Definition 2.5.13 (Layered partial order) A Layered Partial Order (LPO) is a partial
order ≤ that satisfies the following property:
• ∀a, b ∈ S, if a and b are not related (i.e., neither a ≤ b nor b ≤ a), then c(a) = c(b)
They are called layered partial orders because the elements in S are strictly arranged
in layers. A layered partial order determines n disjoint antichains: C1, C2, ..., Cn such
that
⋃n
i=1Ci = S and for each pair of elements (a, b) ∈ Ci × Cj , where i < j, we have
that a ≤ b. Notice that if j = i + 1, we also have that a ≺ b. Each antichain Ci
(i = 1..n) is called a layer of the partial order. An element a ∈ S is in layer i-th if
a ∈ Ci. The layer of an element a ∈ S is denoted as `(a) and it is represented by a
positive number. A layered partial order with n layers is called n-layered partial order
(n-LPO).
For example, the partial order depicted in figure 2.5 is an LPO (concretely a 5-
LPO). As it can be observed, the elements of this partial order are arranged in the
following layers:
{0}, {I}, {IIA, IIB}, {IIIA, IIIB}, {IV }
Observe that the covers of the elements in the same layer are identical and different
from the covers of the elements in other layers. For example, c(IIA) = c(IIB) =
{I, IIIA, IIIB} and c(IIIA) = {IIA, IIB, IV }. The elements within each layer are
not related to each other (e.g., IIA 6≤ IIB and IIB 6≤ IIA) and they are all related
to each of the elements of the next (or previous) layers (e.g., IIA is related to each
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element of the previous layers (0 ≤ IIA, I ≤ IIA) and to each element of the next
layers (IIA ≤ IIIA, IIA ≤ IIIB, IIA ≤ IV ).
Due to its structuring in strict layers of priority, LPOs can be easily represented
as tables. For example, table 2.3 represents the same LPO of figure 2.5. Column 1
contains the number of the layer (`) and column 2, the elements in each layer. The
horizontal lines separate the different layers of the LPO.








It is common to use LPOs to represent medical knowledge that involves partial
orders (BRR07; LVRC07; LVRB12). Their composition in layers of priority makes
them easier to understand and also more natural to medical problems. Therefore, in
the rest of the document, when we are referring to a partial order we are actually
meaning an LPO.
2.5.1.3 Concept hierarchies
Concept hierarchies (taxonomies or is-a hierarchies) organize data or concepts in hier-
archical forms expressing knowledge in concise, high level terms, and facilitating mining
knowledge at multiple levels of abstraction (Lu97). Although they are defined as par-
tially ordered sets, they are explained in an independent section as they usually do not
represent an ordering but semantic relationships of subsumption.
Definition 2.5.14 (Concept hierarchy) A concept hierarchy H is a partially ordered
set (H,≤) where H is a finite set of concepts and ≤ represents a subsumption relation-
ship between concepts.
The partial order ≤ of a concept hierarchy reflects the special general relationship
between concepts, which is also called subsumption relation, subconcept-concept rela-




Since partially ordered sets can be visually sketched using Hasse diagrams, we can
also use this kind of diagrams to express concept hierarchies. In the case of concept
hierarchies, their Hasse diagrams are usually drawn upwards so if a ≤ b then the point
corresponding to a appears higher in the drawing than the point corresponding to b.
Figure 2.6 depicts an example of a concept hierarchy represented as a Hesse diagram
that classifies some diuretic drugs according to the Anatomical Therapeutic Chemical
(ATC) Classification System (fDSM). In this example, C03AA Thiazides, plain is a
subconcept of C03 DIURETICS, and C03BA Sulfonamides, plain is a superconcept of
C03BA04 chlortalidone. Therefore a plain thiazide is a diuretic drug, and chlortalidone
is a plain sulfonamide drug.
Figure 2.6: Example of concept hierarchy
Concept hierarchies may be very large and it can be difficult to visualize them using
a Hesse diagram. Therefore, we can choose a tabular representation. The previous
hierarchy is represented in a tabular way in table 2.4.
Table 2.4: Example of concept hierarchy represented as a table
C03 DIURETICS
C03A LOW-CEILING DIURETICS, THIAZIDES
C03AA Thiazides, plain
C03AA03 hydrochlorothiazide




Definition 2.5.15 (Nearest ancestor) A concept y is called the nearest ancestor of
concept x if x, y ∈ H and x ≤ y, x 6= y, and there is no other concept z ∈ H such that
x ≤ z and z ≤ y (i.e, x is a lower cover of y).
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In the example displayed in table 2.4, C03AA Thiazides, plain is the nearest ances-
tor of C03AA03 hydrochlorothiazide.
Definition 2.5.16 (Regular concept hierarchy) A concept hierarchy H = (H,≤) is




Hl and Hi ∩Hj = ∅ for i 6= j
and, if a nearest ancestor of a concept in Hi is in Hj, then the nearest ancestors of the
other concepts in Hi are all in Hj.
The concept hierarchy in table 2.4 is regular.
Another important term for describing the degree of generality of concepts is the
level. Levels are assigned a number. We assign zero to the level of the greatest element
(called the most general concept) of H, and the level of each other concept is assigned
one plus its nearest ancestor’s level number.
Due to the layered structure of a hierarchy, we notice that all the concepts with
the same level number must be in set Hl for one and only one l, l = 1, ..., n. We thus
simply call Hl as level l of the concept hierarchy.
The Hasse diagram of a concept hierarchy is actually a tree. Therefore, all the
terminology for a tree such as node, root, path, leaf, parent, child, sibling, etc. is
applicable to the concept hierarchy as well.
Definition 2.5.17 (Level name) A level name is a semantic indicator assigned to a
particular level. We denote S the set of level names of a concept hierarchy H.
Definition 2.5.18 (Schema level order) A schema level order of a concept hierarchy
H is a total order < on S such that a < b if there are two concepts x and y such that
x is in Hi whose level name is a and y is in Hj whose level name is b.
For example, in figure 2.6 we have the schema level order specified by the ATC
classification system: therapeutic group < pharmacological subgroup < chemical group
< active principle, where therapeutic group is the name of the level containing the
concept C03 DIURETICS ; pharmacological subgroup is the name of the level contain-
ing the concepts C03A LOW-CEILING DIURETICS, THIAZIDES and C03B LOW-
CEILING DIURETICS, EXCL. THIAZIDES ; chemical group, the name of the level
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containing the concepts C03AA Thiazides, plain and C03BA Sulfonamides, plain; and
active principle the name of the level containing the concepts C03AA03 hydrochloroth-
iazide, C03BA04 chlortalidone and C03BA11 indapamide.
Definition 2.5.19 (Nearest common ancestor) A concept z is the nearest common
ancestor of two concepts x and y in a concept hierarchy H if and only if z ≤ x and
z ≤ y and there is not any concept z′ such that z ≤ z′ ≤ x and z ≤ z′ ≤ y.
In the previous example, C03 DIURETICS is the nearest common ancestor of
C03AA Thiazides, plain and C03BA11 indapamide.
In medicine, several approaches have been done on the automatic induction of
concept hierarchies (SWW94), on the automatic classification according to a concept
hierarchy (SAM05; MCKD+06) or on the use of concept hierarchies as background
knowledge (LWY04; LVRC12b). It is common to use concept hierarchies of a standard
classification system or terminology. Some of the most typical systems containing hier-
archies of concepts which can be used as background knowledge are the Unified Medical
Language System (umls) which is a compendium of many controlled vocabularies in
the biomedical sciences (BBB+96), the snomed ct (Systematized Nomenclature of
Medicine – Clinical Terms) which is a systematically organized computer processable
collection of medical terminology covering most areas of clinical information such as
diseases, findings, procedures, microorganisms, pharmaceuticals etc. (LNM+09) and
the Anatomical Therapeutic Chemical (ATC) Classification System which is used for
the classification of drugs (GKHAF09).
2.5.1.4 Other background knowledge structures
Several other mechanisms are used to represent background knowledge as cost functions,
ontologies or co-occurrences.
Cost functions are used to give cost values to the different elements of a set according
to a certain criterion. They are used in optimization problems, where we want to find
the element in the set that optimizes the cost function.
Definition 2.5.20 (Cost function) A cost function f is defined as a function f : S →
D that represents a certain criterion. The elements s ∈ S are evaluated by f which
gives them a cost value in the range D according to the criterion represented. Cost
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functions are used in optimization problems where the objective is to find the element
in S that optimizes the cost function f .
The criterion represented by a cost function may be, for example, an economic
cost, a duration, a level of health-risk, or a combination of several of them. According
to the criterion, the range D of the function can be, for example, a natural number
representing monetary units (euros), temporal units (seconds), abstract units of utility
(utils), etc. Usually, in cases where the cost function has a maximum value, this range





Cost functions are given a negative sense, so the higher the cost value of a certain
element is, the worse this element is according to the criterion represented. A cost
function f representing health risk is in the correct sense since a high level of risk
has a negative sense. On the contrary, a cost function f representing patient com-
fortability goes in the opposite sense since a high level of comfortability has a positive
sense. In these cases, we talk of benefit instead of cost. The corresponding function f ′
representing the cost on comfortability should be f ′ = 1− f
In medicine, cost functions have been used to represent different kinds of criteria
such as economic costs (LYWZ04; SY06), health risk (FCPB07) or several other medical
criteria as comfortability or medical adherence (LVRB12).
Ontologies are structural frameworks for organizing knowledge and they are often
used to formally represent complex background knowledge to share.
Definition 2.5.21 (Ontology) An ontology is defined as a structural framework that
represents knowledge as a set of concepts within a domain, and the relationships between
those concepts. Regardless of the language in which they are expressed, most ontologies
describe individuals (instances or ground level objects), classes (concepts), attributes
that individuals and classes may have, and relations in which individuals and classes
can be related to one another.
Ontologies have been widely used to formalize and standardize medical knowledge.
For example, MeSH is the National Library of Medicine’s controlled vocabulary the-
saurus which consists of sets of terms naming descriptors in a hierarchical structure
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that permits searching at various levels of specificity. It contains thousands of descrip-
tors which are arranged in both an alphabetic and a hierarchical structure and with
cross-references. Another example is the metathesaurus of umls which contains over 1
million biomedical concepts (definitions) and 5 million concept names from more than
100 controlled vocabularies like ICD-10, MeSH or snomed ct used in patient records,
administrative data, full-text databases and expert systems.
Some examples of the use of ontologies as background knowledge in medicine are
(FYL+06) and (TBK09) where Gene Ontology annotations are used in bioinformatics
to assist a clustering process, and (RRLV+12) that presents an ontology-based system
that helps health care professionals to determine patient conditions and also to provide
a coordinated action plan which is adapted to the patient needs.
Another type of background knowledge specifies which combinations of values (co-
occurrences) of a set of attributes have high importance for a classification problem.
Definition 2.5.22 (Co-occurrence) A co-occurrence (or typical co-occurrence) is de-
fined as a combination of values of a set (grouping) of attributes that represent a char-
acteristic combination.
For example, co-occurrences have been used as background knowledge in (ZD98)
where the possibility of automating the process of acquiring co-occurrences is explored
and studied in the problem domain of rheumatic diseases.
2.5.2 Background knowledge in clustering
Clustering with background knowledge is also usually referred to as semi-supervised
clustering. We identify four approaches of semi-supervised clustering: constrained clus-
tering, seeded clustering, metric-based clustering and rule-based clustering.
In constrained clustering, background knowledge is represented as constraints that
must be respected during the clustering process. The most typical kind of constraints
are pairwise must-links and cannot-links. A must-link constraint between two instances
means that these two instances should be in the same cluster and a cannot-link means
that they should not be in the same cluster. In (WC10) the cop-cobweb is presented
as a modification of the cobweb clustering algorithm including must and cannot-links.
In (WCRS01) the same procedure is followed with the k-means clustering algorithm
obtaining the so-called constrained k-means (COP-kmeans). An evolved version of
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these constraints is used in (KKM02) to modify a hierarchical agglomerative clustering
algorithm. Another approach based in k-means, uses these kind of constraints with
an associated cost of violating each constraint (BBM+04a). Must-link constraints are
used to cluster documents in (JX06).
Seeded clustering uses some labeled instances (instances that have been previously
assigned to a cluster) as background knowledge. A k-means based approach uses seed
instances in (BBM02; SKP03). In (BBM04b) a hierarchical agglomerative clustering
algorithm uses seed clusters.
In metric-based approaches, an existing clustering algorithm that uses a distance
metric is employed; however, the metric is first trained to satisfy the labels or constraints
in the supervised data. (KKM02) uses an Euclidean distance trained by a shortest-path
algorithm, (BM03) uses string-edit distance learned using Expectation Maximization
(EM), (CCM03) adapts KL divergence with gradient descent and (XNJR03) uses Ma-
halanobis distances trained using convex optimization.
Rule-based clustering represents background knowledge by means of rules that
guide the learning process. The isaac algorithm is modified using classification rules
in (TB99). (VBL09) uses conjunctive rules to introduce additional background knowl-
edge to the ClusDM methodology.
Finally, some approaches combine several of the previous methods. In (BBM04c)
the k-means algorithm is modified (mpck-means) using an approach that uses both
constraints and metric learning and (KK08) uses supervision in terms of relative com-
parisons (e.g., x is closer to y than to z) and also learns the underlying dissimilarity
measure.
2.5.3 Background knowledge in decision making
The most common way of including background knowledge in the induction of decision
mechanisms is by means of cost functions. This approach is known as cost-sensitive
learning. In the case of DTs, they are referred to as cost-sensitive decision trees.
The costs considered in cost-sensitive learning may be of different kinds (Tur00) as
for example, cost of misclassification errors or cost of tests.
The cost of misclassification errors measures the error of making a wrong decision.
For example, the error of sending a patient home when it should have been sent to
ICU. It is usually represented by a cost function e(D,D) where D is the set of possible
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decisions. The error e(di, dj) specifies the cost of making a decision di over an instance,
when it is the correct decision is dj . In (LVRB12) a different approach is presented
using the concepts of type I and type II errors. Type I error represents the relevance
of not making a correct decision (e.g., not accepting a patient to an ICU when it is
required) and type II error represents the relevance of making a wrong decision (e.g.,
discharging a patient when it should remain at the hospital). With this approach
we have two cost functions eI(D) and eII(D) representing type I and type II error
respectively. Most approaches deal with constant error costs (i.e., the same value for
all instances) but costs may be conditional (i.e., they may depend on the nature of the
particular instance, the timing, whether errors have been made with other instances or
the answer of one or more questions of the instances). Some reviews of misclassification
costs are (Elk01; GGR02). In medicine, (LYWZ04; SY06) considers economic costs
and (LVRB12) classifies the most important criteria in medical decision making and
includes some of them as misclassification costs.
The cost of tests measures the cost of obtaining the answer to a certain question.
For example, the cost of answering a question that implies a surgical test may be
greater than the cost of a question that can be answered with a non-invasive test. It
is usually represented by a cost function e(Q) where Q is the set of possible questions.
The error e(qi) specifies the cost of answering question qi for an instance. In these
cases, costs can also be constant or conditional. In the case of conditional costs, they
may depend on the previous questions that have been asked, the answer of the previous
questions, the possible side-effects of the test, etc. In the bibliography, some approaches
use cost of tests usually making a trade-off between a cost function and the typical
information gain measure (Nor89; Tan93). In medicine, (LYWZ04; SY06) considers
economic costs, (FCPB07) also includes the health-risk criterion and (LVRB12) uses
several other medical criteria as comfortability or medical adherence.
There are other kinds of cost which have been less considered in the bibliography
like cost of teacher, cost of intervention, cost of unwanted achievements, cost of com-
putation, cost of cases, human-computer interaction cost or cost of instability (Tur00).
In spite of cost-sensitive learning, there are several other ways to include background
knowledge in decision making. For instance, (Nuñ91) combines cost functions with a
IS-A hierarchy and (Tin98) weights the instances of the dataset. In the health care
domain, (LVRC07) represents the adherence to the medical guidelines as a partial order
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over the questions and makes a trade-off with the information gain. Partial orders are
also used in (LVRB12) to represent medical criteria.
2.6 Incrementality
Incrementality is defined as the process of increasing in number, size, quantity, or
extent. In machine learning, incrementality refers to the property of being able to deal
with new incoming data to revise, if necessary, a previously induced mechanism without
re-inducing it from scratch. In (GC00) Giraud-Carrier states that “a learning task is
incremental if the training examples used to solve become available over time, usually
one at a time”.
Incremental induction is desirable for a number of reasons (Utg94). Most impor-
tantly, revision of existing knowledge presumably underlies many human learning pro-
cesses, such as assimilation and generalization. Secondly, knowledge revision is typically
much less expensive than knowledge creation. For example, incrementality is useful for
serial learning tasks, on the assumption that it is more efficient to revise an existing
hypothesis than it is to generate a hypothesis each time a new instance is observed.
Finally, the ability to revise knowledge in an efficient manner opens new possibilities
for algorithms that otherwise would remain prohibitively expensive.
Incremental learning algorithms are usually motivated basically for these three de-
sirable goals:
1. Cost reduction: The incremental cost of updating the current hypothesis with a
new instance should be much lower than the cost of building a new hypothesis
from scratch. It is not necessary however that the sum of the incremental costs
be less than the execution on the complete database.
2. Independence from the size: The update cost should have a high degree of inde-
pendence to the number of training instances on which the decision mechanism
is based.
3. Independence from the order: The hypothesis produced by the incremental al-
gorithm should depend only on the set of instances that has been used, without




The interest in incremental clustering stems from the fact that the main memory usage
is minimal since there is no need to keep in memory the mutual distances between
instances and the algorithms are scalable with respect to the size of the set of instances
and the number of attributes.
One of the most famous incremental clustering algorithms is cobweb (Fis87). It
maximizes a measure called category utility to build a probabilistic hierarchical tree.
The algorithm reads one instance per iteration from a data set and incorporates it into
the tree by descending the tree along an appropriate path to a node where the category
utility is maximal after absorbing the instance and updating statistical information (for
computation of the probabilities) in each node along the way. To find the proper place
to hold the instance, cobweb tries one, or several, or all of the following four possible
operations at each node on the path:
1. place the instance in an existing cluster
2. create a new cluster by itself
3. merge the best two clusters with respect to the values of category utility
4. split a cluster into several clusters by lifting its children one level in the tree to
replace itself
The operation resulting in the largest value of category utility is the final choice on
that node. This procedure is recursively invoked until a leaf node is reached or a new
leaf is created.
Another approach is proposed in (CCFM97) where the number of clusters is fixed.
When a new instance arrives, either it is assigned to an existing cluster or a new cluster
is created while two of the existing clusters are merged. A method based on this ap-
proach is used in (SH01) for document clustering. In (EKS+98) the dbscan clustering
algorithm is adapted to deal with incremental data. The incremental algorithm for
nominal data in (SSK04) is based on a metric on the set of partitions of a finite set of
instances. Other alternative approaches are based on swarm intelligence (LPM06) or
neural networks (HBBC08).
31
2. STATE OF THE ART
In some domains, it is possible that not only the data set evolves with the incor-
poration of new instances, but the set of attributes may be dynamic. In (cC05) an
incremental clustering algorithm Core Based Incremental Clustering (cbic), based on
k-means, is presented which is capable to construct a new partition of the data set,
when the attributes set increases.
In medicine, incremental clustering has been applied in several applications, for
example to detect of infectious outbreaks in hospitals (LGCM01) or in the cancer
domain (dV96).
2.6.2 Incremental decision making
Most of research on incremental decision making has been based on improvements of
the ID3 DT induction algorithm (Qui86) both finding a way to compute the infor-
mation gain with minimal spatial cost and guaranteeing that the DTs incrementally
obtained are equal to those that would generate the non-incremental ID3. The first
approach proposed is the ID4 algorithm (SF86) which follows a ID3 based algorithm
and when the relative ordering of the possible questions at a node changes due to
new incoming instances, all subtrees below that node are discarded and have to be
reconstructed, causing that certain concepts are unlearnable. The minimal informa-
tion needed to compute the information gain for a possible question at a node is kept.
This information consists of positive and negative counts for each possible answer to
each possible question at each node. The ID4 algorithm builds the same tree as the
basic ID3 algorithm only when there is a question at each decision node that is clearly
the best choice in terms of its information gain. The ID5 algorithm (Utg88) does not
discard subtrees, but also cannot guarantee that it will produce the same tree as ID3.
The id5r algorithm (Utg89) produces the same tree as ID3 for a data set regardless of
the incremental training order. This is accomplished by recursively updating the tree’s
subnodes. id5r restructures the tree so that the desired question is at the root. The
restructuring process, called a pull-up, is a tree manipulation that preserves consistency
with the observed training instances, and that brings the indicated question to the root
node of the tree or subtree. The advantage of restructuring the tree is that it allows
recalculating the various positive and negative counts during the tree manipulations,
without reexamining the training instances. The improved ITI algorithm (UBC97) also
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produces the same tree regardless of the presentation order, or whether the tree is in-
duced incrementally or non incrementally (batch mode). It can accommodate numeric
variables, multiclass tasks, and missing values.
In spite of ID3 based incremental algorithms, other approaches are the incre-
mental cart algorithm (Cra89) which is based on the non-incremental cart algo-
rithm (BFOS84), the stagger algorithm (SRG86) which examines concepts that change
over time (concept drift) or the Very Fast Decision Trees learner (vfdt) (DH00) which
reduces training time for large incremental data sets by subsampling the incoming data
stream.
In medicine, incremental decision making has been applied in the retrieval from
manuals and medical texts (WS06), for on-line prediction of hospital resource utiliza-
tion (NML06) or for patient-dependent seizure detection (Wil05) among others.
2.7 The EOC Data Model
Health care deals with the concept of encounter between the patient and the health
care professionals (RLVT08). An Episode Of Care (EOC) of a particular patient is the
sequence of encounters aiming at curing, stabilizing, or palliating one or several of that
patient’s ailments. Notice that chronic diseases define EOCs that remain open for the
patient’s entire life. Concerning a single encounter, the standard behavior of a health
care professional is to observe the current state of the patient (e.g., patient symptoms,
test results, etc.) and then decide some actions (e.g., prescribe drugs, order tests,
start some medical procedure, etc.). Observe that some evidence may exist that justify
these actions. Therefore within the same encounter, several health care measures may
coexist containing, each one, the evidence to a subset of the actions performed during
that encounter. For example, in the hypertension domain, for a particular encounter
the physician may decide both a drug therapy based on the evidence that the patient
is at high risk of cardiac disease, and a recommendation to modify the patient lifestyle,
due to the presence of cholesterol. A representation model for this minimal information
about the treatment of a chronic patient is the EOC data model (Ria10). A simplified
formalization of it can be seen in table 2.5.
Notice that the data about patient condition, evidences and actions is represented by
means of terms in order to fit the terminology used in the SDA knowledge representation
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Table 2.5: Simplified formal description of the EOC data model
episode of care ← sequence of encounters
encounter ← patient condition + list of health care measures
patient condition ← list of state terms
health care measure ← evidence + action
evidence ← list of decision terms
action ← list of action terms
model (see section 2.8). These terms (or vocabulary items) can be of three sorts: state
terms, decision terms and action terms and they are detailed in the next section. Let
enci be an encounter in the EOC database, we call S(enci) the set of state terms that
define the patient condition in enci, and D(enci) and A(enci) the set of decision terms
and action terms contained in each health care measure in enci.
2.8 The SDA knowledge model
The State Decision Action (SDA) knowledge model (Ria07; BRLV12) is used to repre-
sent procedural knowledge in medicine stressing the concept of simplicity without losing
description capability. It is based on the concept of Clinical Algorithms (CAs) (SfMDM92;
Had95) but also includes all the representation primitives that any CIG (Computer-
interpretable guidelines) system is expected to have (PPT+02; PTB+03; MvdAP07;
IM08) (i.e., actions, decision, patient states, execution states, sequences, concurrences,
alternatives, and loops). The SDA knowledge model is founded on the concept of
term or vocabulary item in the medical domain of the procedural knowledge. These
terms can be of the sort state, decision, or action. State terms define the vocabu-
lary that is used to describe the feasible patient conditions and situations in the area
of interest (e.g., terms as Elevated Blood Pressure or Following Drug Treatment to
establish a differential treatment). Decision terms are the terminology that health
care professionals use to condition the sort of treatment to be followed (e.g., terms as
Secondary Cause Suspected or BP at Goal that may derive the course of professional
activities in one direction or another). Action terms are the way that medical, surgical,
clinical or management activities are defined (e.g., terms as LifeStyle Modifications or
Drug Therapy are respective examples of counsel and prescription, which are two of
the types of medical actions that may appear in the description of a treatment. In a
certain medical context, we denote S, D and A, the sets of state, decision and action
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terms respectively. State, decision and action terms are employed to construct three
sorts of elements that once interconnected they will describe the medical procedure.
These elements are, respectively: states, decisions and actions. States, which are sub-
sets Si = {si1 , si2 , ..., sin} where all sx are state terms, represent patient conditions,
situations, or statuses that deserve a particular course of action which is totally or
partially different from the actions followed when the patient is in another state, for
example, to differentiate between the initial treatment and the subsequent treatments
or between the different stages of a disease. Decisions allow the integration of all the
variability that a treatment may have by means of conditions on several decision terms
di1 , di2 , ..., dim which represent some of the available information about the patient and
the current situation. Actions, which are subsets Ai = {ai1 , ai2 , ..., aip} where all ax are
action terms, constitute the proper health care activities involved in the health care
procedure represented. Similar to the CA notation, the SDA model represents states,
decisions, and actions respectively as circles, diamonds, and rectangles which are con-
nected with arrows in order to provide a join representation of a health care procedure,
as the one depicted in figure 2.7 for the treatment of hypertension. It distinguishes
between plain connectors, decisional connectors, and otherwise connectors. Plain con-
nectors represent evolutions of the health care procedure which can be followed by any
patient. Decisional connectors link decisions with other elements, they contain deci-
sion terms, and only the patients who meet all the terms in a connector are able to
follow this connector. Finally, otherwise connectors link decisions with other elements,
they are identified with the word ’otherwise’, and only the patients who fulfill none of
the connectors leaving a decision are able to follow the otherwise connectors of that
decision. The sequence of decisions and actions that connects one state to one or more
next states is called therapeutic sequence. See, for example the SDA in figure 2.7.
Connectors may have time constraints of the form [min, max]; min representing
the minimum time the process must stop before following the connector (e.g., wait two
hours before measuring BP again to confirm high BP), and max the maximum time
the process must stop before moving forward in the treatment (e.g., next visit must be
scheduled for not later than one week).
The interpretation of a SDA diagram is the following: when a patient arrives, all
the SDA states whose state terms are observed in the current patient condition are
eligible to start the treatment. If several states are eligible, a health care professional
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Figure 2.7: Example of SDA diagram for the treatment of hypertension
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has to decide the one to start at among all the eligible states (this is called type-0
non-determinism). Once this is decided, the connectors are followed until either a
non-eligible state is found or a connector with a positive min delay is reached. In
this process, all the actions of the followed path are the SDA recommendations for
the treatment of that patient. When a decision is reached, all the outgoing decision
connectors whose decision terms are part of the patient condition are eligible to follow
the treatment of that patient. If only one decision connector is eligible, the connector
is followed. If there are several eligible connectors, then a health care professional has
to choose one of them to follow the treatment (this is called type-1 non-determinism).
If none of them is eligible, but there is an otherwise connector, then this connector is
followed. If several otherwise connectors exist, then a health care professional decides
which one is the one to be followed (this is also considered type-1 non-determinism). In
case that there are several plain connectors leaving a state or an action, all of them are
eligible and it is the health care professional who has to decide the one to be followed
(this is called type-2 non-determinism). Non-determinism is only observed when there
is not a single accepted and evidence-based procedure to deal with a particular situation
and the choice criterion between the alternatives is not defined.
The SDA model has been thoroughly tested in the context of the k4care project
(www.k4care.net) where it has been successfully used to represent different sorts of
procedural knowledge in medicine, particularly in home care.
2.9 Induction of medical procedural knowledge
Diffusion of Information and Communication Technology tools within the health care
practice, such as electronic clinical charts, computerized guidelines and, more gen-
erally, decision support systems, makes a huge amount of data available which can
be exploited. One of the main uses of this data is the induction of medical procedu-
ral knowledge which consists in mining the hospital databases by means of machine
learning techniques in order to obtain structures that represent the different flowcharts
followed by patients with a certain disease or pathology.
This kind of structures have been widely used in health care for ages. This is the case
of CAs (SfMDM92; Had95) which are included in Clinical Practice Guidelines (CPGs)
to graphically summarize some of the medical procedures described in the guideline.
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The CAs defined by the international Society for Medical Decision Making (SfMDM92)
are flowcharts that start with a clinical state box defining the clinical state or problem,
and then a combination of both, decision boxes representing yes-no questions leading
the process to alternative paths, and action boxes describing actions, either therapeutic
or diagnostic. All these boxes are connected by arrows that show the logical sequence
of application of the CA. For example, the CA in figure 2.8 was published by the
Institute for Clinical Systems Improvement (Sch06) as a generalization of the long
term treatment and follow up of hypertension.
Generally, CAs are hand-made which represents a laborious task that implies the
interaction between several health care experts of different specialties. This is not the
only drawback of the manual creation of CAs. The individual differences of the patients
causes great variances in the application of CAs in daily practice. In real world, chronic
patients use to suffer of more than one disease (comorbidities) and each case has some
particularities that may not be considered by the CA. The induction of structures like
CAs from hospital databases and medical resources solves the previous drawbacks. It
reduces the high costs of the manual generation and it allows the analysis of health
care in comorbidities. Moreover, the automatic induction of CAs can be used to:
• Create different views (or dimensions) about the same clinical activity (e.g. only
pharmacological treatment, only nursing activities, only expensive actions, pa-
tient evolution vs administrative issues, etc.) by the selection of different termi-
nologies to express the induced CAs
• Complement and refine the CAs based on the medical knowledge provided by the
CPGs, because the induced CAs are obtained from clinical experience
• Automatically check guideline compliance
• Increase the understanding of disease processes
• Improve the physician education
• Compare the procedures followed by different health care institutions
One of the main approaches in the induction of medical procedural knowledge from
data is based on the so-called workflow mining (vdAvDH+03). This technique generates
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Figure 2.8: Clinical algorithm on hypertension published by the Institute for Clinical
Systems Improvement
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process related information exploiting the event logs from a process management sys-
tem, database, etc. and has been successfully applied in several domains (vdAvDH+03).
In (MSSvdA08) and (MSL+08) workflow mining is applied in gynecological oncology
and stroke respectively obtaining clinical pathways represented as Petri nets. The
main drawback of this approach is that the structures induced by those systems are
not explicit medical structures that doctors are as familiar to work with as with CAs.
Another approach is the induction of SDA diagrams using machine learning tech-
niques (RLVT08; BRLV12). The SDA knowledge model (Ria07; BRLV12) has been
introduced in section 2.8 as a model to represent medical procedural knowledge which is
similar to CAs with some improvements. Firstly, the presence of states for the different
stages of a certain disease or disorder lets the SDA model to depict several treatments
in an integrated diagram allowing the representation of long term procedures. Another
improvement is that it can deal with multiple entry points corresponding to the states
that represent the different initial patient conditions and, therefore, not only to in-
tegrate the treatment of all these conditions in a single diagram, but also to address
each patient directly to the corresponding part of the treatment. SDA diagrams also
extend the expressiveness of CAs using multi-term decisions. In CAs, decisions are
always (SfMDM92) yes-no questions but, in the SDA model, decisions may have more
than two branches with different decision terms in each one of them. In addition, each
decision may have alternative otherwise branches which are followed by the patients
that fulfill none of the other branches. This results in a more readable sequence of
decisions and also in a more compact representation of treatments. Finally, the rigidity
and strictness of CAs, previously referred to as their main criticism, is reduced in the
SDA model which increases the flexibility of CAs by dealing with non-determinism.
Non-determinism is frequent in medicine and it allows the participation of health care
professionals when there is not proven evidence on a unique or better treatment.
The current approach to induce SDA diagrams (BRLV12) can be summarized in 4
stages:
1. Detecting states: The states of the SDA diagram are detected with a method
based on a syntactic similarity function between states.
2. Detecting actions: The different sorts of actions of the SDA diagram are detected
with a method based on a syntactic similarity function between actions.
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3. Determining evolutions: The sequences of decisions corresponding to the evolu-
tion from each state to each other possible state are determined using induction
of decision trees.
4. Determining actions: For each evolution between states obtained in the previ-
ous stage, the sequences of decisions corresponding to each possible action are
determined using induction of decision trees.
5. Integrating: The different states and sequences of decisions and actions are inte-
grated in the final SDA diagram.
Notice that this approach does not consider any kind of background knowledge of the
domain to guarantee medically correct results and it uses a non-incremental algorithm.
However, it achieved successful results in (RLVT08) where it was applied to hyperten-
sion, cervical cancer, colorectal cancer and chronic obstructive pulmonary disease. Two
sorts of test were performed: one oriented to verify if the algorithm was able to recover
a predefined SDA diagram from a representative sample of patients treated according
to the indications of that SDA diagram, and another one centered on the generation of
a SDA diagram from the medical actions recorded in a certain hospital. In (BRLV12)
the methodology was tested on the medical domain of hypertension with the purpose
of studying the differences between the health care procedures of a hospital database
and some predefined official CAs.
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In the automatic generation of medical decision structures, there is a relevant amount of
background knowledge which is not explicitly included in the input data. The exclusive
use of mathematical or statistical measures to induce structures that summarize the
steps registered in a hospital database has been proved to be not successful because
it leads to results which are not medically correct or which health care professionals
may not be familiar with (LVRC07; LVRB12). In a complex and sensitive domain
like medicine, using measures that consider all the background knowledge involved is
essential in order to assure medically correct results. This kind of knowledge consists
of medical criteria and constraints that health care experts take into account during
their medical activities. It can be provided by the health care experts themselves or
it can be extracted from medical knowledge sources. This background knowledge is of
different kinds and each one is formalized with a different knowledge structure.
As we stated in the introduction, one of the objectives of this thesis is to build
a repository of background knowledge corresponding to the diseases of Hyperten-
sion (HT) (ohhs03), Diabetes Mellitus (DM) (CL08) and the comorbidity of both
diseases (MSRS07). By means of a knowledge engineering process we have obtained
this repository of knowledge structures.
3.1 Formalization of medical background knowledge
The automatic induction of medical decision structures involves several kinds of knowl-
edge. From all the possible kinds of background knowledge in health care we will focus
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on the constraints that affect the desired set of possible health care states, the pref-
erences about the terminology used in health care states, the semantic relationships
between decision terms, the order in which some questions should be done and the
similarity between different medical actions. Each of these kinds of knowledge must
be represented with a certain background knowledge structure. Here we present these
different kinds of medical knowledge needed and the knowledge structures that are used
to formalize them.
3.1.1 Constraints on health care states
The treatment of a pathology usually deals with the so-called health care states which
are used to organize the different patients according to their conditions.
Definition 3.1.1 (Health care state) A health care state is a set of patient conditions,
situations, or statuses which involve a significant group of patients that deserve a par-
ticular course of action which is totally or partially different from the actions followed
when the patient is in another health care state and which has some interest for the
health care professional.
A health care state must have a medical sense that depends on both the coherence
of its description and the coherence of the health care state itself with respect to the
rest of health care states. That is to say that given a description of a health care state
it must not be redundant or medically incorrect, and given the whole set of health care
states they must be defined at the same level of abstraction of the medical terminology.
This medical sense of a health care state is a kind of medical knowledge which consists
in constraints in the description of health care states.
In the SDA model, health care states are represented as SDA states which are
subsets of SDA state terms (see section 2.8). The set of state terms within a SDA state
define its description, so the constraints related to the description of the health care
states are constraints between state terms, and they are called state term constraints.
Definition 3.1.2 (State term constraint) Being S a set of state terms, a state term
constraint c is an unordered pair {si, sj} with si, sj ∈ S, meaning that if a SDA diagram
includes a state Si that contains the term si, then sj will not be allowed in any of the
states of the SDA diagram (including Si).
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We represent these constraints by means of a state constraints graph.
Definition 3.1.3 (State constraints graph) A state constraints graph is defined as an
undirected graph GS = (S,C) (see section 2.5.1.1) where S is a set of state terms and
C is a set of state term constraints between state terms in S.
Table 3.1 contains a state constraints graph for the treatment of hypertension. For
example, if a state is included in the SDA diagram such that it contains the term
HEART RISK, then none of the states of the SDA diagram will contain the term < 40
YEARS OLD.
Table 3.1: State constraints graph for HT (a part of)
HEART NOT < 40 40 .. 65 65 .. 75 > 75
RISK HEART YEARS YEARS YEARS YEARS
RISK OLD OLD OLD OLD
HEART RISK X X X X
NOT HEART RISK X X X X
< 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD
> 75 YEARS OLD
3.1.2 Preference between state terms
Considering all the possible health care states that can be used to classify patients
during the treatment of a pathology, a health care professional may have preference for
some of them depending on the context. For example, for the treatment of hypertension
a general practitioner could prefer organizing the patients according to the stages of
the disease while a hospital administrative assistant could be more interested in the
units or departments where the patients are being treated. This kind of knowledge is
a preference order between the possible health care states.
Therefore a SDA diagram (see section 2.8) is constructed for a concrete purpose
(e.g., visualizing the different stages of a treatment, representing actions in emergence
situations, supporting the selection of drugs, prevention, etc.). The construction of a
SDA diagram is associated to an intentionality which indicates the context in which the
SDA diagram will be used. The set of SDA states is used to express this intentionality,
so a health care professional may have preference for some state terms depending on
the different states that he wants in the final diagram. We represent these preferences
by means of a state terms partial order.
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Definition 3.1.4 (State terms partial order) A state terms partial order ≤S is defined
as a Layered Partial Order (LPO) over the set of state terms S (see section 2.5.1.2)
such that, given two terms si, sj ∈ S, si ≤S sj means that si is preferred than sj.
If si ≤S sj , the state term si will be more likely to appear in some of the states of
the SDA diagram than sj as it is preferred by the health care professional.
Table 3.2 contains a state terms partial order for the treatment of hypertension.
States having FOLLOWING HEALTHY HABITS or TAKING 3 DRUGS will be more
likely to be selected for the SDA diagram than those having CONTROLLED DBP or
65 .. 75 YEARS OLD.
Table 3.2: State terms partial order for HT (a part of)
Priority State term










3 < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD




During an encounter with a patient, the physician determines some evidences in order
to make some actions for the treatment of this patient. These evidences are obtained
by asking questions, by consultations to the records or by performing health care tests.
The sequence of gathering evidences and making a final action is called therapeutic
sequence.
Definition 3.1.5 (Therapeutic sequence) A therapeutic sequence is a tree-like sequence
of evidences gathered by questions, consultations or tests that discriminate the different
sorts of treatment to be followed by the patients evolving from a certain health care state
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to any other states. A therapeutic sequence may have no questions but it must have at
least one treatment.
When the physician decides to ask a question to the patient, to consult his records
or to perform a health care test he expects several possible outcomes (evidences). For
example, a physician may want to determine the blood pressure of the patient. He
knows that the expected outcomes when determining the blood pressure are low blood
pressure, blood pressure at goal or high blood pressure. This is a kind of medical
knowledge that relates these outcomes because they are the different alternative values
of a same question, in this case, the blood pressure of the patient.
In the SDA model (see section 2.8), the separation of patients according to their
medical evidences is made with SDA decisions. Decisions allow the integration of all
the variability that a treatment may have by means of conditions on several decision
terms. These decision terms are the different expected outcomes in a certain decision.
When several decision terms can be the expected outcomes of a same decision, we say
that they are semantically related. Following the previous example, we could have the
decision terms Low BP , BP at goal and High BP which are expected outcomes when
determining the blood pressure of the patient. These decision terms are semantically
related because they represent a certain level of blood pressure. In a SDA diagram we
can place a decision providing these three alternatives according to the blood pressure
level of the patient. The possible alternatives when making a decision do not always
have to be disjoint. In order to represent these semantic relationships as background
knowledge, we use a semantic decisions hypergraph.
Definition 3.1.6 (Semantic decisions hypergraph) A semantic decisions hypergraph
is defined as a hypergraph HD = (D,SD) (see section 2.5.1.1) where D is the set of
decision terms and SD is a set of hyperedges sd such that if d1, d2 ∈ sd then d1 and d2
are semantically related.
The semantic decisions hypergraph defines all the possible semantic decisions.
Definition 3.1.7 (Semantic decision) A hyperedge sd ∈ SD of a semantic decisions
hypergraph HD is called a semantic decision.
All the decisions in a SDA diagram must represent semantic decisions (i.e., their
decision terms must be semantically related).
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Table 3.3 contains part of a semantic decisions hypergraph for the treatment of
hypertension. For each semantic decision it specifies a name and the set of decision
terms that it has. For example, the semantic decision called BMI is composed by the
decision terms NORMAL BMI, OVERWEIGHT BMI and OBESE BMI. Therefore,
considering these semantic decisions, the SDA diagram can include a decision with
NORMAL BMI, OVERWEIGHT BMI and OBESE BMI as alternatives, but a decision
with terms of different semantic decisions will not be allowed (e.g., NORMAL BMI and
TAKING MEDICATION CORRECTLY ).
Table 3.3: Semantic decisions hypergraph for HT (a part of)




Cardiac auscultation NORMAL CARDIAC AUSCULTATION
NOT NORMAL CARDIAC AUSCULTATION
Correct medication TAKING MEDICATION CORRECTLY
NOT TAKING MEDICATION CORRECTLY
3.1.4 Order of decision sequences
The order in which the different needed evidences are gathered during an encounter in
order to decide the treatment for a patient depends on several criteria that the physician
may consider (LVR12). An important criterion is the utility of an evidence to decide
the course of treatment of the patient but the physician may also consider the order
specified in a clinical guideline, the risk on the health of the patient of obtaining this
evidence, the uncomfortability caused to the patient or his own experience. Depending
on one or more of these criteria, the physician will gather evidences in a certain order.
If these evidences are gathered in a different order, the sequence followed may be not
comprehensible by the physician. This kind of medical knowledge is an order between
the evidences.
In the SDA model (see section 2.8) we use decisions to separate patients according
to their evidences. The sequences of decisions must follow an order which is compre-
hensible for the health care expert. All the decisions in a SDA diagram must always
be semantic decisions (see section 3.1.3), so the background knowledge about the or-
der of decisions is represented with a partial order over the set of semantic decisions.
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Concretely we use a layered partial order defined by the health care expert according
to his own criteria called decisions partial order.
Definition 3.1.8 (Decisions partial order) A decisions partial order ≤D is defined as a
Layered Partial Order (LPO) over the set of semantic decisions SD (see section 2.5.1.2
and 3.1.3) such that, given the semantic decisions sdi, sdj ∈ SD, sdi ≤D sdj means
that, according to the criteria of the health care expert, sdi should be asked before sj.
If sdi ≤D sdj , the SDA decision representing the semantic decision sdi will be more
likely to appear before sdj in a therapeutic sequence.
Table 3.4 contains a decisions partial order for the treatment of hypertension. Ac-
cording to this partial order, the decisions about DBP or SBP will be more likely appear
in the SDA diagram before asking for the age, the sex or the heart rate.










3.1.5 Similarity between actions
The actions that can be made by a physician are of different kinds like pharmacologi-
cal, educational, analytical, ECGs, radiological, consultation, verification, procedural,
etc. For example, prescribing Prinivil 5mg or prescribing Enalapril Merck 2 mg is
a pharmacological action. Although being syntactically different, two actions do not
have to be semantically different. Depending on their medical meaning, two different
actions can be similar or even equivalent. Following the previous example, these two
drug prescriptions are syntactically different. However, both drugs are semantically
similar because they are angiotensin converting enzyme (ACE) inhibitors which are
used to prevent the blood pressure raising produced by the ACE. The physicians may
49
3. MEDICAL BACKGROUND KNOWLEDGE
use different drugs interchangeably if they are similar enough. The knowledge about
the similarities between actions consists in their semantical characteristics, the dosage
equivalences, etc.
In the SDA model (see section 2.8) the different actions are represented with action
terms. In the SDA diagrams, these terms are grouped in SDA actions. When inducing
SDA diagrams, the knowledge about the similarities between actions terms and SDA
actions is essential to solve problems like calculating the homogeneity of treatments
within a set of encounters or when deciding the most appropriate SDA actions after
a sequence of SDA decisions in order to obtain correct therapeutic sequences. We
represent this knowledge using an extended concept hierarchy (see section 2.5.1.3) that
contains the semantics of the action terms needed to calculate their similarities.
In the case of action terms representing pharmacological actions, the WHO has
established a system to classify drugs called Anatomical Therapeutic Chemical (ATC)
Classification System (fDSM). This classification system divides drugs into different
groups according to the organ or system on which they act and/or to their therapeutic
and chemical characteristics. It consists of five hierarchical levels: anatomical group,
therapeutic group, pharmacological subgroup, chemical group, and active principle. So,
for instance, the active principle Enalapril (ATC code C09AA02) belongs to the chem-
ical group ACE inhibitors, plain (C09AA), which is in the pharmacological subgroup
C09A with the same name. This subgroup is in the therapeutic group Agents acting
on the renin-angiotensin system (C09) which belongs to the anatomical group Cardio-
vascular system (C). We have made three modifications to the ATC hierarchy in order
to use it as background knowledge:
1. We have added a new level below active principle that contains concrete action
terms. So for example, Enalapril Merck 20mg 80 tablets EFG is an action term
that it is a successor of the active principle Enalapril.
2. Some drugs are compound having more than one active principle. For example,
Eneas 10/20mg 30 tablets contains 10mg of Enalapril and 20mg of Nitrendipine.
In the ATC system, these drugs are located in separate groups. However, in
our hierarchy they have been introduced as successors of all their active princi-
ples. Therefore, Eneas 10/20mg 30 tablets is successor of both active principles
Enalapril and Nitrendipine.
50
3.1 Formalization of medical background knowledge
3. In order to compare prescriptions of different drugs it is essential to know what
is the minimum dose of their respective active principle 1, so we have included
this information in the hierarchy.
The resulting extended concept hierarchy is called pharmacological actions hierarchy.
Definition 3.1.9 (Pharmacological actions hierarchy) The pharmacological actions hi-
erarchy is defined as a regular concept hierarchy HpA = (pC ∪ pA,≤,min) (see sec-
tion 2.5.1.3) where pC is the set of concepts in the ATC hierarchy (except the concepts
involving compound drugs) and pA ⊂ A is the subset of action terms representing drug
prescriptions. The hierarchy reflects with ≤ the subsumption relations in the ATC hi-
erarchy between the concepts in pC. Considering pC ′ ⊂ pC the concepts representing
active principles and given an action term a ∈ pA, we have c ≤ a for each active prin-
ciple c ∈ pC ′ that corresponds to the drug prescription a. The hierarchy is extended
with a function min : pC ′ → Q that matches each active principle with its minimum
dose (generally in milligrams).
Considering the level names of the ATC, the pharmacological actions hierarchy has
a schema level order anatomical group < therapeutic group < pharmacological subgroup
< chemical group < active principle < action term.
As far as non-pharmacological action terms are concerned, we studied the incorpo-
ration of the actions found in the icd9cm and icpc systems, but these actions were
not specific enough to represent the actions terms found in the databases used in this
work. So we created a hierarchical classification for this kind of action terms with the
non-pharmacological actions hierarchy.
Definition 3.1.10 (Non-pharmacological actions hierarchy) The non-pharmacological
actions hierarchy is defined as a not necessarily regular concept hierarchy HnA = (nC∪
nA,≤) (see section 2.5.1.3) where nC is a set of non-pharmacological concepts and
nA ⊂ A is the subset of action terms not representing drug prescriptions. The hierarchy
reflects with ≤ the subsumption relations between the concepts in nC and nA. The
actions terms are located in the lowest levels of the hierarchy (i.e., ∀a ∈ nA, 6 ∃c ∈ nC
— a ≤ c).
Both hierarchies of pharmacological and non-pharmacological concepts and terms
are unified in the action term hierarchy.
1The minimum dose for each active principle is published in CPGs (SAG02; SAG03)
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Definition 3.1.11 (Action term hierarchy) The action term hierarchy is defined as a
concept hierarchy HA = (C ∪ A,≤,min) (see section 2.5.1.3) where C = pC ∪ nC ∪
{Action, Pharmacological,Non − pharmacological} and A = pA ∪ nA (see defini-
tions 3.1.9 and 3.1.10). This hierarchy contains the sum of all the relationships ≤ in
HpA and HnA. Moreover, it has the following relationships:
• Action ≤ Pharmacological
• Action ≤ Non− pharmacological
• ∀c ∈ pC in level 1 of HpA Pharmacological ≤ c
• ∀c ∈ nC in level 1 of HnA Non− pharmacological ≤ c
The hierarchy also contains the function min : pC ′ → Q described in definition 3.1.9.
Table 3.5 contains a part of a pharmacological actions hierarchy used for the treat-
ment of hypertension, where the elements in the lower level (in italics) are action terms
in pA (e.g., APROVEL 150MG 28 TABLETS ) and the rest of elements are concepts
in cA (e.g., C CARDIOVASCULAR SYSTEM). The hierarchy also contains the min
function defined over the set of active principles (column on the right). Notice that
some action terms have a ’*’ mark meaning that they are compound drugs. These
drugs appear more than once in the hierarchy. Concretely they are below each one of
their active principles. For example, COZAAR PLUS 50/12.5 28 COATED TABLETS
is a C09CA01 losartan and a C03AA03 hydrochlorothiazide.
The action term hierarchy presented in the current section establishes some se-
mantic relationships between the different pharmacological and non-pharmacological
terms which are necessary to determine the similarity between different treatments. In
the next sections we explain how this concept hierarchy can be used to calculate the
similarity between two action terms and between two SDA actions, respectively.
3.1.5.1 Calculating the similarity between action terms
The similarity s(ax, ay) between two action terms ax, ay ∈ A is calculated depending
on their position in the action term hierarchy HA. There are five cases:
Case 1: If we compare two action terms ax and ay that are exactly the same (ax = ay),
then their similarity is 1 (i.e., s(ax, ay) = 1).
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C03A LOW-CEILING DIURETICS, THIAZIDES
C03AA Thiazides, plain
C03AA03 hydrochlorothiazide 12.5
COZAAR PLUS 50/12.5 28 COATED TABLETS *
CO-DIOVAN 80MG/12.5MG 28 FILM COATED TABLETS *
PARAPRES PLUS 16/12.5MG 28 TABLETS *
MICARDIS PLUS 80MG/25MG 28 TABLETS *
COAPROVEL 300/25MG 28 COATED TABLETS *
IXIA PLUS 20/12.5MG 28 FILM COATED TABLETS *
HIDROSALURETIL 50MG 20 TABLETS
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN
C09CA Angiotensin II antagonists, plain
C09CA01 losartan 25
COZAAR PLUS 50/12.5 28 COATED TABLETS *
COZAAR 50MG 28 COATED TABLETS
COZAAR 12.5MG 7 FILM COATED TABLETS
C09CA02 eprosartan 600
TEVETENS 600MG 28 COATED TABLETS
C09CA03 valsartan 80
CO-DIOVAN 80MG/12.5MG 28 FILM COATED TABLETS *
DIOVAN 160MG 28 COATED TABLETS
C09CA04 irbesartan 75
COAPROVEL 300/25MG 28 COATED TABLETS *
APROVEL 150MG 28 TABLETS
C09CA06 candesartan 8
PARAPRES PLUS 16/12.5MG 28 TABLETS *
ATACAND 16MG 28 TABLETS
C09CA07 telmisartan 20
MICARDIS PLUS 80MG/25MG 28 TABLETS *
C09CA08 olmesartan medoxomil 10
IXIA PLUS 20/12.5MG 28 FILM COATED TABLETS *
IXIA 40MG 28 COATED TABLETS
* Compound drugs
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Case 2: For pharmacological action terms, if we compare the prescription of two drugs
ax and ay that share the same chemical group, their similarity may be affected
by their difference of dose. A first analysis with a dychotomic search using the
database available showed that the proportion of similarity that depends on the
doses is between 0 and 0.3, being 0 when ax and ay show extreme dose differences
(s(ax, ay) = 0.7) and 0.3 when the drugs have equivalent doses (s(ax, ay) = 1).
The similarity between doses of two prescribed drugs is measured considering the
minimum doses of their respective active principles. For each active principle
a in a chemical group, HA contains a minimum dose value which defines the
unitary dose (ud) of all the drugs with a. This is calculated with the function
min. For example, being a the active principle Candesartan its minimum dose
is min(a) = 8 mg, which is the unitary dose of this active principle. A prescrip-
tion of ATACAND 16MG 28 TABLETS has 16mg per tablet, which is twice the
minimum dose, therefore this dose is equal to 2 ud. Sometimes there are prescrip-
tions with doses lower than the minimum dose (e.g., COZAAR 12.5MG 7 FILM
COATED TABLETS represents 0.5 ud of Losartan) which are usually related to
initial treatments. A unitary dose of two drugs of different active principle but of
the same chemical group represents an identical pharmacological treatment. See
for example in figure 3.1 the equivalences of doses between the active principles
Losartan and Valsartan of the same chemical group Angiotensin II antagonists,
plain with the respective minimum doses of 25 mg and 80 mg. Notice that their
minimum doses represent their unitary dose (1 ud) and determine the equivalence
relationship between both active principles.
Figure 3.1: Equivalence relationship of dosage between Losartan and Valsartan for some
example values
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Therefore we can compare doses of drugs of different active principles in a same
chemical group as long as they are measured in ud’s, and calculate a value of
similarity between doses sdose(ax, ay). We first express the doses of ax and ay in
the ud’s of their respective active principles (i.e., a′x = dose(ax)/min(active −
principle(ax)) where dose(ax) is the dose in the action term ax and active −
principle(ax) is the active principle of ax, and equivalently for a
′
y), and then we
calculate the similarity between doses with equation 3.1.
sdose(ax, ay) = e
−‖a′x−a′y‖ (3.1)
The reduction of similarity between ax and ay caused by the difference of doses
is equal to 0.3 · (1 − sdose(ax, ay)), so the similarity between two drugs ax and
ay of the same chemical group is s(ax, ay) = 1 − 0.3 · (1 − sdose(ax, ay)) = 0.7 +
0.3sdose(ax, ay). In figure 3.2 we can observe the variation of sdose(ax, ay) and
s(ax, ay) for differences of dose lower than 4. Notice that, as we stated before,
the similarity between two pharmacological action terms of the same chemical
group is always greater than 0.7.
Figure 3.2: Variation of sdose(ax, ay) and s(ax, ay) when increasing the difference of doses
between ax and ay
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For example, let ax be COZAAR 12.5MG 7 FILM COATED TABLETS and ay
be DIOVAN 160MG 28 COATED TABLETS which correspond to drugs with
active principles Losartan and Valsartan respectively. Then ax has a dose of 0.5
ud because 12.5 mg/25 mg is 0.5. Similarly, ay contains a dose of 2 ud. In this
case, sdose(ax, ay) = e
−‖0.5−2‖ = e1.5 = 0.22 and so the similarity between both
action terms is s(ax, ay) = 0.77.
Case 3: Pharmacological action terms with different chemical groups but equal pharmaco-
logical subgroup are comparable. Two drugs ax and ay in a same pharmacological
subgroup are used to treat the same concrete symptoms and so they can be con-
sidered partially similar. An analysis of cases of this kind with our data concluded
a constant similarity value of 0.5 (i.e., s(ax, ay) = 0.5).
Case 4: Pharmacological action terms with different pharmacological subgroup but equal
therapeutic group may be comparable depending on each concrete case. Accord-
ing to the ATC classification some therapeutic groups cover drugs with similar
properties and others which are completely different. We analyzed the therapeu-
tic groups involved in the treatments of hypertension and diabetes mellitus and
we concluded the similarity values in table 3.6 for each therapeutic group when
two drugs belong to different pharmacological subgroups.
Table 3.6: Similarity values for the drugs in each therapeutic group of the treatments of
hypertension and diabetes mellitus
Therapeutic group Similarity value
C02 ANTIHYPERTENSIVES 0.0
C03 DIURETICS 0.3
C07 BETA BLOCKING AGENTS 0.3
C08 CALCIUM CHANNEL BLOCKERS 0.0
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 0.5
C02 ANTIHYPERTENSIVES 0
A10 DRUGS USED IN DIABETES 0
Case 5: Finally, any two action terms ax and ay that do not satisfy any of the previ-
ous cases are not medically comparable and therefore, their similarity is 0 (i.e.,
s(ax, ay) = 0).
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3.1.5.2 Calculating the similarity between SDA actions
The similarity between two SDA actions Ax = {ax1, ax2, ..., axm} and Ay = {ay1, ay2, ...,
ayn} according to the action term hierarchy HA depends on the similarity between their
respective action terms and is calculated with the function s(Ax, Ay). If s(Ax, Ay) = 0,
Ax and Ay are completely different actions, and if s(Ax, Ay) = 1, Ax and Ay are
medically equivalent and they can be used interchangeably. To calculate the value of
this function we follow three steps:
Step 1: Expanding compound drugs
Step 2: Pairing action terms
Step 3: Calculating the similarity between actions
The first step consists in replacing all the action terms representing prescriptions
of compound drugs in the compared actions by action terms with prescriptions of all
the drugs that are present in the compound drug, with their corresponding doses.
For example, if MICARDIS PLUS 80MG/25MG 28 TABLETS is found in one of the
actions that are being compared, this action term is replaced by TELMISARTAN 80MG
28 TABLETS and HYDROCHLOROTHIAZIDE 25MG 28 TABLETS.
Once all the prescriptions of compound drugs in Ax and Ay have been replaced by
the prescriptions of their corresponding single drugs, the action terms in Ax are paired
with the action terms in Ay. The aim is to find semantically equivalent action terms
from both interventions. Formally, we want to create a set P of pairs (ap, aq) with
ap ∈ Ax and aq ∈ Ay such that (1) ∀a ∈ Ax,∃!(a, aq) ∈ P , (2) ∀a ∈ Ay, ∃!(ap, a) ∈ P ,
and (3) s(ap, aq) > 0. All the action terms in a SDA action are relevant an so, in order
to reach a successful pairing, Ax and Ay must contain the same number of action terms
(m = n). At this point, if two actions Ax and Ay have a different number of action
terms we can conclude that s(Ax, Ay) = 0. Suppose that Ax and Ay have both n action
terms, then the pairing is performed as follows. For the first action term ax1 in Ax we
calculate its similarity to each one of the action terms in Ay. If ∀ayi ∈ Ay, s(ax1, ayi) = 0
we cannot pair ax1 with an equivalent action term in Ay, therefore we conclude that
s(Ax, Ay) = 0. Otherwise, we create a pair (ax1, ayj) where ayj is the most similar
action term to ax1 in Ay (i.e., ayj = arg maxayi∈Ay s(ax1, ayi)). Then, after discarding
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the actions that have already been paired, we repeat this procedure until n pairs are
created.
If the pairing has succeeded then s(Ax, Ay) > 0. The final value of similarity is








We use this similarity function to determine whether two SDA actions are equivalent
or not by specifying a similarity threshold δ between 0 and 1. If s(Ax, Ay) ≥ δ then Ax
and Ay are considered equivalent SDA actions.
Figure 3.3 depicts an example of applying the previous procedure to determine the
similarity between two actions Ax and Ay. These actions are completely equivalent
because they both contain a compound drug with 2 ud of hydrochlorothiazide (25mg)
and 4 ud of active principle of Angiotensin II antagonists, plain (300mg and 80mg
of Irbesartan and Telmisartan, respectively), and also the non-pharmacological action
Education.
In figure 3.4 there is a less obvious example of completely equivalent actions. These
actions contain a different compound drug and a different single drug. Once expanded
we observe that they actually have the same active principles and dosages.
The calculation of similarities between actions has lots of applications to solve
other medical problems out of the scope of this thesis. One of these applications is
the reduction of treatment costs by detecting dominant alternatives which is presented
in (LVRC12b).
3.1.5.3 Calculating the homogeneity of a set of treatments
The similarity between actions can be applied to calculate the homogeneity of the treat-
ments within a multiset of actions A′ = {A1, A2, ...} of length n. With the previous
similarity function we calculate similarities between each pair of actions. The homo-
geneity h of the treatments in A′ according to the action term hierarchy HA can be
defined as in equation 3.3.
58
3.1 Formalization of medical background knowledge
Figure 3.3: Example 1 of determining the similarity between two SDA actions
Figure 3.4: Example 2 of determining the similarity between two SDA actions
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We can also calculate the homogeneity with the alternative equation 3.4. In this
equation the homogeneity of the set of treatments is equal to the lowest similarity
between two of them. This guarantees a minimum similarity between all the treatments,





3.2 Summary of background knowledge
This chapter has introduced the medical background knowledge needed to support
the automatic generation of SDA diagrams. We have presented the different kinds of
background knowledge needed, as well as their formalization as knowledge structures.
A summary of all the background knowledge required is shown in the following list.
a) Background knowledge related to states:
• For the constraints on health care states: a state constraints graph GS containing
state term constraints.
• For preference between state terms: a state terms partial order ≤S .
b) Background knowledge related to decisions:
• For semantic decisions: a semantic decisions hypergraph HD containing the pos-
sible semantic decisions.
• For order of decision sequences: a decisions partial order ≤D.
c) Background knowledge related to actions:
• For similarity between actions: an action terms hierarchy HA that is used to
calculate the values of the similarity function s and the homogeneity function h.
The formalization of this background knowledge has been included in the pa-
per (LVRC12a).
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3.3 Background knowledge formalization for hypertension,
diabetes mellitus and their comorbidity
This section contains the structures created for the diseases of hypertension, diabetes
mellitus, and the comorbidity of both diseases to represent the required background
knowledge introduced in this chapter: the state constraints graph GS with the con-
straints on state terms, the state terms partial order ≤S that specifies the preference
between state terms, the semantic decisions hypergraph HD, the decisions partial or-
der ≤D over the different semantic decisions and the action terms hierarchy HA which
will be used to calculate the values of the similarity function s and the homogeneity
function h.
This knowledge repository has been created together with health care profession-
als from the SAGESSA Health-Care Group (SAG) using their own preferences and
experience, and also the evidence-based knowledge contained in other resources like
CPGs (SAG02; SAG03) or the Anatomical Therapeutic Chemical (ATC) Classification
System (fDSM).
3.3.1 Hypertension
3.3.1.1 Constraints on health care states
Table 3.7 contains the state constraints graph for hypertension. In order to reduce the
size of the table, the terms that have no constraints have been replaced by ’...’. The
patient is considered to have heart risk depending on his age, sex and the presence
of LVH. Other risk factors related to smoking habits or hypercholesterolemia have
been ignored because here we only consider pure hypertensive patients with no other
pathologies or complications. Therefore, if we use heart risk to describe the states of
the SDA diagram we do not want to use the different signs that may imply high risk
because it could cause redundancy within a state and different levels of abstraction in
the terminology used by the whole set of states.
3.3.1.2 Preference between state terms
The state terms partial order for hypertension is shown in table 3.8. The health care
professionals decided to give more priority to the state terms regarding the situation
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Table 3.7: State constraints graph for HT
HEART NOT < 40 40 .. 65 65 .. 75 > 75 FEMALE MALE LVH NO ...
RISK HEART YEARS YEARS YEARS YEARS LVH
RISK OLD OLD OLD OLD
H. RISK X X X X X X X X
NOT H. RISK X X X X X X X X
< 40 Y. OLD
40 .. 65 Y. OLD
65 .. 75 Y. OLD






of the patient within the treatment of hypertension (e.g., FOLLOWING HEALTHY
HABITS, TAKING 2 DRUGS) rather than to the control of the disease (e.g., NOT
CONTROLLED DBP, CONTROLLED SBP).
Table 3.8: State terms partial order for HT
Priority State term












3 < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD






3.3 Background knowledge formalization for hypertension, diabetes
mellitus and their comorbidity
3.3.1.3 Semantic decisions
Table 3.9 contains the semantic decisions hypergraph for hypertension. Basically, the
different decision terms have been grouped in semantic decisions according to the evi-
dence they are related to.
Table 3.9: Semantic decisions hypergraph for HT
SD name SD terms
Abdominal exploration NORMAL ABDOMINAL EXPLORATION
NOT NORMAL ABDOMINAL EXPLORATION
Adverse effects ADVERSE EFFECTS
NOT ADVERSE EFFECTS
Age < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD






Cardiac auscultation NORMAL CARDIAC AUSCULTATION
NOT NORMAL CARDIAC AUSCULTATION
Correct medication TAKING MEDICATION CORRECTLY













Healthy habits FOLLOWING HEALTHY HABITS
NOT FOLLOWING HEALTHY HABITS
Heart rate LOW HEART RATE
NORMAL HEART RATE
HIGH HEART RATE




Continued on next page
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Table 3.9 – continued from previous page
SD name SD terms








Pulmonary auscultation NORMAL PULMONARY AUSCULTATION





Tibial oscillometry LOW TIBIAL OSCILLOMETRY
HIGH TIBIAL OSCILLOMETRY
3.3.1.4 Order of decision sequences
Table 3.10 shows the decisions partial order for hypertension. The semantic decisions
of priorities 1 and 2 are used to decide on what kind of treatment is needed. The third
level of priority contains the semantic decision Heart rate which can be used to discard
certain types of drugs, and finally, the rest of terms are used to refine the treatment.


















Continued on next page
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3.3.1.5 Similarity between actions
The action hierarchy that contains the pharmacological and non-pharmacological ac-
tions for the treatment of hypertension is shown in table 3.11.






C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02CA Alpha-adrenoreceptor antagonists
C02CA04 doxazosin 1
CARDURAN 4MG 28 TABLETS
...
C03 DIURETICS
C03A LOW-CEILING DIURETICS, THIAZIDES
C03AA Thiazides, plain
C03AA03 hydrochlorothiazide 12.5
COZAAR PLUS 50/12.5 28 COATED TABLETS *
CO-DIOVAN 80MG/12.5MG 28 FILM COATED TABLETS *
PARAPRES PLUS 16/12.5MG 28 TABLETS *
MICARDIS PLUS 80MG/25MG 28 TABLETS *
COAPROVEL 300/25MG 28 COATED TABLETS *
IXIA PLUS 20/12.5MG 28 FILM COATED TABLETS *
AMERIDE 5/50MG 60 TABLETS *
ENALAPRIL/HIDROCL BAYVIT 20/12.5MG 28 TABLETS *
ZESTORETIC 20/12.5MG 28 TABLETS *
HIDROSALURETIL 50MG 20 TABLETS
EMCORETIC 10 MG/25 MG 56 COATED TABLETS *
...
C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES
C03BA Sulfonamides, plain
C03BA04 chlortalidone 12.5
Continued on next page
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Table 3.11 – continued from previous page
min (mg)
BLOKIUM-DIU 28 TABLETS *
HIGROTONA 50MG 30 TABLETS
...
C03BA11 indapamide 1.25





FUROSEMIDA CINFA 40MG 30 TABLETS EFG
...
C03CA04 torasemide 2.5





ALDACTONE 25 MG 20 FILM COATED TABLETS
...
C03DB Other potassium-sparing agents
C03DB01 amiloride 2.5
AMERIDE 5/50MG 60 TABLETS *
...
C07 BETA BLOCKING AGENTS
C07A BETA BLOCKING AGENTS
C07AA Beta blocking agents, non-selective
C07AA05 propranolol 40
SUMIAL 10MG 50 TABLETS
...
C07AB Beta blocking agents, selective
C07AB02 metoprolol 50
BELOKEN 100MG 40 TABLETS
LOGIMAX 5/50MG 30 TABLETS *
...
C07AB03 atenolol 25
BLOKIUM-DIU 28 TABLETS *
ATENOLOL ALTER 50MG 60 TABLETS EFG
...
C07AB07 bisoprolol 2.5
EMCONCOR 5MG 30 COATED TABLETS
EMCORETIC 10 MG/25 MG 56 COATED TABLETS *
...
C07AB12 nebivolol 2.5
LOBIVON 5MG 28 TABLETS
...
C07AG Alpha and beta blocking agents
C07AG02 carvedilol 12.5
COROPRES 25MG 28 TABLETS
...
Continued on next page
66
3.3 Background knowledge formalization for hypertension, diabetes
mellitus and their comorbidity
Table 3.11 – continued from previous page
min (mg)
C08 CALCIUM CHANNEL BLOCKERS
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
C08CA Dihydropyridine derivatives
C08CA01 amlodipine 2.5
ASTUDAL 10MG 30 TABLETS
EXFORGE 5MG/160MG 28 FILM COATED TABLETS *
...
C08CA02 felodipine 2.5
PLENDIL 5MG 30 TABLETS
LOGIMAX 5/50MG 30 TABLETS *
...
C08CA05 nifedipine 30
ADALAT OROS 30MG 28 TABLETS
...
C08CA08 nitrendipine 10
BAYPRESOL 20MG 30 TABLETS
...
C08CA12 barnidipine 10
BARNIX 20MG 56 CAPSULES
...
C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08DA Phenylalkylamine derivatives
C08DA01 verapamil 120




UNI MASDIL 200 MG 28 CAPSULES
...
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09A ACE INHIBITORS, PLAIN
C09AA ACE inhibitors, plain
C09AA01 captopril 25
CAPTOPRIL STADA 25MG 60 TABLETS EFG
...
C09AA02 enalapril 5
ENALAPRIL MERCK 20MG 28 TABLETS
ENALAPRIL/HIDROCL BAYVIT 20/12.5MG 28 TABLETS *
...
C09AA03 lisinopril 5
LISINOPRIL MYLAN 20 MG 28 TABLETS
ZESTORETIC 20/12.5MG 28 TABLETS *
...
C09AA04 perindopril 2
COVERSYL 4MG 30 TABLETS
...
C09AA05 ramipril 1.25
ACOVIL 5MG 28 TABLETS
...
Continued on next page
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Table 3.11 – continued from previous page
min (mg)
C09AA06 quinapril 5
ECTREN 20MG 28 COATED TABLETS
...
C09AA16 imidapril 2.5
HIPERTENE 10MG 28 TABLETS
...
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN
C09CA Angiotensin II antagonists, plain
C09CA01 losartan 25
COZAAR PLUS 50/12.5 28 COATED TABLETS *
COZAAR 50MG 28 COATED TABLETS
...
C09CA02 eprosartan 600
TEVETENS 600MG 28 COATED TABLETS
...
C09CA03 valsartan 80
CO-DIOVAN 80MG/12.5MG 28 FILM COATED TABLETS *
EXFORGE 5MG/160MG 28 FILM COATED TABLETS *
DIOVAN 160MG 28 COATED TABLETS
...
C09CA04 irbesartan 75
COAPROVEL 300/25MG 28 COATED TABLETS *
APROVEL 150MG 28 TABLETS
...
C09CA06 candesartan 8
PARAPRES PLUS 16/12.5MG 28 TABLETS *
ATACAND 16MG 28 TABLETS
...
C09CA07 telmisartan 20
MICARDIS PLUS 80MG/25MG 28 TABLETS *
...
C09CA08 olmesartan medoxomil 10
IXIA PLUS 20/12.5MG 28 FILM COATED TABLETS *
IXIA 40MG 28 COATED TABLETS
...
C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09XA Renin-inhibitors
C09XA02 aliskiren 150











Continued on next page
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3.3.2.1 Constraints on health care states
No constraints on health care states have been required by health care professionals in
the case of diabetes mellitus.
3.3.2.2 Preference between state terms
The state terms partial order for diabetes is shown in table 3.12. In this case, both
the situation of the patient within the treatment (e.g., FOLLOWING HEALTHY
HABITS, TAKING INSULINS) and the control of the disease in terms of glucose
(NORMAL/HIGH GLUCOSE) are of major interest for health care professionals and
so, they are given priority 1. It would be more medically logical to consider the level
of HbAlC before the level of glucose as an indicator of the control of the disease, but
the health care professionals argued that, due to the low rate of encounters in their
databases that contain the level of HbAlC, it would be more suitable to use the level of
glucose. This is a clear example of using background knowledge not only to represent
theorical medical knowledge but also to express concrete preferences of a certain health
care center.
3.3.2.3 Semantic decisions
Table 3.13 contains the semantic decisions hypergraph for diabetes where the different
decision terms have been grouped in semantic decisions according to the evidence they
are related to.
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Table 3.12: State terms partial order for DM
Priority State term










Table 3.13: Semantic decisions hypergraph for DM
SD name SD terms
Abdominal exploration NORMAL ABDOMINAL EXPLORATION
NOT NORMAL ABDOMINAL EXPLORATION
Adverse effects ADVERSE EFFECTS
NOT ADVERSE EFFECTS
Age < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD




Cardiac auscultation NORMAL CARDIAC AUSCULTATION
NOT NORMAL CARDIAC AUSCULTATION
Correct medication TAKING MEDICATION CORRECTLY











Healthy habits FOLLOWING HEALTHY HABITS
NOT FOLLOWING HEALTHY HABITS
Heart rate LOW HEART RATE
NORMAL HEART RATE
HIGH HEART RATE
Heart risk HEART RISK
NOT HEART RISK
Continued on next page
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Table 3.13 – continued from previous page
SD name SD terms
LVH LVH
NO LVH










Pulmonary auscultation NORMAL PULMONARY AUSCULTATION
NOT NORMAL PULMONARY AUSCULTATION




3.3.2.4 Order of decision sequences
Table 3.14 shows the decisions partial order for diabetes. The semantic decisions of
priority 1 basically determine the treatment of the patient, while those of priority 2 are
used to refine it.


















Continued on next page
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3.3.2.5 Similarity between actions
The action hierarchy that contains the pharmacological and non-pharmacological ac-
tions for the treatment of diabetes is shown in table 3.15.




A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10A INSULINS AND ANALOGUES
A10AB Insulins and analogues for injection, fast-acting
A10AB01 insulin (human) 100
ACTRAPID INNOLET 100UI/ML
...
A10AB05 insulin aspart 100
NOVORAPID FLEXPEN 100UI/ML
...
A10AC Insulins and analogues for injection, intermediate-acting
A10AC01 insulin (human) 100
INSULATARD NPH FLEXPEN 100UI/ML
...
A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting
A10AD01 insulin (human) 100
MIXTARD 30 INNOLET 100UI/ML
...
A10AD05 insulin aspart 100
NOVOMIX 30 FLEXPEN 100UI/ML
...
A10AE Insulins and analogues for injection, long-acting
A10AE04 insulin glargine 100
LANTUS 100UI/ML OPTISET
...
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BA Biguanides
Continued on next page
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Table 3.15 – continued from previous page
min (mg*)
A10BA02 metformin 850
DIANBEN 850MG 50 TABLETS
...
A10BB Sulfonamides, urea derivatives
A10BB01 glibenclamide 2.5
EUGLUCON 5MG 100 TABLETS
...
A10BB09 gliclazide 40
DIAMICRON 80MG 60 TABLETS
...
A10BB12 glimepiride 1
AMARYL 4MG 120 TABLETS
...
A10BF Alpha glucosidase inhibitors
A10BF01 Acarbose 75




AVANDIA 4MG 28 TABLETS
...
A10BG03 pioglitazone 15
ACTOS 30MG 56 TABLETS
...
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH01 sitagliptin 100

















* UI/ml for A10A INSULINS AND ANALOGUES
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3.3.3 Hypertension + Diabetes mellitus
3.3.3.1 Constraints on health care states
The state constraints graph for hypertension plus diabetes mellitus is the same that
for hypertension (see table 3.7). No constraints were needed for the case of diabetes
mellitus, and no additional constraints were found when combining hypertension with
diabetes mellitus.
3.3.3.2 Preference between state terms
Health care professionals proposed two state terms partial orders in order to generate
to different SDA diagrams for hypertension plus diabetes mellitus that gave different
visions of the treatment. The first one is shown in table 3.16 and it gives more priority
to the terms related to the situation of the patient within the treatment of the dis-
eases (e.g., FOLLOWING HEALTHY HABITS, TAKING OHDS+1 HYPOTENSIVE
DRUG).
Table 3.16: State terms partial order for HT+DM (1)
Priority State term






TAKING 1 HYPOTENSIVE DRUG
TAKING 2 HYPOTENSIVE DRUGS
TAKING OHDS+1 HYPOTENSIVE DRUG
TAKING OHDS+2 HYPOTENSIVE DRUGS





3 < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD





Continued on next page
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Table 3.17 contains the other state terms partial order which gives more priority to
the control of the diseases (e.g., CONTROLLED BP, HIGH GLUCOSE).












TAKING 1 HYPOTENSIVE DRUG
TAKING 2 HYPOTENSIVE DRUGS
TAKING OHDS+1 HYPOTENSIVE DRUG
TAKING OHDS+2 HYPOTENSIVE DRUGS
TAKING OHDS+INSULINS+2 HYPOTENSIVE DRUGS
3 < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD
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3.3.3.3 Semantic decisions
Table 3.18 contains the semantic decisions hypergraph for hypertension plus diabetes
mellitus. Basically, the different decision terms have been grouped in semantic decisions
according to the evidence they are related to.
Table 3.18: Semantic decisions hypergraph for HT+DM
SD name SD terms
Abdominal exploration NORMAL ABDOMINAL EXPLORATION
NOT NORMAL ABDOMINAL EXPLORATION
Adverse effects ADVERSE EFFECTS
NOT ADVERSE EFFECTS
Age < 40 YEARS OLD
40 .. 65 YEARS OLD
65 .. 75 YEARS OLD








Cardiac auscultation NORMAL CARDIAC AUSCULTATION
NOT NORMAL CARDIAC AUSCULTATION
Correct medication TAKING MEDICATION CORRECTLY
















Healthy habits NOT FOLLOWING HEALTHY HABITS
FOLLOWING HEALTHY HABITS
Heart rate LOW HEART RATE
NORMAL HEART RATE
HIGH HEART RATE
Continued on next page
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Table 3.18 – continued from previous page
SD name SD terms









TAKING 1 HYPOTENSIVE DRUG
TAKING 2 HYPOTENSIVE DRUGS
TAKING OHDS+1 HYPOTENSIVE DRUG
TAKING OHDS+2 HYPOTENSIVE DRUGS
TAKING OHDS+INSULINS+2 HYPOTENSIVE DRUGS
Nutrition NUTRITIONAL RISK
NOT NUTRITIONAL RISK




Pulmonary auscultation NORMAL PULMONARY AUSCULTATION
NOT NORMAL PULMONARY AUSCULTATION




Tibial oscillometry LOW TIBIAL OSCILLOMETRY
HIGH TIBIAL OSCILLOMETRY
3.3.3.4 Order of decision sequences
Table 3.19 shows the decisions partial order for the treatment of hypertension and
diabetes mellitus. The semantic decisions of priority 1 are used to decide whether
pharmacological treatment is required or not, or if it must be changed. Those of
priority 2 may determine the type of treatment (e.g., a young patient should be treated
with insulin, an obese patient should be treated with metformin). Finally, the semantic
decisions of priority 3 can be used to decide details as for example the dosage.
Table 3.19: Decisions partial order for HT+DM
Priority SD
1 BP
Continued on next page
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3.3.3.5 Similarity between actions
The action hierarchy that contains the pharmacological and non-pharmacological ac-
tions for the treatment of patients with hypertension and diabetes is shown in table 3.20.




A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10A INSULINS AND ANALOGUES
A10AB Insulins and analogues for injection, fast-acting
A10AB05 insulin aspart 100
NOVORAPID FLEXPEN 100UI/ML
...
Continued on next page
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Table 3.20 – continued from previous page
min (mg**)
A10AC Insulins and analogues for injection, intermediate-acting
A10AC01 insulin (human) 100
INSULATARD NPH FLEXPEN 100UI/ML
...
A10AD Insulins and analogues for injection, intermediate-acting combined with fast-acting
A10AD05 insulin aspart 100
NOVOMIX 30 FLEXPEN 100UI/ML
...
A10AE Insulins and analogues for injection, long-acting
A10AE04 insulin glargine 100
LANTUS 100UI/ML OPTISET
...
A10AE05 insulin detemir 100
LEVEMIR 100U/ML INNOLET
...
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BA Biguanides
A10BA02 metformin 850
DIANBEN 850MG 50 TABLETS
AVANDAMET 2MG/500MG 112 TABLETS *
EUCREAS 50MG/850MG 60 TABLETS *
...
A10BB Sulfonamides, urea derivatives
A10BB01 glibenclamide 2.5
EUGLUCON 5MG 100 TABLETS
...
A10BB09 gliclazide 40
DIAMICRON 80MG 60 TABLETS
...
A10BB12 glimepiride 1
AMARYL 4MG 120 TABLETS
...
A10BF Alpha glucosidase inhibitors
A10BF01 Acarbose 75
GLUMIDA 100MG 100 TABLETS
...
A10BF02 Miglitol 75




AVANDIA 4MG 28 TABLETS
AVANDAMET 2MG/500MG 112 TABLETS *
...
A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
A10BH02 vildagliptin 1
EUCREAS 50MG/850MG 60 TABLETS *
...
A10BX Other blood glucose lowering drugs, excl. insulins
Continued on next page
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Table 3.20 – continued from previous page
min (mg**)
A10BX02 repaglinide 1.5




C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02CA Alpha-adrenoreceptor antagonists
C02CA04 doxazosin 1
CARDURAN 8MG 28 TABLETS
...
C03 DIURETICS
C03A LOW-CEILING DIURETICS, THIAZIDES
C03AA Thiazides, plain
C03AA03 hydrochlorothiazide 12.5
COZAAR PLUS 50/12.5 28 COATED TABLETS *
CO-DIOVAN 160MG/12.5MG 28 FILM COATED TABLETS *
COAPROVEL 300/25MG 28 COATED TABLETS *
AMERIDE 5/50MG 60 TABLETS *
ENALAPRIL/HIDROCL BAYVIT 20/12.5MG 28 TABLETS *
ZESTORETIC 20/12.5MG 28 TABLETS *
HIDROSALURETIL 50MG 20 TABLETS
...
C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES
C03BA Sulfonamides, plain
C03BA04 chlortalidone 12.5
HIGROTONA 50MG 30 TABLETS
...
C03BA11 indapamide 1.25
TERTENSIF 1.5MG 30 COATED TABLETS
...
C03D POTASSIUM-SPARING AGENTS
C03DB Other potassium-sparing agents
C03DB01 amiloride 2.5
AMERIDE 5/50MG 60 TABLETS *
...
C07 BETA BLOCKING AGENTS
C07A BETA BLOCKING AGENTS
C07AB Beta blocking agents, selective
C07AB03 atenolol 25
ATENOLOL ALTER 50MG 60 TABLETS EFG
...
C07AB07 bisoprolol 2.5
EMCONCOR 5MG 30 COATED TABLETS
...
C07AB12 nebivolol 2.5
LOBIVON 5MG 28 TABLETS
...
C08 CALCIUM CHANNEL BLOCKERS
C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Continued on next page
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ASTUDAL 10MG 30 TABLETS
EXFORGE 10MG/160MG 28 FILM COATED TABLETS *
...
C08CA05 nifedipine 30
ADALAT OROS 30MG 28 TABLETS
...
C08CA08 nitrendipine 10
ENEAS 10/20MG 30 TABLETS *
...
C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
C08DA Phenylalkylamine derivatives
C08DA01 verapamil 120
TARKA 180/2MG 28 TABLETS *
...
C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09A ACE INHIBITORS, PLAIN
C09AA ACE inhibitors, plain
C09AA01 captopril 25
CAPTOPRIL STADA 25MG 60 TABLETS EFG
...
C09AA02 enalapril 5
ENALAPRIL MERCK 20MG 28 TABLETS
ENALAPRIL/HIDROCL BAYVIT 20/12.5MG 28 TABLETS *
ENEAS 10/20MG 30 TABLETS *
...
C09AA03 lisinopril 5
LISINOPRIL MYLAN 20 MG 28 TABLETS
ZESTORETIC 20/12.5MG 28 TABLETS *
...
C09AA04 perindopril 2
COVERSYL 4MG 30 TABLETS
...
C09AA06 quinapril 5
ECTREN 20MG 28 COATED TABLETS
C09AA10 trandolapril 0.5
TARKA 180/2MG 28 CAPSULAS *
...
C09C ANGIOTENSIN II ANTAGONISTS, PLAIN
C09CA Angiotensin II antagonists, plain
C09CA01 losartan 25
COZAAR 100MG 28 COATED TABLETS
COZAAR PLUS 50/12.5 28 COATED TABLETS *
...
C09CA03 valsartan 80
DIOVAN 160MG 28 COATED TABLETS
CO-DIOVAN 160MG/12.5MG 28 FILM COATED TABLETS *
EXFORGE 10MG/160MG 28 FILM COATED TABLETS *
Continued on next page
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PARAPRES 32MG 28 TABLETS
...
C09CA08 olmesartan medoxomil 10


















** UI/ml for A10A INSULINS AND ANALOGUES
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4
Incremental generation of SDA
diagrams with background
knowledge
In this section we describe a procedure to generate SDA diagrams (see section 2.8) which
considers all the relevant background knowledge introduced in chapter 3. Moreover, this
procedure works incrementally and therefore, once a SDA diagram is generated for the
first time, it can be updated as soon as new data arrives rather than being generated
from scratch. The general scheme of the methodology presented is summarized in
figure 4.1.
The data used to generate SDA diagrams is extracted from the EOC database which
contains episodes of care, encounters, etc. of patients treated for a certain pathology,
represented with the EOC data model (see section 2.7). This EOC database is created
starting from a hospital database which uses a representation format as for example,
HL7, env13606, OpenEHR, etc. A filtering and preprocessing procedure (which is not
included in the scope of this thesis) is performed over this database in order to obtain
an EOC database. Each time a new encounter is introduced in the hospital database,
it is transformed to the EOC data model in order to generate a new SDA diagram.
The procedure needs some background knowledge in order to guarantee that the
generated SDA diagram is in accordance with the medical knowledge which is not ex-
plicit in the EOC database. In this thesis, this background knowledge is obtained from
the repository described in section 3.3. This repository can be filled with knowledge ex-
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Figure 4.1: Scheme of the methodology to generate SDA diagrams
tracted from medical knowledge resources like CPGs (SAG02; SAG03), the Anatomical
Therapeutic Chemical (ATC) Classification System (fDSM) or other hospital databases,
or from health care professionals representing their preferences, experience, etc. No-
tice that each time that a SDA diagram is generated, the repository of background
knowledge is consulted.
In addition to the patient data in the EOC database and the medical knowledge
in the repository, the procedure may start from a previously generated SDA diagram.
The first time that we generate a SDA diagram we do not have any previous one so it
will be generated only using the EOC database and the background knowledge. The
successive next times that we generate a new SDA diagram, the last SDA diagram
obtained is used as an additional input of the SDA generation. This last SDA diagram
is modified to incorporate the knowledge contained in the new encounters in the EOC
database and the background knowledge, obtaining a new updated SDA diagram.
The procedure to generate SDA diagrams is divided into three steps each one solving
a different problem (see figure 4.2). The first one solves the identification of states. The
identification of states is the procedure used to identify the different health care states
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(see definition 3.1.1) in which a certain patient may be located during the treatment
of a disease. The set of states identified corresponds to the set of SDA states that
the generated SDA diagram will have. In the successive incremental generations of the
SDA diagram, the set of SDA states of the current SDA diagram is used as the starting
point and it is updated according to the new patient data and medical knowledge.
Figure 4.2: Scheme of the three steps to generate SDA diagrams
The second step is the determination of therapeutic sequences (see definition 3.1.5).
The determination of therapeutic sequences is the procedure used to induce a sequence
of concatenated questions to condition the sort of treatment to be followed for the pa-
tients evolving from a certain health care state to any other states. This corresponds to
a sequence of connected SDA decisions that lead to different SDA actions, representing
the treatment followed when evolving from one state to one or more next states. In
the successive incremental generations of the SDA diagram, the therapeutic sequences
in the current SDA diagram are used as baseline and they are updated considering the
new patient data and medical knowledge.
Finally, the third step is the integration. In this step the resulting SDA diagram
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is built by connecting the SDA states with the SDA decisions and the SDA actions
obtained from the previous two steps.
4.1 Identification of states
The identification of states is the procedure used to identify the different health care
states (see definition 3.1.1) in which a certain patient may be located during the treat-
ment of a pathology. In the SDA model, health care states are represented as SDA
states which are subsets of SDA state terms (see section 2.8).
We want to identify a set of states such that it has a maximum quality and medical
sense, so we will start defining the concepts of quality of a state (section 4.1.1) and
medical sense of a state (section 4.1.2). Then these two concepts will be used in an
incremental algorithm to identify the set of states (section 4.1.3).
4.1.1 The quality of a state
The definition 3.1.1 of health care state expresses that a state must represent a signif-
icant group of patients that deserve a particular course of action and that this state
must have some interest for the health care professional. Therefore, the quality of a
SDA state involves three points of view which are classified as epidemiological, ther-
apeutic and preferential. Each one of these views provides an answer to a different
question:
• Epidemiological: Is this state representing a significant number of patients?
• Therapeutic: Are the treatments followed by the patients represented by the state
homogeneous?
• Preferential: Does the health care expert consider this state relevant?
The epidemiological view is related to the significance of the set of encounters
represented by this state. The epidemiological quality of a state can be calculated then
as the number of encounters represented by this state divided by the total number
of episodes. Given a state Si we denote ε(Si) the proportion of encounters that Si
represents.
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The therapeutic view is related to the homogeneity of the treatments proposed for
the patients in this state. Given a state Si, let ε(Si) be the set of encounters of patients
being in state Si and A(ε(Si)) the multiset containing the clinical action performed in
each ε(Si), we calculate the treatment homogeneity h(A(ε(Si))) of the state Si with the
procedure described in section 3.1.5.
The preferential view is related to the relevance of the state according to the health
care expert preferences. To represent these preferences we use a partial order ≤S on the
state terms (see section 3.1.2). This LPO can be then transformed into a preference
function p : S → [0, 1] preserving the information provided by the LPO (LVR11).
This is formalized by the properties of normality (i.e., ∀s ∈ S, {0 ≤ p(s) ≤ 1}) and
monotonicity (i.e., ∀s1, s2 ∈ S, {s1 ≤S s2 ⇒ p(s1) ≤ p(s2)}). As ≤S does not provide
information about the distance between elements, we assume that the distance between
consecutive layers of the LPO is constant, we call this the equidistance property. So, if
≤S has n layers and `(s) is the layer where the element s is, equation 4.1 defines the
only preference function p which preserves the partial order of ≤S for all the values





if n > 1
1 otherwise
(4.1)
Finally, the preferential quality p(Si) of a state Si is computed as the average of
the preference values of the state terms in Si (i.e., p(Si) =
∑
s∈Si p(s)/|Si|).
Given a state Si, we calculate the quality of this state with the function quality(Si)
which can be equal to ε(Si), h(A(ε(Si))) or p(Si) depending on whether we want an
epidemiological, therapeutic or preferential view. Notice that the epidemiological view
has a bias towards the states with less state terms while the therapeutic view has a
bias towards the states with more state terms. Another approach is to combine the
three points of view giving a certain weight α to each of them (i.e., quality(Si) =
αeε(Si) + αth(A(ε(Si))) + αpp(Si)).
4.1.2 The medical sense of a state
In spite of the epidemiological, therapeutic or preferential quality of health care states,
they must have a medical sense. The medical sense depends on both the coherence
of the description of the state and the coherence of the state itself with respect to
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the rest of states as it is explained in section 3.1.1. The knowledge used to guarantee
medical sense is represented with a state constraints graph GS (see definition 3.1.3).
This background knowledge is necessary to assure that, on the one hand, given a SDA
state its terms are not redundant or medically incorrect and, on the other hand, all
the SDA states in a SDA diagram are defined at the same level of abstraction of the
medical terminology. Therefore, although the state constraints graph contains one type
of constraint, these constraints are used to guarantee two aspects: the medical sense
within each state and the medical sense of the whole set of states.
In order to incorporate the constraints in GS to the identification of states, we
distinguish between: intra-state constraints and inter-state constraints.
Definition 4.1.1 (Intra-state constraint) Each constraint c = {si, sj} in the state con-
straints graph GS represents an intra-state constraint, meaning that the state terms si
and sj cannot be in the same state (i.e., we do not allow a state Si such that si, sj ∈ Si
to be in the SDA diagram).
Definition 4.1.2 (Inter-state constraint) Each constraint c = {si, sj} in the state con-
straints graph GS represents an inter-state constraint, meaning that the states Si and
Sj cannot be in the same SDA diagram if si ∈ Si and sj ∈ Sj (i.e., if a state Si that
contains si is included in a SDA diagram, we cannot include a state Sj that contains
sj in the same SDA diagram, and vice versa).
For example, considering the state constraints graph for hypertension in table 3.7,
there is a constraint between the terms HEART RISK and LVH. Therefore, this con-
straint will represent an intra-state constraint that will not allow these two terms to
be in a same state; and a inter-state constraint that will not allow two states to be in
the same diagram if they contain the terms HEART RISK and LVH respectively.
4.1.3 State identification algorithm
The identification of states is solved as a clustering problem (see section 2.1). The
encounters of the EOC database have to be assigned a cluster (i.e., a health care state).
According to the type-0 non-determinism of the SDA model (see section 2.8), the two
sets of patients that satisfy two health care states may intersect, thus we are dealing
with an overlapping clustering problem (see section 2.3). Moreover, we must assure the
medical sense of the health care states by means of constrains so it is also a constrained
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clustering problem (see section 2.5.2), and the constant arrival of new data in the EOC
database suggests that the clustering must be done incrementally (see section 2.6.1).
Nevertheless, the existing clustering methods are not useful to identify health care states
because the quality of a set of health care states depends on criteria which cannot be
derived from the state terms.
The problem of state identification is formally defined as the following. Given a set
of encounters of the EOC database E = {enc1, ..., encn}, each encounter is a meeting
patient-physician where the physician observes a set of characteristics S(enci), repre-
sented as state terms, that describe the state of the patient at this moment; and pro-
poses some health care measures. We generate the best set of clusters S = {S1, ..., Sk},
where k is not given a priori and each cluster Si ∈ S represents a SDA state Si =
{s1, ..., sj}, si ∈ S. If S(enci) ⊆ Si, Si ∈ S then this encounter is represented by this
SDA state. Notice that one encounter can be represented by more than one SDA state.
The quality of a set of states is calculated as the average of the qualities quality(Si) of
each state Si, where quality is implemented as it is explained in section 4.1.1. There
are five constraints that we want the set of states generated to fulfill:
1. The number of terms in a state must be greater or equal than a constant minS
(∀Si ∈ S, |Si| ≥ minS) in order to avoid diagrams with too less states and which
are too general.
2. The number of terms in a state must be lower or equal than a constant maxS
(∀Si ∈ S, |Si| ≤ maxS) in order to avoid diagrams with too much states and
which are too specific.
3. A health care state must represent one or more encounters (∀Si ∈ S, |ε(Si)| > 0)
in order to be representative enough to be considered for the diagram.
4. States having intra-state constraints between some of their terms are not allowed
(given a state constraints graph GS = (S,C) and (si, sj) ∈ C, then si, sj ∈ Si ⇒
Si /∈ S)
5. States having inter-state constraints between them are not allowed (given a state
constraints graph GS = (S,C), (si, sj) ∈ C, si ∈ Si and sj ∈ Sj , then Si ∈ S ⇒
Sj /∈ S and Sj ∈ S⇒ Si /∈ S)
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Starting from the EOC database we propose two algorithms to solve the identifi-
cation of the states: the non-incremental identification algorithm and the incremental
identification algorithm. If we do not have previously identified states, we apply the
non-incremental identification algorithm. This happens the first time that we identify
the states of a SDA. Once a set of states exists, we apply the incremental algorithm to
incorporate the information contained in new encounters to the previous SDA.
Both algorithms are explained in the next paragraphs.
Non-incremental identification algorithm: Algorithm 1 shows the procedure
followed in the non-incremental identification of states.
This algorithm receives as input a set of encounters EPC . The encounters of this
set only contain the patient condition, that is to say the set of state terms (see sec-
tion 2.7) because decision and action terms are not needed. We omit showing the
different background knowledge structures and functions used in the algorithm. It
starts by generating the space of possible states S′ making all the combinations of
state terms s ∈ S. S′ will contain a state for each one of the subsets of S except
the empty set (i.e., P(S) − {∅}). We can restrict the minimal and maximal number
of terms in the states of S′ with the parameters minS and maxS, respectively (i.e.,
S′ = s ∈ P (S) : minS ≤ |s| ≤ maxS − ∅). This process uses the intra-state constraints
of the state constraints graph GS = (S,C) to avoid states having incompatible terms
si, sj , ... such that (si, sj) ∈ C. Each encounter in EPC describes a patient that is
in each one of the states in S′ whose terms are all observed for that patient in that
encounter. If ε(Si) is the set of encounters represented by a certain state Si (i.e.,
ε(Si) = {encj ∈ EPC , S(encj) ⊆ Si}), then S′ does not contain states s such that
epsilon(s) = ∅ (i.e., S′s ∈ P (S) : ε(s) = ∅ = ∅). A state Si which does not repre-
sent any encounter in EPC (ε(Si) = ∅) is not included in S′. So, the final number of






less the number of states having an intra-state constraint
|{Si ⊆ P(S) : ∃(si, sj) ∈ C, si, sj ∈ Si}| and less the number of states that do not
represent any encounter |{Si ⊆ P(S) : ε(Si) = ∅}|.
In order to show an example of the construction of a space of states, consider a set
of encounters EPC that contains these following combinations of state terms about one
or more patients in states e1, e2, e3, or e4, with:
• e1: SMOKES, HEART RISK, S1 HYPERTENSIVE SBP, HIGH CREATININE
90
4.1 Identification of states
Algorithm 1: non-incremental identification of states
Input: EPC : set of encounters (only their patient condition)
Output: S : set of identified states, S′′ : initial space of states,
qualities : double[]
1 S′ ← generate space of states(EPC , minS, maxS, C);
2 qualities : double[|S′|];
3 foreach Si ∈ S′ do
4 qualities[Si] = calculate quality(Si);
5 S← ∅;
6 represented← ∅;
7 S′′ ← S′;
8 while S′ 6= ∅ do
9 best = arg maxSi∈S′ qualities[Si];
10 S← S ∪ best;
11 represented← represented ∪ ε(best);
12 foreach Si ∈ S′ do
13 if (ε(Si) ⊆ represented) OR
(∃{si, sj} ∈ C : si ∈ Si ∧ sj ∈ Sj ∧ Sj ∈ represented) then
14 S′ ← S′ − Si;
15 return S, S′′, qualities;
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• e2: DOES NOT SMOKE, NO HEART RISK, NORMAL SBP
• e3: DOES NOT SMOKE, NO HEART RISK, PREHYPERTENSIVE SBP
• e4: SMOKES, HEART RISK, PREHYPERTENSIVE SBP
Then, figure 4.3 depicts the space of states S′ for minS = 1 and maxS = 3 and
considering the set of intra-state constraints represented in the state constraint graph
of the case is C = {(SMOKES, NO HEART RISK), (DOES NOT SMOKE, HEART
RISK), (DOES NOT SMOKE, NOT HEART RISK)}.
Figure 4.3: Example of space of states
For each state s ∈ S′ the algorithm calculates the quality of this state quality(s)
(lines 2-4). The quality of a state can be calculated with epidemiological, therapeutic
and preferential approaches as it is proposed in section 4.1.1. Finally, we repeat the
removal of states in S′ until S′ is empty. The removal criteria are:
1. Remove from S′ the state with the greatest quality, at each loop.
2. Remove from S′ all the states representing encounters which are represented by
one of the identified states.
3. Remove from S′ all the states having terms with an inter-state constraint with
any term in one of the identified states.
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Algorithm 1 returns S a set of states which is representative of the patient states in the
encounters EPC , a copy of the initial space of states S
′′ and the qualities of each state
in S′′.
Following the previous example, in table 4.1 we specify for each state in the initial
space of states S′ (column 2), the kinds of encounters that it represents (column 3) and
a possible quality value (column 4). The states are given an id number (column 1)
and they are ordered according to their quality. The identified states are in bold and,
for each of them, we specify the id number of the states removed. The first identified
state (the one with the highest quality) is HEART RISK,S1 HYPERTENSIVE SBP.
It removes all the states representing only e1 (see last column). We suppose that there
is a inter-state constraint between HEART RISK and SMOKES, and between HEART
RISK and DOES NOT SMOKE so other states like SMOKES,PREHYPERTENSIVE
SBP are also removed. The other identified states are NORMAL SBP and PREHY-
PERTENSIVE SBP which also remove some states.
Incremental identification algorithm: Algorithm 2 shows the procedure fol-
lowed in the incremental identification of states.
The algorithm receives as input a set of new encounters EPC , as well as the
three output parameters of the previous identification procedure (prev S, prev S′ and
prev qualities). We omit showing the different background knowledge structures and
functions used in the algorithm. First of all, it extends the space of states with the new
states obtained from the new encounters, if there are any (line 1).
Consider the previous example and suppose that there is a new state:
• e5: DOES NOT SMOKE, NO HEART RISK, HYPOTENSIVE SBP
The previous space of states S′ is extended with states: HYPOTENSIVE SBP,
DOES NOT SMOKE,HYPOTENSIVE SBP and NO HEART RISK, HYPOTENSIVE
SBP.
Then, the quality values of the states representing any new encounter are updated
(lines 3-5). Then it keeps two sets that contain the only states that must be revised
(at the moment). The first set is called revise and it initially contains the states
that have advanced other states in terms of quality with respect to the last identifica-
tion. (Si ∈ revise ⇔ ∃Sj , (prev qualities[Sj ] > prev qualities[Si]) ∧ (qualities[Sj ] <
qualities[Si])) (line 6). The other set is called revise encounters and it contains the
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4.1 Identification of states
Algorithm 2: incremental identification of states
Input: EPC : set of encounters (only their patient condition), prev S : set of
previously identified states, prev S′ : previous space of states,
prev qualities : array of previous qualities
Output: S : set of identified states, S′′ : initial space of states,
qualities : double[]
1 S′ ← prev S′ + determine new states(EPC ,minS,maxS,C);
2 qualities : double[|S′|];
3 foreach Si ∈ S′ do
4 if represents new encounters(Si) then qualities[Si] = calculate quality(Si);
5 else qualities[Si] = prev qualities[Si];
6 revise← advancing states(S′, prev qualities, qualities);
7 revise encounters← prev S′ − revise;
8 S← ∅;
9 represented← ∅;
10 foreach Si ∈ revise ∪ revise encounters in descendant order of quality(Si) do
11 if Si ∈ revise encounters then
12 S← S ∪ Si;
13 represented← represented ∪ ε(Si);
14 else
15 if ε(Si) 6⊆ represented then
16 S← S ∪ Si;
17 represented← represented ∪ ε(Si);
18 revise← revise ∪ identified advanced(Si);
19 if Si /∈ prev S then revise← revise ∪ identified behind(Si);
20 else
21 if Si ∈ prev S then revise← revise ∪ not identified behind(Si);
22 revise encounters← revise encounters− revise;
23 return S, S′, qualities;
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previously identified states not included in revise (i.e., revise encounters = prev S−
revise) (line 7).
Each one of the states Si in these sets is revised with the following procedure start-
ing from the one with a highest quality. If Si ∈ revise encounters, we identify this
state (lines 12-13). Otherwise, the state is identified if it represents patient states in
encounters which have not been represented by any encounters of any identified state
(ε(Si) 6⊆ represented) (lines 16-17). If Si is identified, there is an additional set of
states that must be revised. These states were identified in the previous identifica-
tion and now they may be not identified because of Si. This set of states is called
identified advanced(Si) (line 18) and contains all the states Sj that fulfill:
• They were identified in the previous identification (Sj ∈ prev S).
• They had a quality greater than Si in the previous identification (prev qualities[Sj ] >
prev qualities[Si]).
• They have a quality lower than Si in the current identification (qualities[Sj ] <
qualities[Si]).
Moreover, if Si was not identified in the previous identification (Si /∈ prev S), we must
also revise the states in identified behind(Si) (line 19) which are the states Sj that
fulfill:
• They were identified in the previous identification (Sj ∈ prev S).
• They have a quality lower than Si in the current identification (qualities[Sj ] <
qualities[Si]).
In case that Si is not identified in the current procedure, if Si was identified in the
previous identification (Si ∈ prev S) there is another set of states that must be revised.
These states were not identified in the previous identification maybe because of Si.
Now that Si is not identified, their situation may change. This set of states is called
not identified behind(Si) (line 21) and contains all the states Sj that fulfill:
• They were not identified in the previous identification (Sj /∈ prev S).
• They have a quality lower than Si in the current identification (qualities[Sj ] <
qualities[Si]).
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Finally, the new states in revise are removed from revise encounters (line 22). The
algorithm returns the set of identified states S, the initial space of states S′ and the
qualities of each state in S′.
Following the same example than before, table 4.2 contains the updated ranking
of states. The column +/- is used to mark the states that have advanced other states
(’+’) and those that have been advanced (’-’). Finally, a ’*’ mark in column Revised
means that this state will be revised during the identification process.
Initially, the set revise contains the states HEART RISK, HYPOTENSIVE SBP,
NO HEART RISK, HYPOTENSIVE SBP, and DOES NOT SMOKE,HYPOTENSIVE
SBP. The set revise encounters contains HEART RISK,S1 HYPERTENSIVE SBP,
NORMAL SBP and PREHYPERTENSIVE SBP.
We start revising the state HEART RISK,S1 HYPERTENSIVE SBP which is in
revise encounters so it is automatically identified. The same happens with the next
state NORMAL SBP. The third state to be revised is HEART RISK which is not
in revise encounters. In this case we identify it because it represents the encounters
of the kind e4, which are not represented by the previous identified states. Then we
must also revise identified advanced(HEART RISK ) which contains the state PRE-
HYPERTENSIVE SBP, and also identified behind(HEART RISK ) which in this case
is empty. Finally we remove PREHYPERTENSIVE SBP from revise encounters. The
next state to revise is PREHYPERTENSIVE SBP which is identified again. The sets
identified advanced(PREHYPERTENSIVE SBP) and identified behind (PREHY-
PERTENSIVE SBP) are empty. The last states to be revised are the three new states.
The first one is HYPOTENSIVE SBP which is identified. The set identified advanced
(HYPOTENSIVE SBP) is empty but the set identified behind(HYPOTENSIVE SBP)
contains all the states that have been advanced by this new state, and have to be revised.
All the remaining states are not identified. So with this new incremental identification
of states, two additional states have been identified. Notice that only half of the states
have been revised.
The incremental identification of states allows us to deal more efficiently with the
constant arrival of data of new encounters because for each new identification of states
we do not have to create the whole space of possible states from scratch but to add the
new ones. Likewise, only the quality of states involving new encounters has to be recal-
culated. Another advantage of this incremental solution is that the proposed algorithm
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4.2 Determination of therapeutic sequences
just revises the minimum subset of states that is necessary to guarantee a correct iden-
tification. Moreover, the set of identified states only depends on the encounters used,
without regard to the sequence in which those encounters were presented. As far as
memory requirements is concerned, the proposed solution, instead of keeping the whole
set of encounters for each incremental identification, it only stores one encounter for
each combination of state terms together with an identifier. Each state has a list with
the identifiers of the encounters that it represents and the amount of them, avoiding
the storage of redundant data.
4.2 Determination of therapeutic sequences
The determination of therapeutic sequences (see definition 3.1.5) is the procedure used
to induce a sequence of questions to determine the sort of treatment to be followed for
the patients with a certain health care state.
In the SDA model, questions are represented as SDA decisions that allow the in-
tegration of all the variability that a treatment may have by means of conditions on
several SDA decision terms representing available information about the patient and
the patient’s health care condition. The variability of a treatment is represented with
SDA actions, which are subsets of SDA action terms, constituting the proper health
care activities involved in the health care procedure represented (see section 2.8).
We want to induce a therapeutic sequence such that it is medically comprehensible
and correct (LVRB12). We will start defining the concepts of comprehensibility (sec-
tion 4.2.1) and correctness (section 4.2.2) of a therapeutic sequence. In section 4.2.3
these two concepts will be used in an incremental algorithm to induce comprehensible
and correct therapeutic sequences.
4.2.1 Comprehensibility of a therapeutic sequence
Comprehensibility (LVRB12) is a measure of the adherence to the order followed by
a physician when gathering evidences (represented as SDA decisions) in a therapeutic
sequence. In the induction of therapeutic sequences, comprehensibility is guaranteed
by means of a partial order ≤D (see section 3.1.4) on the decision terms D. This partial
order represents the background knowledge available about what are the questions that
should be asked before which other questions in a therapeutic sequence. This knowledge
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should be provided by a health care expert considering several health care criteria
such as the order suggested in CPGs, care preferences or past experiences (LVR12).
This background knowledge should be considered during the induction of therapeutic
sequences in order to foster that decisions with a higher priority appear before in
therapeutic sequences.
4.2.2 Correctness of a therapeutic sequence
Correctness (LVRB12) is a measure of how relevant are the treatment errors made
when a SDA action is decided at the end of a therapeutic sequence. In the induction
of therapeutic sequences, correctness is guaranteed by means of a similarity function s
(see section 3.1.5). This similarity function represents the background knowledge that
is used to calculate the medical homogeneity h of a multiset of actions. During the
induction of therapeutic sequences, we calculate the homogeneity between the treat-
ments that received a certain set of patients. If it is homogeneous enough, there is no
need for more questions (i.e., SDA decisions) and a single global treatment (i.e., SDA
action) can be given.
4.2.3 Therapeutic sequences induction algorithm
The induction of a therapeutic sequence can be seen as a decision tree induction prob-
lem (see section 2.4). Considering the set of encounters in the EOC database of patients
in a certain health care state, a Decision Tree (DT) can be induced such that the ques-
tions are decision terms and the final decisions are sets of action terms. This sort of DT
uses decision terms to discriminate between the sorts of treatments that have been pre-
scribed in these encounters. This DT can be transformed into a therapeutic sequence
represented with the SDA model replacing the internal nodes with SDA decisions and
the leaves with SDA actions. We can guarantee medical comprehensibility and correct-
ness of the therapeutic sequence with cost-sensitive learning (see section 2.5.3). The
constant arrival of new data in the EOC database suggests that the induction process
must be incremental (see section 2.6.2).
In order to accomplish all the above mentioned requirements, we propose an incre-
mental DT induction algorithm which is based on the ITI family of algorithms (Utg88;
Utg89; UBC97) with an alternative measure to choose questions and decisions which
takes into account the background knowledge of the domain.
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The problem of induction of a therapeutic sequence is formally defined as it follows.
Given a SDA state S1, we consider ε(S1) the set of encounters in the EOC database of
patients in state S1. Starting from ε(S1), we induce the most medically comprehensible
and correct DT that classifies each encounter enci ∈ ε(S1) according to their action
terms A(enci), making partitions using sets of decision terms D(enci).
In order to generate these DTs, we use sets of encounters EHC where each encounter
only contains health care measures; that is to say, decision and action terms. State
terms are no needed. The incremental approach presented in this section uses the
storage of counters instead of sets of encounters EHC within the internal nodes of the
decision trees. The counters are used to avoid the redundant storage of encounters
in the DT. When generating DTs, instead of maintaining the corresponding sets of
encounters in each node (which is the usual approach), we maintain counters. In
figure 4.4(a) we can see an example of a set of encounters used in the induction of
therapeutic sequences for the domain of Hypertension (HT). Each row represents a
different encounter and contains its decision terms (column 1) and its actions (column
2), which can be {ALCOHOL, NOT ALCOHOL, SMOKES, DOES NOT SMOKE} and
{EDUCATION, ENALAPRIL MERCK 20MG 28 TABLETS}, respectively. As this
way of representation maintains all the different combinations of decision and action
terms it can imply a huge amount of memory for large sets of encounters. Figure 4.4(b)
depicts the same example represented by means of two counters (one for each semantic
decision which are called Alcohol and Smoking). Each counter has one column for each
action, and one row for each decision term in the semantic decision plus the otherwise
alternative if none of the decision terms appear in the encounter. The counters contain
the number of encounters having each action while having each decision term (or not).
With this representation the amount of memory used by the decision trees does not
grow with the number of encounters and we still keep all the information needed to
induce the therapeutic sequences. The sets of encounters EHC are only kept in the
leaves of the DT, where they are needed in order to expand the leaves if it is necessary.
Most of the algorithms to induce DTs have three key points in which a decision
has to be made according to one or more criteria (LVRB12). Here we call them choice
points and these are the following:
• Condition for placing a decision node (or not): If this condition is fulfilled the
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(a) An example of set of encounters (b) An example of counters
Figure 4.4: Sets of encounters vs counters
algorithm places a decision node and otherwise it keeps placing question nodes
to partition the set of encounters.
• Selection of the best decision: A certain measure is used to decide which one of
the possible decisions is the best for the current set of encounters.
• Selection of the best question: A certain measure is used to decide which one of
the remaining questions is the best to partition the current set of encounters.
Considering these three choice points, we define three functions that will be used in
the algorithm to induce a therapeutic sequence. These are the functions similar action,
best action and best decision. They are described in detail in the next paragraphs.
Notice that these functions work both with counters or sets of encounters, however we
always refer to sets of encounters EHC to clarify the explanation:
similar action(EHC)
During the induction of a DT, when each one of the encounters in a set has a similar
action, a final decision can be made proposing a common action for all these encounters.
The boolean function similar action(EHC) is true when all the encounters in EHC have
a similar action. In this case, the condition for making a decision on the medical action
is fulfilled. When a final decision is made over a set of encounters, this decision may
not be completely correct from a medical point of view for each one of the encounters.
In order to guarantee the medical correctness of the therapeutic sequence induced,
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the medical errors committed must not be relevant (see section 4.2.2). Therefore,
the function similar action(EHC) uses the background knowledge of the similarity
function s to determine how similar are the different actions in the encounters of EHC .
Concretely, it calculates the homogeneity h(A(EHC)) of the treatments in the set of
encounters EHC (see section 3.1.5). If and only if the homogeneity is greater than a
predefined similarity threshold δ, then similar action(EHC) is true.
best action(EHC)
Given a set of encounters EHC , the function best action(EHC) provides the best
action to make (i.e., the most correct action from a medical point of view). In order to
guarantee medical correctness (see section 4.2.2), the function chooses the action with
a higher average similarity with all the actions in the encounters of EHC . For each
action Ai contained in A(EHC) (i.e., each action in some of the encounters in EHC),
we calculate 1#EHC
∑
enci∈EHC s(Ai, A(enci)). The action obtaining a higher results is
considered the best one.
best decision(EHC,SD)
Given a set of encounters EHC and a set of possible semantic decisions SD, the
function best decision(EHC , SD) provides the best semantic decision in terms of med-
ical comprehensibility, and which is also a useful decision to decide the final action
(i.e., a decision that when partitions EHC leads to a better situation to decide a fi-
nal action for the therapeutic sequence). In order to select a decision that fulfills
both points, the best decision(EHC , SD) function follows the next procedure. First
of all, it chooses the most comprehensible semantic decisions (see section 4.2.1) us-
ing the decisions partial order ≤D. This is done by selecting those semantic decisions
which have a higher priority according to ≤D (i.e., we select the semantic decisions in
SD1 = {sdi ∈ SD : 6 ∃sdj ∈ SD, sdi 6= sdj |sdj ≤D sdi}.
Then, for each one of the selected semantic decisions in SD1, the function calculates
the expected homogeneity (eh) (LVRB12). Given a semantic decision sd, eh(sd,EHC)
represents the average homogeneity of a pairwise comparison of the homogeneities of
the treatments in the subsets of encounters obtained after partitioning EHC with sd.
This eh(sd,EHC) value is useful to determine whether the use of sd at this point of the
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therapeutic sequence leads to a better situation to decide a final action, or not. eh is







The difference between the expected homogeneity for a semantic decision and the
homogeneity of the current set of encounters is called the homogeneity gain (∆h) defined
in equation 4.3.
∆h(sd,EHC) = eh(sd,EHC)− h(EHC) (4.3)
We will only consider semantic decisions whose ∆h is greater than a threshold η.
The best decision will be the one with the highest ∆h. If several semantic decisions in
SD1 have the same ∆h then the best decision is selected in lexicographic order.
If none of the semantic decisions in SD1 fulfills this condition, then we start the
procedure once again selecting the semantic decisions in the second layer of priority
of ≤D (i.e., we select the semantic decisions in SD2 = {sdi ∈ SD :6 ∃sdj ∈ SD, sdi 6=
sdj , sdj /∈ SD1|sdj ≤D sdi}. We follow the same procedure with the rest of the layers
of ≤D until we find a semantic decision whose ∆h is greater than the threshold η. If
none of the semantic decisions in SD fulfills this condition, then the function will not
be able to provide a best decision.
To solve the induction of a therapeutic sequence from a state S1 starting from the
set of encounters ε(S1) we propose two algorithms: the non-incremental determination
algorithm and the incremental determination algorithm. To induce the therapeutic
sequence incrementally we apply the non-incremental determination only the first time,
which does not have information about a previous therapeutic sequence. Then, the
incremental determination is used when we already have a therapeutic sequence and
we want to incorporate information about new encounters. This may lead to a different
therapeutic sequence from S1.
Both algorithms are explained in the next paragraphs.
Non-incremental determination algorithm: Algorithm 3 shows the procedure
followed in the non-incremental determination of a therapeutic sequence.
This is a recursive algorithm which receives as input a set of encounters EHC and
a set of semantic decisions SD. We omit showing the different background knowledge
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Algorithm 3: non-incremental induction of TP
Input: EHC : set of encounters (only the health care measures), SD : semantic
decisions
Output: DT : decision tree
1 calculate similarities(EHC);
2 Create a root node for DT ;
3 Update counters of DT ;
4 if similar action(EHC) then
5 DT is a leaf labeled with best action(EHC);
6 Store EHC in DT ;
7 else
8 if ∀enci, encj , D(enci) = D(encj) ∨ (SD = ∅) then
9 DT is a leaf labeled with all the different actions in EHC ;
10 Store EHC in DT ;
11 else
12 sd← best decision(EHC , SD);
13 if (sd=null) then
14 DT is a leaf labeled with all the different actions in EHC ;
15 Store EHC in DT ;
16 else
17 foreach di ∈ sd do
18 E′HC ← encounters enci in EHC such that di ∈ D(enci);
19 if E′HC 6= ∅ then
20 Add a new branch bi below DT labeled di;
21 DT ′ ← non-incremental induction of TP((E′HC , SD − sd));
22 Add the subtree DT ′ below bi;
23 return DT ;
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structures and functions used in the algorithm. In the first call of the algorithm,
the parameter SD is equal to the set SD of hyperedges of the semantic decisions
hypergraph HD. First of all, the algorithm calculates the similarity between actions
s(A(enc1), A(enc2)) for each pair of encounters enc1, enc2 ∈ EHC with the procedure
described in section 3.1.5 (line 1). All the similarities are calculated in this previous step
avoiding to recalculate them each time they are needed during the induction process.
Then it creates a root node for the DT (line 2). The next step consists in updating
the counters of the DT (line 3). In case that all the encounters in EHC have a similar
action (line 4) the algorithm places the leaf with the best action for EHC (line 5) and
stores the current set of encounters EHC in the DT for future uses (line 6). Otherwise,
it checks if all the encounters in EHC have the same decision terms or if there are no
more semantic decisions left (line 8). In this case, the algorithm places a leaf labeled
with all the different actions in EHC (line 9) and stores EHC in the DT (line 10). On
the contrary, it determines the best decision sd (line 12). If the function is not able to
find any useful semantic decision (line 13), the algorithm places a leaf labeled with all
the different actions in EHC (line 14) and stores EHC in the DT (line 15). Otherwise,
for each decision term di in the semantic decision sd, we determine the set of encounters
E′ ⊂ E that have di (line 18). If the set of encounters E′ is not empty, a new branch
bi is created labeled di (line 20). Then the algorithm is called recursively receiving
as parameter the set of encounters E′, and the set of remaining semantic decisions
SD − sd, returning a DT which is connected to bi (lines 21-22).
Notice that in lines 9 and 14 the algorithm places a leaf labeled with all the different
actions in E. This does not refer to syntactically different actions but to semantically
different actions. In this two cases the homogeneity of the actions in EHC is lower than
the threshold δ and thus similar action(EHC)=false. However, some of the actions in
EHC may be similar enough to be considered equivalent. To solve this problem we per-
form an agglomerative hierarchical clustering (LVRC12b) over the set of actions in EHC
(see section 2.3). We use a dendrogram based on the similarity function s described
in section 3.1.5 and the similarity threshold δ. Being A(EHC) = {A1, A2, ..., An} the
set of actions in EHC , we assign each action of A(EHC) in a different cluster. A den-
drogram can be created by successively unifying the two clusters with a higher value
of similarity. The similarity between two clusters is calculated as the average of the
similarities between each action of one cluster with all the actions in the other cluster
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(average linkage clustering). The similarity threshold δ is used to cut the dendrogram
obtaining a final clustering Cδ = {c1, c2, ..., cn} where each cluster ck contains a set of
semantically equivalent actions. Finally, the leaf is labeled with one representative ac-
tion of each cluster. This action is chosen with the method explained in the description
of the function best action(EHC).
Incremental determination algorithm: Algorithm 4 contains the incremental
algorithm to update an existing therapeutic sequence with new encounters.
Algorithm 4: incremental induction of TP
Input: DT : decision tree, EHC : set of encounters (only the health care
measures), SD : semantic decisions
Output: DT : decision tree
1 calculate new similarities(EHC);
2 introduce encounters(DT , EHC , SD);
3 ensure best decision(DT , SD);
4 return DT ;
The incremental algorithm receives as input the same parameters as the non-
incremental algorithm plus the previous DT representing a therapeutic sequence. We
omit showing the different background knowledge structures and functions used in the
algorithm. In the first call of the algorithm, the parameter SD is equal to the set SD
of hyperedges of the semantic decision hypergraph H. Firstly, the algorithm calculates
the similarities that involve new actions included in the set of encounters EHC in order
to avoid repetitive calculations during the induction (line 1). Then, it basically consists
of two steps. The first step, as described below, is to incorporate the new encounters
into the DT by passing them down the proper branches until they reach their proper
leaf (line 2). The second step, also described below, is to traverse the DT from root
to leaves, restructuring it as necessary so that each internal node employs the best
available decision at each moment (line 3). The procedure for the first step is detailed
in algorithm 5.
It starts by updating the counters (line 1). If DT is an internal node (line 2),
the new encounters are recursively passed through the branches of DT and they are
introduced in the proper internal nodes (lines 3-9). Each one of these updated internal
nodes is marked as stale (line 3). Notice that before applying the incremental algorithm
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Algorithm 5: introduce encounters
Input: DT : decision tree, EHC : set of encounters (only the health care
measures), SD : semantic decisions
1 Update counters of DT ;
2 if DT is an internal node then
3 Mark DT as stale;
4 sd← semantic decision used in this node;
5 foreach branch bi below DT labeled di do
6 E′HC ← encounters enci in EHC such that di ∈ D(enci);
7 if E′HC 6= ∅ then
8 DT ′ ← subtree below bi;
9 introduce encounters(DT ′, E′HC , SD − sd);
10 else
11 if similar action(EHC + ε(DT )) then
12 Label DT with best action(EHC + ε(DT ));
13 Store EHC in DT ;
14 else
15 DT = non-incremental induction of TP(EHC + ε(DT ), SD − sd);
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all the nodes of the DT are not stale. In case that DT is a leaf (line 10), it checks if
the encounters in DT (represented as ε(DT )) plus the set of new encounters EHC still
have a similar action (line 11). If so, DT is labeled with the best action (line 12) and
the new encounters are stored in DT (line 13). On the contrary, the non-incremental
algorithm is called in order to obtain a subtree for EHC + ε(DT ) (line 15).
Following with the explanation of algorithm 4, at this point the new encounters have
been introduced in the previous DT, updating counters and generating new subtrees
if necessary. Moreover, all the existing internal nodes that have been modified by new
encounters, have been marked as stale. The other step before returning the new DT is
a call to a procedure that restructures the DT as necessary so that each internal node
employs the best available decision at each moment (line 3). It is fully described in
algorithm 6.
Algorithm 6: ensure best decision
Input: DT : decision tree, SD : semantic decisions
Output: DT : decision tree
1 if DT is an internal node ∧ DT is stale then
2 if similar action(ε(DT )) then
3 DT is a leaf labeled with best action(ε(DT ));
4 Collect and store ε(DT ) in DT ;
5 else
6 if ∀enci, encj , D(enci) = D(encj) then
7 DT is a leaf labeled with all the different actions in ε(DT );
8 Collect and store ε(DT ) in DT ;
9 else
10 sd← best decision(ε(DT ), SD);
11 pull up(DT ,sd);
12 Mark DT as not stale;
13 foreach successor DT ′ of DT do
14 ensure best decision(DT ′, SD − sd);
15 return DT ;
This is a recursive algorithm that only involves modified internal nodes. Therefore,
it first checks if DT is an internal node and whether it is marked as stale (line 1). If
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so, it determines if it should be a leaf with the function similar action (line 2) and if
it is the case, the node is assigned the best action (line 3). Otherwise, the algorithm
first checks if all the encounters in ε(DT ) have the same decision terms (line 6) and
if it is the case it places a leaf labeled with all the semantically different actions in
ε(DT ) (line 7)1. In lines 4 and 8, as we are placing a leaf, we have to store the set of
encounters in the DT. The current node was an internal node so it does not contain
any set of encounters. Therefore we have to collect these encounters from the leaves
of DT and store them. In the case that DT is not transformed into a leaf (line 9), we
determine the best decision (line 10) and then we perform a pull-up of this semantic
decision (line 11). The pull-up of a semantic decision consists in moving it to the top
of the DT so that pull up(DT, sd) always returns a DT with the semantic decision sd
at its root. The algorithm is detailed in 7.
In the pull-up procedure, if DT is a leaf the algorithm transforms it into a subtree
with the semantic decision sd in the root (lines 2-11). Otherwise, if it is an internal
node with a semantic decision sd′ such that sd′ 6= sd, the algorithm can deal with 3
cases. In the general case (line 27) it makes a pull-up of sd for each one of the subtrees
of DT (lines 28-29). This procedure is performed to fulfill the preconditions of the
transpose operation depicted in figure 4.5, which moves the best semantic decision to
the top of the DT (line 30).
Figure 4.5: Transposing a decision tree
Notice that we have a DT with an internal node that uses the semantic decision
sd′ and, in the next level of the DT, we have used the pull-up operator in order to
1Here we refer to the set of encounters ε(DT ) in the decision tree to clarify the explanation but
instead of sets of encounters we use counters.
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Algorithm 7: pull up
Input: DT : decision tree, sd: semantic decision
1 if DT is a leaf then
2 DT is not a leaf;
3 Update counters of DT ;
4 foreach di ∈ sd do
5 E′HC ← encounters enci in ε(DT ) such that di ∈ D(enci);
6 if E′HC 6= ∅ then
7 Add a new branch bi below DT labeled di;
8 DT ′ ← non-incremental induction of TP((E′HC , SD − sd);
9 Add the subtree DT ′ below bi;
10 Remove encounters from DT ;
11 else
12 if semantic decision used in DT is not sd then
13 if DT has exactly one successor DT ′ which is not a leaf then
14 pull up(DT ′,sd);
15 DT ← DT ′;
16 E′HC ← encounters in the successors which are leaves;
17 introduce encounters(DT,E′HC , SD);
18 else if all the successors of DT are leaves then
19 foreach di ∈ sd do
20 E′HC ← encounters enci in ε(DT ) such that di ∈ D(enci);
21 if E′HC 6= ∅ then
22 Add a new branch bi below DT labeled di;
23 DT ′ ← non-incremental induction of TP((E′HC , SD − sd);
24 Add the subtree DT ′ below bi;
25 else
26 foreach successor DT ′ of DT do
27 pull up(DT ′,sd);
28 transpose(DT );
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have subtrees that use the semantic decision sd. We do not mind about the next level
of the tree which will contain internal nodes or leaves (nodes A, B, C and D in the
figure). With these preconditions, we can transpose the DT in order to move sd to
the root. Observe that the subtrees A, B, C and D do not need to be examined or
revised. Each subtree corresponds to a set of encounters, and because the set has not
changed during the transposition, the subtree does not need to be changed in any way.
Similarly, the set of encounters corresponding to the root node of the DT does not
change. Therefore, only the information in the nodes in the middle needs to be revised.
This is done inexpensively, without re-examining encounters, by simply combining the
information kept in their counters. The semantic decision of the nodes in the middle
has not changed due to the incorporations of new encounters but because we needed to
satisfy the preconditions of the transpose operation. Therefore, these nodes will have
to be revised so they are marked as stale.
In the example used to explain the transposition we have supposed that both se-
mantic decisions sd and sd′ contained two decision terms. Usually, there will be more
than two decision terms in a semantic set, but the procedure is equivalent.
As we stated before, when performing a pull-up, we can find two exceptions to the
general case (line 27) which are depicted in figure 4.6. The first case, in figure 4.6(a),
is when the DT has exactly one successor which is a not a leaf (line 14). Here we move
sd to the top of the successor which is not a leaf using a pull-up (line 15). Then we
replace the current DT by this successor (line 16) and introduce the encounters of the
successor leaves (lines 17-18). The second exception, in figure 4.6(b), is when all the
successors of DT are leaves (line 19). In this case we assign the best decision to DT
and generate the branches below it using the non-incremental algorithm (lines 20-26).
Continuing with algorithm 6, after the pull-up procedure, we already know that
the node uses the correct semantic decision so we can mark it as not stale (line 12).
Then we recursively call the same algorithm for each one of the successors of DT (lines
13-14). With this procedure, the modified subtrees of DT are revised so that we finally
ensure the best decision in each node of the decision tree.
In the following we will illustrate an example of how the presented algorithm updates
a therapeutic sequence when introducing new encounters. Consider the DT in figure 4.7
which represents a simple therapeutic sequence that could be obtained during the
generation of a SDA diagram for the treatment of hypertension.
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(a) DT has exactly one successor which is not a leaf
(b) All the successors of DT are leaves
Figure 4.6: Two exceptions to the general case when performing a pull-up
Figure 4.7: Example of updating a therapeutic sequence (1)
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As soon as new encounters arrive, we have to introduce them into the DT and then
ensure the best decision for each node. In figure 4.8 some encounters have been intro-
duced which have passed through the branches ALCOHOL and S1 HYPERTENSIVE
SBP. The nodes which have incorporated new encounters are marked as stale (painted
in gray). Some of these new encounters do not contain the action EDUCATION pro-
posed by the DT, so the corresponding leaf has been replaced by a subtree.
Figure 4.8: Example of updating a therapeutic sequence (2)
Once the encounters have been introduced into the DT, we ensure the best decision
for each node. Now we suppose that the best semantic decision for the root node is
the one related to SBP. This node currently separates patients that take alcohol from
those who do not, so we have to perform a pull-up. As we have the desired decision
in both successors of the root node we simply transpose the DT (see figure 4.9). We
have to mark as stale the internal nodes during the transposition and remove the stale
mark from the root node.
Finally, we ensure the best decision for each remaining stale node. We suppose that
the node at the left that asks for alcohol already contains the best decision and the
one at the right should ask for smoking habits. In the latter case, we make a pull-up
following the first exception (the DT has exactly one successor which is not a leaf) and
obtain the final DT in figure 4.10.
The incremental determination of therapeutic sequences includes several features
that allow dealing more efficiently with the constant arrival of data of new encounters.
For each new incremental determination of a therapeutic sequence we do not have to
induce the whole DT from scratch. The new encounters are introduced through the
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Figure 4.9: Example of updating a therapeutic sequence (3)
Figure 4.10: Example of updating a therapeutic sequence (4)
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existing DT creating new branches if necessary. Finally only the nodes of the DT which
have been affected by the new encounters are revised and restructured so that the best
decision is made at each node. Therefore, the therapeutic sequence only depends on
the encounters used, without regard to the sequence in which those encounters were
presented.
Another advantage of the algorithm is that instead of storing sets of encounters
in each internal node of the DT, it uses counters that represent essentially the same
information but in a more efficient way. With this representation the amount of memory
used by the DTs does not grow with the number of encounters and it still keeps all the
information needed to induce the therapeutic sequences.
4.3 Integration of the procedures to generate SDA dia-
grams
Once the procedures of identifying the states and determining the therapeutic sequences
have been detailed, in this section we will explain how these two procedures are inte-
grated in order to generate SDA diagrams.
We start considering that the identification of states is based on the data contained
in each one of the encounters. Observe also that therapeutic sequences start from a
certain state and that this state and treatment leads to another state. This next state is
not included in the therapeutic sequence itself but it is necessary in the integration step
in order to make the proper connections. To generate therapeutic sequences we use data
contained in each one of the encounters, but to connect these therapeutic sequences
we need to know the state of each following encounter. Therefore, for each one of
the episodes of care in the EOC database we will have to discard the last encounter
because we still do not know the state of its following encounter. These last encounters
will be used in the identification of states but will be ignored in the determination of
therapeutic sequences. Nevertheless, these encounters will not be lost but they will be
stored together with the identification number of their corresponding episode of care.
The next time that we update the SDA diagram, the stored encounters are added at
the top of their respective episode of care. This procedure is depicted with an example
in figure 4.11. The first time that we generate a SDA diagram we do not use the
last encounters of each EOC (enc14, enc22, enc33) in the determination of therapeutic
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sequences but we store them for future uses (see figure 4.11(a)). In a next incremental
generation of the SDA diagram we recover the stored encounters of the involved EOCs
and store the last encounters of each current EOC (see figure 4.11(b)). Notice that
enc14 is not recovered this time because there are no new encounters of EOC 1 in the
database.
(a) Example of storage of encounters in the initial generation of the SDA diagram
(b) Example of storage and recovery of encounters in a next incremental generation of the SDA diagram
Figure 4.11: Storage and recovery of encounters in the generation of the SDA diagram
In order to generate SDA diagrams integrating the procedures explained in the
previous sections we follow these steps:
1. Identification of states and transformation to the SDA model
2. Determination of therapeutic sequences from the identified states and transfor-
mation to the SDA model
3. Connection of SDA actions with the corresponding following SDA states
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4. Selection of a suitable level of abstraction for SDA action terms
5. Unification of SDA actions
The first step consists in applying the procedure of identification of states described
in section 4.1 using all the encounters in the EOC database. The first time that we
generate the SDA diagram we will identify these states from scratch while the next
times, the set of states of an existing SDA diagram will be modified with the incremental
algorithm. The resulting set of states is easily transformed to the SDA model creating
a SDA state for each one of the states identified that contains the corresponding set of
SDA terms. Notice that for each incremental generation of the SDA diagram, the set
of identified states may change and thus some SDA states may be removed from the
SDA diagram and some new SDA states may appear.
In the second step, a therapeutic sequence (decision tree) is determined for each of
the identified states in step 1. As we explained before in this section, the last encounter
of each episode of care in the EOC database is ignored and stored for the future while the
rest of encounters are used to apply the procedure in section 4.2. For the non-identified
states we do not have to induce the DT representing its therapeutic sequence because
it will not be included in the SDA diagram. However, the non-identified states also
represent sets of encounters which have to be stored because they may become identified
states in the future. When we update the SDA diagram with new encounters, some
non-identified states may be identified and we must consider all the encounters that
have been in this state in order to induce a correct therapeutic sequence. Therefore,
we will store the set of encounters for each non-identified state in order to be used in
the future. Similarly, a state which was identified in a previous generation may not be
identified in the current one. In this situation we created a therapeutic sequence for this
state which now will not appear in the SDA diagram. This therapeutic sequence must
be stored so that, in the future, it can be updated with new encounters. In general, we
will deal with 14 different situations which are summarized in table 4.3.
The first row corresponds to the case of the first time we generate the SDA diagram
where neither encounters nor DTs have been stored. If the state is identified we generate
and store the DT which will appear in the SDA diagram. Otherwise, we store the new
encounters for future uses. For the first generation, the cases where there are no new
encounters are impossible. In the second row, for the current state, some encounters
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Table 4.3: Summary of operations with DTs and the stored encounters for each possible
situation
Identified Not identified
Stored New encounters No new encounters New encounters No new encounters
Nothing Generate/store DT - Store encounters -
Merge encounters, Reset old encounters Merge/store No operation
Encounters reset old encounters and generate/store DT encounters No operation
and generate/store DT No operation
DT Update/store DT No operation Store encounters No operation
Encounters Merge encounters, Reset old encounters Merge/store No operation
+ reset old encounters and update/store DT encounters No operation
DT and update/store DT No operation
where stored in a previous generation. If the state is identified, a DT must be created
using the stored encounters and thus they can be removed. Moreover, if there are new
encounters they must be also considered so we merge old and new encounters before
generating the DT. If the state is not identified there is no need to generate a DT. We
merge old and new encounters if necessary. Following the third row, we may deal with
the situation where a DT was stored previously for the current state. If this state is
identified we must update the DT with the new encounters and if it is not identified
the new encounters are stored. If there are no new encounters, no operation is needed.
Finally, in the forth row, we have the case where we have both old encounters and an
old DT. In this case, the operations to be followed are the same that when we only
have old encounters stored, but if the state is identified, we update the old DT instead
of generating it from scratch.
At this point we have a set of DTs which represent therapeutic sequences that start
from each of the identified states. These therapeutic sequences are then transformed
to the SDA model by replacing the internal nodes of the tree by SDA decisions and the
leaves by SDA actions. Each branch leading from an internal node is labeled with a
decision term, and they are transformed to decision connectors containing this term and
pointing to the next internal node (the branches labeled ’otherwise’ are transformed
into otherwise connectors). The leaves are labeled with an action containing a set of
action terms, so a different SDA action is created for each leaf, containing its action
terms. Finally, each therapeutic sequence is connected with its respective identified
state. Therefore, in the SDA diagram we place a plain connector from each SDA
state created in step 1 pointing to the SDA decision in the root of the corresponding
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therapeutic sequence.
In the third step we connect each therapeutic sequence to the following next states.
In order to do this we must have stored, for every encounter of each identified state,
which is the state of the following encounter. Therefore, for each SDA action at the end
of a therapeutic sequence we will have a set of following states. In the SDA diagram,
we create a plain connector leading from a SDA action to each one of the corresponding
SDA states (type-2 non-determinism).
After the third step, the SDA diagram is already finished. However, two modifi-
cations are made that improve the visualization of the SDA diagram. The forth step
consists in selecting a suitable level of abstraction for the SDA action terms. The thresh-
old δ defined in the process of calculating if a set of encounters have a similar action in
section 4.2.3 is related to the level of abstraction of the actions in the diagram. If δ has
a low value, we want our final diagram to consider as equivalent two actions with a low
similarity. Thus if, for example, δ = 0.3 two different diuretics like hydrochlorothiazide
and indapamide will be considered equivalent in the diagram. Therefore, if we specify
such a low δ, we are interested in knowing that the treatment contains a diuretic rather
than knowing if it should be hydrochlorothiazide or indapamide. Otherwise, with a
higher value of δ, these two diuretics will not be considered equivalent and they will
lead to two different actions in the diagram. In this case, we are interested in knowing
exactly which kind of diuretics are needed. Therefore, with δ we are actually defining
a level of abstraction for the terminology in the SDA actions. As a consequence, for
each one of the action terms in the SDA actions we will go up through its predecessors
in the action terms hierarchy HA and we will choose the last concept whose successors
are considered equivalent according to δ. Following the previous example, with δ = 0.3,
we may find the action term HIDROSALURETIL 50MG 20 TABLETS in one of the
SDA actions. Going up one level we find out that its active principle is C03AA03
hydrochlorothiazide whose successors have a similarity of at least 0.7. The same hap-
pens with the next level which is C03AA Thiazides, plain. We keep going up to C03A
LOW-CEILING DIURETICS, THIAZIDES whose successors have a similarity of 0.5.
The successors of the next concept C03 DIURETICS have a similarity of 0.3, so they
are still considered equivalent. This would be the level of abstraction selected because
the next one, C CARDIOVASCULAR SYSTEM, has successors with similarity equal
to 0.0 (< δ). So we choose the concept C03 DIURETICS to replace the original action
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term HIDROSALURETIL 50MG 20 TABLETS. With this procedure we guarantee a
proper terminology for actions in the final SDA diagram.
The other modification done in the fifth step aims at reducing the number of SDA
actions in order to simplify the diagram. Our procedure to generate SDA diagrams
creates a different DT for each state. Each one of these DTs has several SDA actions
as leaves. A concrete SDA action may appear several times in the diagram in different
therapeutic sequences. It is also possible that some of these equal SDA actions lead to
the same states. In these cases, we can unify these SDA actions because they represent
the same treatment followed by the same expected transition to a next state. In the
fifth step, we detect sets of equal SDA actions that are also connected to the same next
states. We unify these SDA actions by removing all of them except one and redirecting
each connector that pointed to the removed SDA actions, to the SDA action that
remains in the diagram as it is depicted in figure 4.12. In figure 4.12(a) there is a SDA
diagram with 7 actions. The action containing the action terms {a2, a3} and pointing
to the state {s3} is repeated twice and thus they can be unified. The same happens
with action {a1} pointing to states {s1, s2} and {s3} and with action {a4} pointing
to state {s3}. The resulting SDA diagram after unifying SDA actions is depicted in
figure 4.12(b). Notice that there are still two actions containing {a1} but they could
not be unified because they are pointing to different states.
4.4 Summary of the incremental generation of SDA dia-
grams with background knowledge
This chapter has introduced two procedures to automatically induce two basic elements
of medical procedural knowledge structures, concretely SDA diagrams, which are health
care states (see definition 3.1.1) and therapeutic sequences (see definition 3.1.5). Both
procedures automatically generate these medical structures from an EOC database
which contains episodes of care, encounters, etc. of patients treated for a certain
pathology. They are also based on background knowledge which is not explicit in the
EOC database. Finally, both procedures are able to work in an incremental way in
order to deal with the constant arrival of new medical data.
Table 4.4 includes a list of all the parameters that have been used during the
explanation of both procedures:
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(a) SDA diagram with 7 actions before unification
(b) SDA diagram with 4 actions after unification
Figure 4.12: Unification of SDA actions
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Table 4.4: Parameters of the procedures of identification of states and determination of
therapeutic sequences
Parameter Explanation
δ threshold to determine whether two or more action terms or actions are equivalent or not
αe weight given to the epidemiological view of the quality of a state
αt weight given to the therapeutic view of the quality of a state
αp weight given to the preferential view of the quality of a state
minS minimum number of terms per state
maxS maximum number of terms per state
η minimum homogeneity gain for semantic decisions to be chosen as best decisions
A method to integrate both procedures has been presented at the end of the chapter
in order to incrementally generate whole SDA diagrams using background knowledge.
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There are three main aspects that we want to verify about the proposed methodology
which are:
1. The good performance at the levels of the use of background knowledge and
incrementality.
2. The adherence of the obtained SDA diagrams to the databases used to generate
them.
3. The medical correctness and comprehensibility of the obtained SDA diagrams.
With regard to the first aspect, we have designed some tests to determine whether
the use of background knowledge implies an increase of temporal cost or not, and
whether the methodology fulfills the desirable goals of incrementality.
The second aspect is tested calculating the adherence of the SDA diagrams gen-
erated for Hypertension (HT), Diabetes Mellitus (DM) and the comorbidity of both
diseases to the source databases containing the details of treatment for real primary
care patients assisted in SAGESSA. For the case of HT, we also generate a SDA dia-
gram using the incremental approach during a period of time and analyze the adherence
to the database during its evolution.
Regarding the third aspect, we have decided to generate definitive SDA diagrams
for each one of the previous pathologies in order to test them at a medical level. More-
over, we compare these diagrams with those generate with the knowledge-free approach
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in (BRLV12) from a medical point of view. Finally, we follow the evolution of the SDA
diagram of HT during a period of time and analyze it.
All these tests have been done considering the background knowledge presented
in section 3.3 in order to guarantee medically correct results. Both the tests and the
results obtained are detailed in next sections.
Regarding the parameters (see table 4.4), we have performed several tests and
consultations with the health care professionals in order to determine their value. The
parameters related to the quality of a state have been assigned αe = 0.0, αt = 0.3 and
αp = 0.7 for all the tests because the health care professionals were interested in giving
a great weight to their preferences and a lower weight to the therapeutic view. With
regard to the constraints about the number of terms within a state, the health care
professionals decided that for all these tests it was not necessary to specify a minimum
number of terms (minS = 0). The maximum number of terms maxS has been always
fixed (maxS = 2 for HT and HT+DM, and maxS = 3 for DM). The value for parameter
η has been determined after generating the same therapeutic sequences changing the
values of η and showing the results to the health care professionals. The experience
suggests that η = 0.1 is the best choice, so this value has been fixed for all the tests.
Finally, giving different values to the parameter δ is very interesting because it let us
change the level of abstraction of the terminology of the actions in the SDA diagram.
Therefore, during the following tests, we have tried different values for δ as it is clearly
detailed.
The proposed methodology has been implemented and integrated into an existing
software called SDA Lab which is used to manually develop, manage and execute SDA
diagrams.
5.1 Integration in SDA Lab
SDA Lab (LV07) is a software platform created in 2007 with the main purpose to
manually develop, manage and execute SDA diagrams. Figure 5.1 contains a screen
shot of SDA Lab v1.4. In v1.4, it also includes a tool to automatically generate SDA
diagrams from data using the approach in (BRLV12).
We have evolved SDA Lab to v1.5, replacing the previous method to generate SDA
diagrams by the knowledge-based incremental methodology presented in this thesis.
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Figure 5.1: Developing a SDA diagram with SDA Lab
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Concretely, SDA Lab v1.5 has the following new features:
• Incremental learning of SDA diagrams
• Incremental incorporation of encounters into a SDA diagram one-by-one
• Knowledge-based learning of SDA diagrams
• Management of background knowledge (graphs, hypergraphs, partial orders and
concept hierarchies)
• Manual or automatic (from a file) creation of background knowledge structures
• Execution of SDA diagrams
• Quality assessment of SDA diagrams
When we decide to generate a new SDA diagram we can introduce or modify all the
background knowledge regarding states, decisions and actions. For example, figure 5.2
depicts the window to select semantic decisions, to decide their priority and to choose a
minimum level of homogeneity (the similarity threshold δ introduced in section 4.2.3).
All the tests presented in this chapter have been performed with SDA Lab v1.5.
5.2 Performance tests of background knowledge
The use of background knowledge in the generation of SDA diagrams is essential to
guarantee medically correct results as we will show in future sections. However, before
analyzing these benefits we have to make some performance tests in order to determine
whether considering background knowledge of the medical domain implies an excessive
increase of temporal cost of the knowledge-based solution presented in the thesis or not
with respect to previous knowledge-free solutions (BRLV12).
In this section we compare our approach with the one proposed in (BRLV12) which
generates SDA diagrams with a different methodology that does not consider the back-
ground knowledge of the domain. We have generated four SDA diagrams with 100, 200,
400 and 800 encounters with patients of HT in SAGESSA during the year 2009, using
the algorithm in (BRLV12) and with our knowledge-based approach. The results ob-
tained are shown in figure 5.3 where performance is measured in terms of the execution
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Figure 5.2: Introducing the background knowledge related to decisions with SDA Lab
v1.5
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time expressed in seconds (vertical axis) and conditioned to the number of encounters
(horizontal axis).
Figure 5.3: Comparison of time cost with and without background knowledge
The blue lines represent the results of the induction with the algorithm in (BRLV12)
and the green lines represent the results of our background knowledge based approach.
The simple method used to identify states without background knowledge in (BRLV12)
implies a low temporal cost of less than 0.5 s whereas our approach, which considers sev-
eral constraints between terms, partial orders, etc., has a greater cost that grows to 5.5 s
(for 800 encounters). Contrarily, the determination of therapeutic sequences is favorable
to our approach which grows linearly while the method in (BRLV12) clearly does not.
A deeper analysis of the causes of this improvement concludes that in our knowledge-
based approach the calculation of similarities between actions to detect equivalences
and the use of semantic decisions drastically reduces the size of our decision trees. More-
over, the number of states identified is lower in our approach, so less decision trees are
induced. This implies a small average increment of 3 s for each test until a maximum of
10.9 s, for 800 encounters. The approach to determine therapeutic sequences proposed
in (BRLV12) shows a non-linear trend that reaches the duration of 100 s in the last test.
This great difference between both approaches can also be reinforced by the fact that
our approach reduces the number of steps used to determine therapeutic sequences,
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from three (detecting actions, determining evolutions and determining actions) to one
(determining therapeutic sequences).
The results obtained show evidence that the use of background knowledge not only
does not imply an increase of temporal cost but it severely reduces the time spent
determining therapeutic sequences and, therefore, the total duration of the process
(1.6 s for 100 encounters, 5.8 s for 200, 32.2 s for 400 and 83.8 s for 800).
5.3 Performance tests of incrementality
The use of the incremental approach has to be empirically justified. In section 2.6 we
introduced three desirable goals which usually motivate the use of incremental learning
algorithms. These are:
1. Cost reduction: The incremental cost of updating the current hypothesis with a
new instance should be much lower than the cost of building a new hypothesis
from scratch. It is not necessary however that the sum of the incremental costs
be less than the execution on the complete database.
2. Independence from the size: The update cost should have a high degree of inde-
pendence to the number of training instances on which the decision mechanism
is based.
3. Independence from the order: The hypothesis produced by the incremental al-
gorithm should depend only on the set of instances that has been used, without
regard to the sequence in which these instances were presented.
We have performed several tests to determine whether these goals are achieved
or not. These tests are presented in the following sections together with the results
obtained. For all of these tests we have used the data of patients of HT in SAGESSA
during the year 2009.
5.3.1 Cost reduction
A desirable goal of our incremental algorithm is that the cost of incorporating a new
encounter to a previously built SDA diagram should be much lower than the cost of
inducing the new SDA diagram from scratch. However, it is not necessary that the sum
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of the different incremental costs be less than the execution on the complete database
of encounters.
In order to check whether this goal is achieved or not, we have performed the
following test. Initially we induce a SDA diagram using 200 encounters. Then we
incrementally incorporate a new encounter to the diagram and we calculate the time
spent with this updating. We repeat 10 times this incremental procedure adding a new
encounter to each resulting SDA diagram. Finally, we generate the same SDA diagrams
with the non-incremental procedure (one induced with 201 encounters, one with 202
encounters, etc.) and we calculate the duration of the procedure. With this test we are
able to compare the time spent updating a SDA diagram with several new encounters,
with the time spent generating the same SDA diagrams from scratch. Figure 5.4 shows
the results of the test.
Figure 5.4: Comparison of time cost between the incremental and the non-incremental
approach
The blue lines represent the results of the non-incremental induction and the green
lines represent the results of the incremental induction. The durations of the identi-
fication of states are very constant in both cases, with an average of 1301.6 ms for
the non-incremental approach, and 332.8 ms for the incremental approach. The time
spent determining therapeutic sequences is constant in the non-incremental approach
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and highly variable in the incremental approach. This is caused by the fact that the
number of decision trees to be revised will not always be the same and therefore each
updating will require a different number of operations of pull-up, transposition, etc. In
the case of determining the therapeutic sequences the average durations are 2891.3 ms
for the non-incremental approach, and 368.6 ms for the incremental one. A particular
step that increases the time cost in the non-incremental approach is the calculation
of similarities between actions which is performed in the beginning in order to avoid
recalculations. This procedure takes about 1694.2 ms in the non-incremental approach
because the similarities between all the pairs of actions have to be calculated. In the
incremental approach only the similarities with new actions (if there are any) have to
be calculated so the time spent is reduced to an average 41.5 ms. If we only consider
the time spent generating decision trees (avoiding the time used to calculate similarities
between actions) we observe that in the incremental approach, the steps that require
more modifications of the existing decision trees (4,6) have a cost almost as high as
the non-incremental approach, while the steps that do not require any modification of
existing decision trees (5,7,8,10) have a cost equal to 0.
The total temporal cost of updating an existing SDA diagram with a new encounter
is averaged 3491.5 ms lower than generating a new SDA diagram from scratch, so we
can conclude that the first desirable goal is achieved.
If we update an existing SDA diagram with more than one encounter at the same
step, the time spent will increase because more decision trees will have to be revised.
Now we want to determine whether it is still worth or not updating an existing SDA
diagram rather than generating it from scratch if the updating is performed at the end
of the day. We perform another test to check this. As we did in the previous test, we
induce a SDA diagram with 200 encounters. Now we incrementally update it with the
set of encounters that have taken place during one day. We calculate the time spent
with this updating and repeat the procedure 10 times corresponding to 10 consecutive
days. We compare the duration of this procedure with the duration of generating the
same SDA diagrams from scratch. In this case, the incremental approach still obtains
better results of time cost. Concretely, the incremental approach is averaged 1295.2 ms
faster.
Repeating the previous test but updating the SDA diagram every two days, the
difference grows to 1475.6 ms. Finally, when making the test updating the SDA diagram
133
5. TESTS AND RESULTS
every three days, the incremental approach increases its costs and takes 129.6 ms more
than the non-incremental approach. Therefore, the results suggest that, in the case of
SAGESSA or other health care centers with a similar rate of patients per day, for SDA
diagrams based on about 200 encounters, if we generate them every two days or less,
the approach with lower costs is the incremental one. If we generate the SDA diagram
every three days or more, then the non-incremental approach is preferred.
However, the recommended practice is always to update the SDA diagram as soon
as a new encounter arrives because the temporal cost will be the lowest and the SDA
diagram used as a support to make decisions will always be up to date.
5.3.2 Independence from the size
Another desirable goal of the incremental algorithm is that the cost of updating the
SDA diagram with new data should have a high degree of independence to the number
of encounters that have been used to generate the initial SDA diagram.
We have checked this goal by performing the following test. We generate a SDA
diagram with one encounter and then we keep updating it with one new encounter until
200 encounters are incorporated. Figure 5.5 shows a linear graph with the results of
the test related to the cost of identifying states.
Figure 5.5: Evolution of the cost of identifying states when incorporating the first 200
encounters to a SDA diagram
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The pink line shows the evolution of the time spent in milliseconds (right vertical
axis) to identify states when incorporating the first 200 encounters to a SDA diagram,
and the blue line represents the size of the space of states (left vertical axis) which
increases with the incorporation of new encounters. The graph also includes a trend
line of the evolution of the update cost. The results show that the update cost increases
linearly about 1.8 ms for each new encounter incorporated. A linear trend with such
slope suggests that the update cost of identifying states has a light dependence on the
number of encounters used.
On the other hand, figure 5.6 shows another linear graph with the results of the
test related to the cost of determining therapeutic sequences.
Figure 5.6: Evolution of the cost of determining therapeutic sequences when incorporat-
ing the first 200 encounters to a SDA diagram
In this case, the pink line shows the evolution of the time spent in milliseconds
(right vertical axis) to determine therapeutic sequences when incorporating the first
200 encounters to a SDA diagram. We compare this evolution with the blue line which
represents the total number of nodes (left vertical axis) of all the decision trees which
gives us an idea of the current size of the problem of determining therapeutic sequences.
Notice that the temporal cost of each updating is very variable because it may affect
a different number of decision trees and also a different number of operations such as
pull-up, transposition, etc. The results show that the cost increases linearly about
0.8 ms for each new encounter incorporated. Therefore, when determining therapeutic
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sequences the dependence on the number of encounters used is even lower than when
identifying states.
We can confirm that we achieve this desirable goal because the degree of inde-
pendence to the number of encounters used is very high according to the results (an
increase of 1.8 ms and 0.8 ms for each additional encounter when identifying states and
determining therapeutic sequences respectively).
5.3.3 Independence from the order
The last desirable goal is that the SDA diagram generated by the incremental algorithm
should depend only on the set of encounters that has been used, without regard to the
sequence in which those encounters were presented.
We have checked this property with the following test. We generate a SDA diagram
with 200 encounters incrementally incorporated one by one. Then we randomly shuffle
these encounters and we generate once again the SDA diagram. This procedure has
been done 5 times obtaining 5 SDA diagrams. In all the cases, the diagrams generated
were exactly the same, concluding that the desired goal is achieved.
5.4 Database adherence tests
Once the performance has been checked, we want to determine the adherence of the
SDA diagrams to the hospital database that has been used to generated them in order
to conclude whether the diagrams are able to correctly represent the treatments in
the database or not. Moreover, we want to generate a SDA diagram for HT using
the incremental approach during year 2009 and analyze the adherence to the database
during its evolution.
In section 3.1.5 we proposed a method to calculate the similarity between clinical
actions. This method can be used to compare the medical treatment given to a patient
in an encounter with the treatment that a SDA diagram proposes to this patient,
obtaining a value of similarity between both treatments. In general, we can obtain
the average similarity between the treatments in an EOC database and a certain SDA
diagram.
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5.4.1 Database adherence for each pathology
We have generated a SDA diagram for each of the pathologies: HT, DM and the
comorbidity of both diseases, with different values of the parameter δ (see section 4.2.3),
which determines the level of granularity of the actions in the diagram. If δ ≈ 0 then
the SDA diagram will be more generic and smaller, otherwise if δ ≈ 1 it will be more
concrete but bigger.
Table 5.1 contains the results obtained for different values of δ. Observe that with
δ = 1 (i.e., when no abstraction is made in medical actions registered in the database)
we always obtain an average similarity of 1. The SDA diagram exactly reflects all the
concrete treatments in the database. However, for extremely low values of δ, which
imply a high level of abstraction in the actions of the SDA diagram, we still obtain an
acceptable average similarity of 0.76, 0.68 and 0.76 respectively, for each pathology. A
reduction of 0.7 in δ only implies an average reduction of 0.27 in average similarity.
Moreover, the growth on average similarity is not always linear with the increase of δ
as it can be seen in figure 5.7. In the case of HT, the average similarity stabilizes for
values δ ∈ [0.4, 0.8] and in the case of HT+DM it grows oscillating.
Table 5.1: Results of average similarity and number of elements in the SDA diagram for
each pathology for different values of δ
HT DM HT+DM
δ Average sim. # elements Average sim. # elements Average sim. # elements
0.3 0.76 35 0.68 23 0.76 36
0.4 0.88 39 0.79 35 0.76 36
0.5 0.86 43 0.81 42 0.87 54
0.6 0.84 44 0.88 61 0.93 70
0.7 0.86 47 0.88 62 0.93 83
0.8 0.84 49 0.90 67 0.87 86
0.9 0.95 55 0.95 75 0.91 90
1 1.00 103 1.00 159 1.00 229
Regarding the number of elements in the SDA diagram, we can observe that the
three cases share the same trend. There is a, more or less, linear increase for values of
δ lower than 1, and for δ = 1 the number of elements grows drastically. This behavior
is due to the fact that two action terms only have a similarity equal to 1 when they
are exactly the same or, in the case of pharmacological action terms, if they belong to
the same chemical group and have the same dose (see section 3.1.5.1). Therefore, it
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is very difficult to generalize with this δ and the SDA diagram becomes very concrete
(overfitting).
In general, we can conclude that δ = 0.3 is usually the best choice because it
provides diagrams with a low number of elements and the average similarity results are
satisfactory.
5.4.2 Evolution of database adherence for hypertension during 2009
In order to conclude the tests about the adherence to the database, we have incremen-
tally generated the diagram for HT with δ = 0.3 during the year 2009. The purpose
is to observe the evolution of the average similarity and the number of elements in
the diagram for each month. Starting from January of 2009 we have incrementally
updated an SDA diagram every single month with the new encounters that have taken
place until December of the same year. The average similarity is calculated comparing
the partial SDA diagram with the total database of patients of 2009 with the aim of
observing how the SDA diagram progressively becomes complete.
The linear graph in figure 5.8 shows the results obtained.
The average similarity lasts about eight months to stabilize. Observe that in August
the average similarity is 0.72, which is almost equal to the result at the end of the year
(0.76). Before these eight months there have not taken place enough encounters to
represent all the variability of the treatment. Regarding the number of elements in the
diagram, it grows faster and it is almost stabilized by May with 31 elements (only 4 less
than the final diagram). These results suggest that in future updates of the diagram,
the number of elements will keep more stable, while the average similarity will slowly
increase.
5.5 Medical tests
In this section we present the definitive SDA diagrams for HT, DM and the comorbidity
of both diseases which have been generated from the hospital databases of SAGESSA
during the year 2009 with the non-incremental approach. The background knowledge
from the repository in section 3.3 has been used to guarantee medical correctness of the
results. For each diagram we have chosen a δ = 0.3 because, according to the health






Figure 5.7: Linear graphs of average similarity and number of elements in the SDA
diagram for each pathology for different values of δ
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Figure 5.8: Linear graph of average similarity and number of elements in incremental
SDA diagrams for hypertension during 2009
Here we analyze these diagrams from a medical point of view with the support of health
care experts.
Moreover, we medically compare these diagrams with those generated with the
knowledge-free approach in (BRLV12), reporting the advantages of our approach. We
conclude the medical tests analyzing the evolution of the SDA diagram of HT generated
in section 5.4.2.
5.5.1 SDA diagram and medical analysis for each pathology
Figure 5.9 depicts the SDA diagram for the treatment of HT that has been induced
from a database of SAGESSA with all the patients treated in 2009.
The states of the diagram are based on the situation of the patient within the
treatment of the disease. The level of control of the disease always appears in the first
decisions after each state (except for patients taking 2 drugs).
According to the health care professionals, the SDA diagram reflects all the common
situations in the treatment of HT. Due to the fact that the diagram is only based on
pure hypertensive patients (without comorbidities), there are no situations of extreme
treatment (e.g., patients taking 3 hypotensive drugs).
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Figure 5.9: SDA diagram for the treatment of HT obtained from patients in 2009
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We can observe some of the most typical cases represented in the SDA diagram.
For example, when the patient is following none pharmacological treatment but his
disease is controlled. In this case the SDA diagram indicates to continue with the same
successful treatment. Another typical case reflected in the SDA diagram is when the
patient is not following any kind of pharmacological treatment and his disease is not
controlled so the SDA diagram indicates to start taking 1 hypotensive drug, and when
the patient is taking 1 hypotensive drug and his disease is not controlled so he starts a
treatment with 2 hypotensive drugs.
The SDA diagram does not include any information about drug replacement or dose
modification, but this is because we have not used such low level of abstraction in the
terminology of the actions.
Figure 5.10 depicts the SDA diagram for the treatment of DM that has been induced
from a database of SAGESSA with the patients of 2009. The states of the diagram are
based both on the situation of the patient within the treatment and the level of control
of the disease.
When the diagram was validated by health care professionals, they reported that
it lacked of several common clinical situations. A deeper analysis of the causes drove
us to detect that in the data registered for the patients treated of DM in SAGESSA
during 2009, there were no examples of all the common situations that can be found
in the treatment of DM. Our algorithm must be seen as a tool to model health care
treatments reflected in the input data, therefore it will not describe medical actions
that are not present in the database.
The treatment of the DM without comorbidities has a low range of alternatives.
Moreover, having grouped Oral Hypoglycemic Drugs (OHDs) in a unique action term,
leads to a diagram which is small with a great proportion of states and very few
decisions. The diagram is divided into three disconnected sub-diagrams. Health care
professionals argued that there is a low ratio of patients taking insulins or OHDs that
start taking both kind of drugs together. If these two situations were more common,
the three sub-diagrams would be connected.
Another fact that has been detected is the absence of young people in the database,
which causes OHDs to be the only pharmacological starting treatment.
For the combined treatment of HT and DM we have generated two different SDA
diagrams with the patients of 2009, because we have two different versions of the
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Figure 5.10: SDA diagram for the treatment of DM obtained from patients in 2009
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background knowledge in the repository 3.3.3. The first one is depicted in figure 5.11.
In this first diagram, the states describe the situation of the patient within the
treatment of the disease. The level of control of the diseases always appears in the first
decisions after each state.
In general, this SDA diagram reflects all the common situations in the treatment
of HT+DM.
Compared with the diagram of diabetes (see figure 5.10), the SDA diagram in fig-
ure 5.11 incorporates the transition between taking insulins and taking OHDs+insulins.
However, there are several other transitions which our algorithm has not considered to
include in the diagram, due to its low proportion in the database. Therefore, the
diagram is composed by six disconnected sub-diagrams.
Our algorithm has been able to show evidence of several typologies of patients that
do not appear in the database. For example, there are cases in which the treatment
for HT is changed without knowing if the level of hypertension is controlled or not.
This situation happens because there is a typology of patients, whose treatment for
HT is not changed because it is not necessary, which is not registered in the database.
A similar situation happens in some cases in which decisions are made without asking
anything related to DM.
The other SDA diagram generated for the treatment of HT and DM is depicted in
figure 5.12.
In this case, the states represent the level of control of the two diseases whereas
the situation of the patient within the treatment always is left to appear in the first
decisions after each state.
From the health care professionals’ point of view, a logical tracking of the diagram
can be made from any of the states. The SDA contains the four possible situations
about the level of control of HT and DM and they are all connected.
This organization of the states leads to a SDA diagram for HT+DM which is pre-
ferred by health care professionals than the previous one.
5.5.2 Medical comparison with a knowledge-free approach
We have compared our diagrams with the ones obtained with the non-incremental ap-
proach that does not use background knowledge in (BRLV12). Due to the size of these
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Figure 5.11: SDA diagram for the treatment of HT+DM obtained from patients in 2009
(states based on the stage of the treatment)
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Figure 5.12: SDA diagram for the treatment of HT+DM obtained from patients in 2009
(states based on the level of control of the disease)
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diagrams (more than 100 elements) we have considered not to include them in this doc-
ument. The results obtained with this comparison have been included in (LVRC12a).
The main conclusions reported in the paper are:
• The approach in (BRLV12) allows a syntactical adjustment of the number of
states by means of a parameter, while our approach makes this adjustment in
a semantical way, basically with the help of the background knowledge. For
example, the number of states of the diagrams for HT obtained with the approach
in (BRLV12) goes from 1 state (one state for all the encounters) to 57 states (one
state for each different encounter) depending on the value given to the parameter.
With our approach, the number of states for HT is always 4 because of the clinical
priorities and constraints specified in the background knowledge.
• As we are not able to specify semantic decisions with the approach in (BRLV12),
we cannot guarantee the absence of odd decisions in the SDA diagram. For
example, one of the decisions in the diagram of HT of patients treated during
2009 asks whether the patient shows ADEQUATE PHYSICAL ACTIVITY or
NORMAL GLUCOSE, which is a strange medical question to ask. This fact,
together with the absence of priorities between decision terms, makes the resulting
diagrams usually to be less comprehensible by physicians.
• The approach in (BRLV12) is not able to semantically compare actions, thus
all the syntactically different actions are considered to be different even if they
represent medically equivalent measures. This fact causes that the SDA diagram
may contain unnecessary decisions and a great number of actions. For example,
the diagram of the treatments of HT in 2009 has 67 syntactically different actions
while our approach reduces them to 30 semantically different clinical actions.
As a conclusion, the approach that does not use background knowledge may be
useful in controlled settings with a low number of state, decision and action terms as
it shown in (BRLV12) where different SDA diagrams for HT are generated at a high
level of abstraction for highly preprocessed data. In order to obtain medically correct
diagrams in any setting, the use of background knowledge is essential. In addition,
it also allows us to generate several diagrams with different intentionalities (using the
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background knowledge related to the states) and different levels of abstraction for the
same input data (modifying the value of δ).
5.5.3 Evolution of the SDA diagram for hypertension during 2009
Finally, we analyze the evolution of the SDA diagram of HT generated in section 5.4.2.
Figure 5.13 depicts the diagram obtained using the encounters with patients during
January of 2009.
Figure 5.13: SDA diagram for the treatment of HT obtained from encounters in January
of 2009
We can observe that only a few situations have taken place, leading to a very simple
diagram. During this month, there were only situations of patients not following healthy
habits and not taking medication which have been treated without the use of drugs.
The state representing patients that are taking 1 drug appears in the diagram because
some encounters with this kind of patient took place. However, no information is yet
registered about the following encounters, therefore the algorithm is not able to indicate
the treatment and evolution of these patients. After updating the previous diagram
with the encounters of February we obtain the SDA diagram in figure 5.14.
With these new data, the diagram describes two non-deterministic clinical behav-
iors on patients not following healthy habits and not taking medication. The state
representing patients that are taking 1 drug has been connected with the rest of the
diagram showing a continuous evolution of the care. This connection comes represented
by a clinical procedure described as a single clinical action that confirms the treatment
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Figure 5.14: SDA diagram for the treatment of HT obtained from encounters in January-
February of 2009
with a single drug. A new isolated state for patients taking 2 drugs has also appeared.
Since these patients in the database are only visited once, the diagram is unable to
reflect any evolution from this state to any other. The incremental update at the end
of March leads to the diagram in figure 5.15.
This diagram contains the first decisions and increases treatment variability. The
diagram is increased with new decisions and actions during the next months as we can
see in figures 5.16, 5.17, 5.18 and 5.19.
By August, the diagram is almost equal to the final diagram (see figure 5.9). We
have not included in the document the SDA diagrams of the next months because
they are very similar. As it is expected, the final diagram obtained in December, after
this incremental generation, is equal to the one generated with the non-incremental
approach.
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Figure 5.16: SDA diagram for the treatment of HT obtained from encounters in January-
April of 2009
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Figure 5.18: SDA diagram for the treatment of HT obtained from encounters in January-
June of 2009
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The main objective of this thesis has been to solve two of the main drawbacks of the
current technologies to automatically induce CAs from hospital databases, which are:
• They are only based on statistical measures that do not necessarily respect med-
ical criteria and semantics which can be essential to guarantee medical correct
structures.
• They are not prepared to deal with the incremental arrival of new data which is
worth to consider in health care, where hospital databases are constantly updated
with new information about new arriving patients, and with the follow up of
chronic patients.
Regarding the first drawback, we have studied several structures used to represent
background knowledge and with the help of health care professionals we have proposed
a formalization of all the background knowledge required to assist the automatic induc-
tion of medically correct and comprehensible CAs (contribution 1). This background
knowledge includes constraints, preferences, semantic relationships and concept hierar-
chies, which condition the states, decisions and actions more appropriate to be part of
the CAs.
Focusing our work in the diseases of HT, DM and the comorbidity of both diseases,
we have constructed a repository of background knowledge. This knowledge is used
to formalize the preferences and experience of health care professionals as well as the
evidence-based knowledge contained in other resources like CPGs (SAG02; SAG03) or
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the Anatomical Therapeutic Chemical (ATC) Classification System (fDSM) (contribu-
tion 2).
In order to solve the second drawback, we have proposed an incremental method-
ology to induce CAs which is partially inspired in some of the current incremental
induction algorithms (Utg88; Utg89; UBC97). This new methodology includes two
main procedures which are the identification of states and the determination of thera-
peutic sequences, which are integrated to generate CAs. In this work we represented
CAs as SDA diagrams, according to the SDA knowledge model. This incremental
methodology uses the formalized background knowledge to guarantee medically correct
and comprehensible CAs (contribution 3).
The methodology has been evaluated with different kinds of tests. First of all, some
tests have been done to verify the good performance at the level of background knowl-
edge and incrementality. With respect to the former, the results show that the use of
background knowledge does not imply an increase of temporal cost but a severe reduc-
tion of the time spent determining therapeutic sequences and, therefore, a reduction of
the total duration of the process. The good performance of the incremental technology
is confirmed after checking whether the methodology fulfills the three desirable goals
of cost reduction, independence from the size and independence from the order.
A second kind of technological tests determined the adherence of the induced SDA
diagrams to the hospital database that has been used to generated them. The tests
have been done for HT, DM and HT+DM (comorbidity of both diseases) with different
levels of abstraction in the terminology of the SDA diagrams. The results suggest
that diagrams with a high level of abstraction are usually the best option because
they have a low number of elements but keep satisfactory results on adherence to the
database. A low level of abstraction slightly improves the adherence but it also increases
the number of elements, and in some cases the SDA diagram can be unnecessarily
concrete. The evaluation of the results by health care professionals reported that the
diagrams were expressed at a good level of abstraction. More abstract diagrams would
imply a lack of medical interest, while more detailed diagrams would cause the lack
of alternative correct treatments not observed in the data and therefore a sense of
uncompleteness in the diagrams. We have done another test following an incremental
generation of a SDA diagram for HT during 2009, concluding that the number of
elements in the diagram stabilizes faster than the adherence (four months and eight
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months respectively) suggesting that, in future updates of the diagram, the number of
elements will keep more stable, while the average similarity will slowly increase.
We have generated final SDA diagrams for the previous diseases to be analyzed from
a medical point of view (contribution 4). In the case of HT the diagram obtained reflects
all the common situations in the treatment of the disease. The health care professionals
we have worked with were able to find the most typical situations in HT as for example,
when the patient is not following any kind of pharmacological treatment and his disease
is not controlled so treatment starts with taking 1 hypotensive drug. With regard to
DM, with the generation of the diagram, we could determine that there were several
situations which were not found in the database. Thus showing that our system could
also be used to help physicians and health care managers to identify the casemix a
health care center has to provide a service to and the set of treatments provided in
that center. For the case of HT+DM we generated two diagrams, one with states
based on the treatment of the diseases (i.e., the diagram showed the evolution of the
treatment), and one with states based on the control of the diseases (i.e., the diagram
showed the evolution of the diseases as the patient was treated). Thus showing not only
that our methodology can be used to generate correct CAs that represent alternative
views of the same treatments, but also that it is a valid methodology to represent
the treatment of comorbidities. This last is particularly relevant since this sort of
knowledge cannot be found explicitly represented since the CAs that appear in CPGs
are restricted to one single disease. All these SDA diagrams have been compared with
the knowledge-free approach in (BRLV12) and the results obtained show evidence that,
in order to guarantee medically correct diagrams in any setting, the use of background
knowledge is essential, and it is also very useful to generate several diagrams with
different intentionalities and different levels of abstraction for the same input data.
Finally, we have analyzed the evolution of the SDA diagram of HT during 2009 and
confirmed that the diagram generated incrementally is equal to the one generated with
the non-incremental approach.
The culmination of this thesis is another step forward in improving the automatic
generation of clinical algorithms. The fact that the structures extracted from the
hospital databases are medically correct and comprehensible will help the acceptance
of this kind of methodologies by the medical community.
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Moreover, being an incremental system, it will fit daily clinical practice allowing the
representation of up-to-date procedural knowledge with acceptable costs. Therefore, it
will be applicable in health care centers in order to supervise their medical procedures
or to determine whether certain CPGs are being followed or not, or even to improve
these guidelines with the knowledge extracted from the experience.
At the moment, the work on the development of this thesis has implied the publi-
cation of two papers in scientific journals of impact:
• In (BRLV12) we present a first approach to the automatic generation of SDA
diagrams which does not consider background knowledge and does not work in-
crementally as a first step to the methodology presented in this thesis. In the
paper we generate SDA diagrams for HT using the databases of SAGESSA and
we study the deviations of the treatments with respect to official and predefined
protocols and clinical algorithms, showing a high level of adherence to the treat-
ment proposed by the National Heart Foundation of Australia and the Spanish
Society for Hypertension with about 90.4% of coincident treatment.
• In (LVRB12) we propose a method to induce medically correct and comprehensi-
ble DTs based on some medical criteria included as background knowledge, using
cost functions and partial orders. The results suggest that the method obtains
DTs that physicians evaluate as more comprehensible and correct than the DTs
obtained by previous approaches as they keep an equivalent accuracy.
The results of the thesis have been included in another journal paper (LVRC12a)
which introduces all the formalizations related to the background knowledge, compares
our methodology with the one without background knowledge and reports the conclu-
sions that have been detailed in this document. The results about incrementality will
give rise to another journal paper.
We have also presented two papers in international conferences:
• In (TRLV10) we present another approach to induce medically correct and com-
prehensible DTs which is not based on background knowledge structures. The
paper proposes a slight variation of classical DTs, provides four quality ratios
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to measure the medical correctness of a DT, and introduces an algorithm to in-
duce DTs whose final decisions are both correct and the result of a sequence of
observations with a medical sense.
• In (LVRC12b) we present the method to semantically compare clinical actions (see
section 3.1.5). In the paper, the method is applied to analyze the data about the
treatment of HT in a health care center in order to analyze feasible cost reductions
after replacing medical interventions by their corresponding optimal, observed,
dominant alternatives. This study shows that the use of this methodology reduces
the average cost of each clinical encounter in 1.37.
Finally, we have published two research reports in the Universitat Rovira i Virgili:
• In (LVR11) we present cost functions and partial orders as a way to represent
background knowledge and some mathematical operations to transform a cost
function into a partial order (and vice versa) and also to combine several cost
functions and partial orders into a common structure.
• In (LVR12) we present a hierarchy of medical criteria and we formalize their






Medicine is an evolving science and, therefore, it is common that the protocols used to
treat patients change over time, or even that new drugs or procedures are discovered
causing variations in the physicians’ daily practice. In the approach proposed in this
thesis this behavior is partially considered. During the incremental learning of a SDA
diagram we are able to change the background knowledge obtaining different results.
For example, we can add new constraints between state terms or change their priorities
so that the induced SDA diagram will divide the treatment into different new stages.
We can even add new semantic decisions with a high priority that will lead to different
therapeutic sequences. However, since our approach always considers the whole set of
encounters with patients that have arrived over time, without giving higher priority to
the newer ones, it is not able to forget the health care procedures that have become
obsolete.
Incremental learning systems can be classified according to their memory model
that dictates how to treat past training examples into three categories (MM00):
• full instance memory : the learner retains all past training examples.
• partial instance memory : the learner retains some of the past training examples.
• no instance memory : the learner retains none of the past training examples.
Our approach to induce SDA diagrams is an incremental learning system with full
instance memory. Both the identification of states and the determination of therapeutic
sequences store the whole set of encounters presented (though in an optimized way)
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and it is always fully considered in these learning tasks. Other examples of incremen-
tal learning systems with full instance memory are GEM (RM88), ID5 (Utg88) and
ITI (UBC97).
In order to deal with the situation described in the first paragraph, we are planning
to modify our approach so that it forgets the encounters of patients that contain actions
that have become obsolete. This forgetting behavior is also known as aging and it is
usually related to partial instance memory (and also no instance memory) learning
systems. There are at least three types of aging in the bibliography. The first type
is the proximity-based aging like the one used by the system darling (Sal93). This
partial instance memory algorithm initializes the weight of each new example to one and
decays the weights of examples within a neighborhood of the new example. When an
examples weight falls below a threshold, it is removed. A second type is the frequency-
based aging which is used by the favorit system (KK92a; KK92b). This system to
induce decision trees with no instance memory, ages training examples either positively
or negatively with respect to time (i.e., the newer the example is, the more important
it becomes, and vice versa). If incoming training examples do not reinforce a nodes
presence in the tree, then the nodes score decays. If the score falls below a threshold,
then the algorithm forgets the node. Conversely, if incoming training examples continue
to reinforce and revise the node, its score increases. If the score surpasses an upper
threshold, then the nodes score is fixed and remains so. The last type of aging is
time-based. The partial instance memory flora2 system (W96) is an example of
this kind of aging. It selects a consecutive sequence of training examples from the
input stream and forgets those examples that are older than a threshold, which is set
adaptively. This system was designed to handle drifting concepts, so during periods
when the system is performing well, the size of the window is increased and thus it
keeps more examples. If the performance of the system drops, presumably due to some
change in the target concepts, it reduces the size of the window and forgets the old
examples to accommodate the new examples from the new target concept. As the
systems concept descriptions begin to converge toward the target concepts, the size of
the window increases again, as does the number of training examples maintained in
partial memory.
A time-based aging similar to the one used by the flora2 system is the one that
best suits our problem. In the future we are planning to incorporate it to our approach
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to induce SDA diagrams in order to handle obsolete actions. Being A1 the action
used to treat a certain kind of patient, if new encounters of patients of this kind start
using an alternative action A2, the system may consider either that A1 and A2 are
two alternative actions that coexist or that A2 is a new action that will replace A1.
Therefore it will keep a window of encounters whose size will increase or decrease in
order to determine if A1 and A2 are current treatments (type-1 non-determinism) or if
A1 has become obsolete.
We will also explore other applications of aging for the induction of SDA diagrams.
For example, the removal of old encounters which essentially contain the same health
care procedures that some newer ones, with the aim of reducing the spatial cost of the
knowledge structures stored.
Apart from the incorporation of aging, we are also planning to keep experimenting
with the parameters of the methodology in order to refine them, to construct alterna-
tive structures of background knowledge that allow the induction of SDA diagrams with
different views of the same diseases studied in this thesis, and also to apply our method-
ology to other chronic diseases and comorbidities such as chronic heart failure, chronic
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